,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,855811,2818,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11110967,2818,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,357,2,1,,11110968,2818,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,361,1,2,,855811,2818,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
4,364,1,3,,855811,2818,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
5,368,2,3,,855811,2818,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
6,371,1,1,,855811,2818,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
7,373,1,4,,855811,2818,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
8,374,2,3,,855811,2818,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
9,375,2,3,,855811,2818,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
10,377,1,3,,10321650,2818,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
11,410,1,5,,11110967,2818,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
12,410,1,5,,11110968,2818,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
13,410,1,5,,11113341,2818,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
14,411,2,1,,855811,2818,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
15,411,2,1,,11110967,2818,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
16,411,2,1,,11110968,2818,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
17,411,2,1,,11113341,2818,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
18,422,1,5,,855811,2818,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
19,422,1,5,,17404839,2818,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
20,425,3,2,,855811,2818,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
21,429,1,5,,855811,2818,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
22,429,1,5,,855811,2818,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
23,429,1,5,,17404839,2818,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
24,429,1,5,,17404839,2818,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
25,430,2,4,,855811,2818,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
26,431,2,4,,855811,2818,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
27,432,2,4,,855811,2818,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
28,436,2,1,,855811,2818,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
29,436,2,1,,17404839,2818,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
30,438,1,4,,855811,2818,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
31,440,3,3,,855811,2818,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
32,441,3,3,,855811,2818,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
33,444,1,1,,855811,2818,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
34,444,1,1,,11110967,2818,Active,,,,,NFAT Signaling Pathway,Confirmatory,,
35,444,1,1,,11110968,2818,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
36,445,3,1,,11110967,2818,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
37,445,3,1,,11110968,2818,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
38,445,3,1,,11113341,2818,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
39,446,1,1,,855811,2818,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
40,446,1,1,,11110967,2818,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
41,446,1,1,,11110968,2818,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
42,447,1,1,,11110967,2818,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
43,447,1,1,,11110968,2818,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
44,447,1,1,,11113341,2818,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
45,448,1,2,,11110967,2818,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
46,448,1,2,,11110968,2818,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
47,448,1,2,,11113341,2818,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
48,449,1,5,,855811,2818,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
49,450,1,2,,855811,2818,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
50,450,1,2,,11110967,2818,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
51,450,1,2,,11110968,2818,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
52,450,1,2,,11113341,2818,Active,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
53,451,1,2,,11110967,2818,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
54,451,1,2,,11110968,2818,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
55,451,1,2,,11113341,2818,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
56,453,2,2,,855811,2818,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
57,454,1,7,,855811,2818,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
58,455,1,7,,855811,2818,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
59,456,1,7,,855811,2818,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
60,457,1,7,,855811,2818,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
61,460,2,2,,855811,2818,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
62,483,1,6,,855811,2818,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
63,485,1,8,,855811,2818,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
64,487,1,2,,855811,2818,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
65,488,2,1,,855811,2818,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
66,501,2,2,,855811,2818,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
67,518,2,6,,855811,2818,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
68,521,2,5,,855811,2818,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
69,522,1,2,,855811,2818,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
70,524,1,3,,855811,2818,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
71,525,1,3,,855811,2818,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
72,526,1,1,,11110967,2818,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
73,526,1,1,,11110968,2818,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
74,526,1,1,,11113341,2818,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
75,527,3,1,,855811,2818,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
76,528,1,4,,855811,2818,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
77,529,1,4,,855811,2818,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
78,530,1,1,,11110967,2818,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
79,530,1,1,,11110968,2818,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
80,530,1,1,,11113341,2818,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
81,538,2,2,,855811,2818,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
82,539,1,2,,855811,2818,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
83,547,1,4,,17404839,2818,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
84,552,1,3,,855811,2818,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
85,555,1,2,,855811,2818,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
86,556,1,3,,855811,2818,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
87,559,2,2,,855811,2818,Inactive,147728.0,,,,RNA polymerase,Screening,,
88,560,1,2,,855811,2818,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
89,561,1,3,,855811,2818,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
90,565,1,4,,855811,2818,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
91,567,1,4,,855811,2818,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
92,568,1,7,,855811,2818,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
93,568,1,7,,855811,2818,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
94,570,1,4,,855811,2818,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
95,571,1,4,,855811,2818,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
96,572,1,5,,855811,2818,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
97,573,1,4,,855811,2818,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
98,574,1,3,,855811,2818,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
99,575,1,4,,855811,2818,Inconclusive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
100,576,1,2,,855811,2818,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
101,577,1,1,,855811,2818,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
102,580,1,5,,855811,2818,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
103,581,2,2,,855811,2818,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
104,583,2,6,,855811,2818,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
105,584,1,3,,11110967,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
106,584,1,3,,11110968,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
107,584,1,3,,11113341,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
108,585,1,4,,11110967,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
109,585,1,4,,11110968,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
110,585,1,4,,11113341,2818,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
111,587,1,5,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
112,587,1,5,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
113,587,1,5,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
114,588,1,4,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
115,588,1,4,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
116,588,1,4,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
117,589,1,3,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
118,589,1,3,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
119,589,1,3,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
120,590,1,3,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
121,590,1,3,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
122,590,1,3,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
123,591,1,4,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
124,591,1,4,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
125,591,1,4,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
126,592,1,6,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
127,592,1,6,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
128,592,1,6,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
129,593,1,4,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
130,593,1,4,,11110967,2818,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
131,593,1,4,,11110968,2818,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
132,594,1,4,,855811,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
133,594,1,4,,11110967,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
134,594,1,4,,11110968,2818,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
135,595,1,3,,11110967,2818,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
136,595,1,3,,11110968,2818,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
137,595,1,3,,11113341,2818,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
138,596,1,2,,11110967,2818,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
139,596,1,2,,11110968,2818,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
140,596,1,2,,11113341,2818,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
141,597,1,3,,855811,2818,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
142,597,1,3,,11110967,2818,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
143,597,1,3,,11110968,2818,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
144,597,1,3,,11113341,2818,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
145,598,1,4,,855811,2818,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
146,601,1,4,,855811,2818,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
147,602,1,4,,855811,2818,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
148,603,1,2,,11110967,2818,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
149,603,1,2,,11110968,2818,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
150,603,1,2,,11113341,2818,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
151,604,1,3,,855811,2818,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
152,605,1,2,,11110967,2818,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
153,605,1,2,,11110968,2818,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
154,605,1,2,,11113341,2818,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
155,606,1,3,,855811,2818,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
156,606,1,3,,855811,2818,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
157,607,1,3,,11110967,2818,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
158,607,1,3,,11110968,2818,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
159,607,1,3,,11113341,2818,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
160,609,1,2,,855811,2818,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
161,614,1,6,,855811,2818,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
162,615,1,6,,855811,2818,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
163,618,2,6,,855811,2818,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
164,620,2,5,,855811,2818,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
165,622,1,2,,855811,2818,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
166,623,1,3,,855811,2818,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
167,624,1,2,,855811,2818,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
168,625,1,2,,855811,2818,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
169,626,1,3,,855811,2818,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
170,628,2,4,,855811,2818,Active,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
171,629,1,3,,855811,2818,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
172,630,1,1,,855811,2818,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
173,631,1,4,,855811,2818,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
174,631,1,4,,855811,2818,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
175,633,1,3,,855811,2818,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
176,636,1,4,,855811,2818,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
177,637,1,4,,855811,2818,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
178,639,1,2,,855811,2818,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
179,641,1,4,,855811,2818,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
180,645,1,4,,855811,2818,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
181,648,1,3,,855811,2818,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
182,662,1,1,,11110967,2818,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
183,662,1,1,,11110968,2818,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
184,662,1,1,,11113341,2818,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
185,677,1,4,,855811,2818,Inactive,18249941.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Confirmation Screen,Other,,
186,678,1,4,,855811,2818,Inactive,120660252.0,2914.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Secondary Assay 1,Other,,
187,680,1,10,,855811,2818,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
188,684,1,12,,855811,2818,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
189,686,1,1,,855811,2818,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
190,687,1,17,,855811,2818,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
191,694,1,1,,17404839,2818,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
192,701,1,17,,855811,2818,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
193,708,1,4,,855811,2818,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
194,709,1,2,,855811,2818,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
195,719,1,3,,855811,2818,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
196,731,1,5,,855811,2818,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
197,731,1,5,,855811,2818,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
198,732,1,2,,17404839,2818,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
199,746,1,1,,855811,2818,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
200,750,1,3,,855811,2818,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
201,751,1,3,,855811,2818,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
202,757,1,4,,855811,2818,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
203,758,1,4,,855811,2818,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
204,759,1,4,,855811,2818,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
205,760,1,4,,855811,2818,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
206,761,1,4,,855811,2818,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
207,764,1,4,,855811,2818,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
208,770,1,1,,855811,2818,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
209,771,1,2,,855811,2818,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
210,772,1,2,,855811,2818,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
211,774,1,2,,855811,2818,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
212,775,1,3,,855811,2818,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
213,781,1,1,,855811,2818,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
214,782,1,2,,855811,2818,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
215,782,1,2,,855811,2818,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
216,784,1,4,,855811,2818,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
217,793,1,2,,855811,2818,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
218,795,1,1,,855811,2818,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
219,797,1,1,,855811,2818,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
220,798,2,12,,855811,2818,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
221,799,1,5,,855811,2818,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
222,800,2,11,,855811,2818,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
223,803,1,4,,855811,2818,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
224,804,1,3,,855811,2818,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
225,813,1,4,,855811,2818,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
226,817,1,1,,855811,2818,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
227,818,1,2,,855811,2818,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
228,827,1,2,,855811,2818,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
229,828,1,5,,855811,2818,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
230,834,1,3,,855811,2818,Inactive,,,,,C. albicans biofilm killing,Screening,,
231,841,1,1,,855811,2818,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
232,847,1,2,,855811,2818,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
233,861,1,1,,855811,2818,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
234,862,1,2,,855811,2818,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
235,868,1,3,,855811,2818,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
236,871,1,2,,855811,2818,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
237,873,1,13,,855811,2818,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
238,875,1,2,,855811,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
239,875,1,2,,11110968,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
240,875,1,2,,11113341,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
241,878,1,2,,855811,2818,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
242,879,1,2,,855811,2818,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
243,879,1,2,,855811,2818,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
244,880,2,1,,855811,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
245,880,2,1,,855811,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
246,880,2,1,,11110968,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
247,880,2,1,,11110968,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
248,880,2,1,,11113341,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
249,880,2,1,,11113341,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
250,880,2,1,,26747001,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
251,880,2,1,,26747001,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
252,880,2,1,,26751524,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
253,880,2,1,,26751524,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
254,880,2,1,,50104084,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
255,880,2,1,,50104084,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
256,880,2,1,,50104086,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
257,880,2,1,,50104086,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
258,880,2,1,,50104087,2818,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
259,880,2,1,,50104087,2818,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
260,881,2,2,,855811,2818,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
261,881,2,2,,11110968,2818,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
262,881,2,2,,11113341,2818,Inactive,317373425.0,247.0,3.1623,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
263,883,1,3,,11110967,2818,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
264,883,1,3,,11110968,2818,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
265,883,1,3,,11113341,2818,Inconclusive,13699818.0,1559.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
266,884,1,2,,855811,2818,Inconclusive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
267,884,1,2,,11110968,2818,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
268,884,1,2,,11113341,2818,Inconclusive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
269,885,1,2,,855811,2818,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
270,885,1,2,,11110968,2818,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
271,885,1,2,,11113341,2818,Inactive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
272,886,1,2,,855811,2818,Inconclusive,122921310.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
273,886,1,2,,855811,2818,Inconclusive,122921311.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
274,886,1,2,,11110967,2818,Inconclusive,122921310.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
275,886,1,2,,11110967,2818,Inconclusive,122921311.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
276,886,1,2,,11110968,2818,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
277,886,1,2,,11110968,2818,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
278,886,1,2,,11113341,2818,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
279,886,1,2,,11113341,2818,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
280,887,1,2,,855811,2818,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
281,887,1,2,,11110968,2818,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
282,887,1,2,,11113341,2818,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
283,889,1,3,,855811,2818,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
284,889,1,3,,11110968,2818,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
285,889,1,3,,11113341,2818,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
286,891,1,2,,11110967,2818,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
287,891,1,2,,11110968,2818,Inconclusive,40805836.0,1565.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
288,891,1,2,,11113341,2818,Inconclusive,40805836.0,1565.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
289,892,1,2,,855811,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
290,892,1,2,,11110968,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
291,892,1,2,,11113341,2818,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
292,893,1,2,,855811,2818,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
293,893,1,2,,855811,2818,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
294,893,1,2,,11110968,2818,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
295,893,1,2,,11110968,2818,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
296,893,1,2,,11113341,2818,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
297,893,1,2,,11113341,2818,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
298,894,2,1,,855811,2818,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
299,894,2,1,,11110968,2818,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
300,894,2,1,,11113341,2818,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
301,894,2,1,,26747001,2818,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
302,894,2,1,,50104084,2818,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
303,895,1,2,,855811,2818,Inconclusive,21620132.0,4790.0,1.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
304,898,1,1,,855811,2818,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
305,899,1,2,,11110967,2818,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
306,899,1,2,,11110968,2818,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
307,899,1,2,,11113341,2818,Inconclusive,4503219.0,1557.0,25.1189,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
308,900,1,3,,855811,2818,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
309,900,1,3,,11110968,2818,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
310,900,1,3,,11113341,2818,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
311,901,1,2,,855811,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
312,901,1,2,,11110968,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
313,901,1,2,,11113341,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
314,902,1,2,,855811,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
315,902,1,2,,11110968,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
316,902,1,2,,11113341,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
317,910,1,2,,855811,2818,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
318,912,1,2,,11110967,2818,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
319,912,1,2,,11110968,2818,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
320,912,1,2,,11113341,2818,Inconclusive,21392848.0,,31.6228,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
321,914,1,3,,855811,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
322,914,1,3,,11110967,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
323,914,1,3,,11110968,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
324,915,1,3,,855811,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
325,915,1,3,,11110967,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
326,915,1,3,,11110968,2818,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
327,917,1,3,,855811,2818,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
328,918,1,3,,855811,2818,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
329,920,1,2,,855811,2818,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
330,923,1,2,,855811,2818,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
331,923,1,2,,11110968,2818,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
332,923,1,2,,11113341,2818,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
333,924,1,2,,855811,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
334,924,1,2,,11110968,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
335,924,1,2,,11113341,2818,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
336,925,1,2,,11110967,2818,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
337,925,1,2,,11110968,2818,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
338,926,1,2,,11110967,2818,Unspecified,38016895.0,7253.0,31.6228,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
339,926,1,2,,11110968,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
340,926,1,2,,11113341,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
341,927,1,3,,855811,2818,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
342,927,1,3,,11110968,2818,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
343,928,1,2,,855811,2818,Inconclusive,21620132.0,4790.0,1.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
344,930,1,2,,855811,2818,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
345,932,1,4,,855811,2818,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
346,938,1,2,,11110967,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
347,938,1,2,,11110968,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
348,938,1,2,,11113341,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
349,940,1,2,,855811,2818,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
350,940,1,2,,17404839,2818,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
351,940,1,2,,26612026,2818,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
352,943,1,2,,855811,2818,Active,18249941.0,25229.0,0.0316,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
353,944,1,2,,855811,2818,Active,18249941.0,25229.0,0.1,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
354,945,1,4,,855811,2818,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
355,950,1,1,,855811,2818,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
356,951,1,1,,855811,2818,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
357,952,1,1,,855811,2818,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
358,954,1,2,,855811,2818,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
359,957,1,2,,855811,2818,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
360,958,1,2,,855811,2818,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
361,959,1,4,,855811,2818,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
362,992,1,3,,855811,2818,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
363,995,1,2,,855811,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
364,995,1,2,,11110968,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
365,995,1,2,,11113341,2818,Inactive,66932916.0,5594.0,31.6228,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
366,997,1,2,,855811,2818,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
367,998,1,2,,855811,2818,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
368,1001,2,2,,855811,2818,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
369,1006,1,6,,855811,2818,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
370,1007,1,1,,855811,2818,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
371,1008,1,2,,855811,2818,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
372,1009,1,2,,855811,2818,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
373,1012,1,4,,855811,2818,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
374,1016,1,4,,855811,2818,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
375,1018,2,5,,855811,2818,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
376,1019,1,4,,855811,2818,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
377,1020,1,5,,855811,2818,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
378,1021,1,1,,855811,2818,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
379,1022,1,1,,855811,2818,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
380,1027,1,3,,855811,2818,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
381,1030,2,1,,855811,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
382,1030,2,1,,11110968,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
383,1030,2,1,,11113341,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
384,1030,2,1,,26747001,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
385,1030,2,1,,26751524,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
386,1030,2,1,,50104084,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
387,1030,2,1,,50104086,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
388,1030,2,1,,50104087,2818,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
389,1032,1,2,,855811,2818,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
390,1032,1,2,,855811,2818,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
391,1040,1,2,,855811,2818,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
392,1048,1,1,,855811,2818,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
393,1048,1,1,,855811,2818,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
394,1049,1,1,,855811,2818,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
395,1049,1,1,,855811,2818,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
396,1051,1,1,,855811,2818,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
397,1051,1,1,,855811,2818,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
398,1063,1,1,,855811,2818,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
399,1066,1,2,,855811,2818,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
400,1085,1,1,,855811,2818,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
401,1135,1,3,,855811,2818,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
402,1136,1,3,,855811,2818,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
403,1195,1,2,,48415815,2818,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
404,1203,1,3,,855811,2818,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
405,1209,2,2,,855811,2818,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
406,1214,1,4,,855811,2818,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
407,1216,1,5,,855811,2818,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
408,1217,1,4,,855811,2818,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
409,1220,2,2,,855811,2818,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
410,1222,1,6,,855811,2818,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
411,1229,1,3,,855811,2818,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
412,1235,1,2,,855811,2818,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
413,1236,1,1,,855811,2818,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
414,1239,1,3,,855811,2818,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
415,1239,1,3,,855811,2818,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
416,1242,1,1,,855811,2818,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
417,1251,1,1,,855811,2818,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
418,1273,1,1,,855811,2818,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
419,1274,1,2,,855811,2818,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
420,1276,1,1,,855811,2818,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
421,1285,1,1,,855811,2818,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
422,1296,1,1,,855811,2818,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
423,1304,1,2,,855811,2818,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
424,1321,1,2,,855811,2818,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
425,1325,1,2,,855811,2818,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
426,1326,1,4,,855811,2818,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
427,1332,1,1,,49698447,2818,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
428,1359,1,4,,855811,2818,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
429,1362,1,2,,855811,2818,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
430,1376,1,2,,855811,2818,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
431,1377,1,1,,855811,2818,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
432,1379,1,2,,855811,2818,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
433,1379,1,2,,11110968,2818,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
434,1379,1,2,,11113341,2818,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
435,1379,1,2,,26747001,2818,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
436,1379,1,2,,50104084,2818,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
437,1381,1,1,,855811,2818,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
438,1385,2,2,,855811,2818,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
439,1415,1,2,,855811,2818,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
440,1415,1,2,,855811,2818,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
441,1416,1,2,,855811,2818,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
442,1422,1,1,,855811,2818,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
443,1422,1,1,,17404839,2818,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
444,1422,1,1,,26612026,2818,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
445,1423,1,2,,855811,2818,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
446,1423,1,2,,855811,2818,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
447,1424,1,1,,855811,2818,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
448,1430,1,1,,855811,2818,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
449,1434,2,3,,855811,2818,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
450,1434,2,3,,855811,2818,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
451,1439,1,1,,855811,2818,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
452,1439,1,1,,855811,2818,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
453,1440,1,1,,855811,2818,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
454,1440,1,1,,855811,2818,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
455,1441,1,1,,855811,2818,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
456,1441,1,1,,855811,2818,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
457,1443,1,3,,855811,2818,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
458,1445,1,1,,855811,2818,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
459,1446,1,3,,855811,2818,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
460,1448,1,3,,855811,2818,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
461,1452,1,1,,855811,2818,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
462,1452,1,1,,11110968,2818,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
463,1452,1,1,,11113341,2818,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
464,1454,1,1,,855811,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
465,1454,1,1,,11110968,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
466,1454,1,1,,11113341,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
467,1454,1,1,,26747001,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
468,1454,1,1,,50104084,2818,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
469,1456,1,1,,855811,2818,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
470,1457,1,1,,855811,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
471,1457,1,1,,11110968,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
472,1457,1,1,,11113341,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
473,1457,1,1,,26747001,2818,Inconclusive,44888968.0,83523.0,4.4668,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
474,1457,1,1,,26751524,2818,Inconclusive,44888968.0,83523.0,5.6234,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
475,1457,1,1,,50104084,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
476,1457,1,1,,50104086,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
477,1457,1,1,,50104087,2818,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
478,1458,1,1,,855811,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
479,1458,1,1,,11110968,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
480,1458,1,1,,26747001,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
481,1458,1,1,,26751524,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
482,1458,1,1,,50104084,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
483,1458,1,1,,50104086,2818,Inactive,10937869.0,6607.0,12.5893,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
484,1458,1,1,,50104087,2818,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
485,1459,1,1,,50104084,2818,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
486,1460,1,3,,855811,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
487,1460,1,3,,11113341,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
488,1460,1,3,,26747001,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
489,1460,1,3,,26751524,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
490,1460,1,3,,50104084,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
491,1460,1,3,,50104086,2818,Inconclusive,92096784.0,4137.0,25.1189,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
492,1460,1,3,,50104087,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
493,1461,1,2,,855811,2818,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
494,1461,1,2,,50104084,2818,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
495,1463,1,1,,855811,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
496,1463,1,1,,11113341,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
497,1463,1,1,,26747001,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
498,1463,1,1,,26751524,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
499,1463,1,1,,50104084,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
500,1463,1,1,,50104086,2818,Inconclusive,,,17.7828,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
501,1463,1,1,,50104087,2818,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
502,1465,1,1,,855811,2818,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
503,1466,1,2,,855811,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
504,1467,1,3,,855811,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
505,1467,1,3,,11110968,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
506,1467,1,3,,11113341,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
507,1467,1,3,,26747001,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
508,1467,1,3,,50104084,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
509,1468,1,1,,855811,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
510,1468,1,1,,11113341,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
511,1468,1,1,,26747001,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
512,1468,1,1,,26751524,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
513,1468,1,1,,50104084,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
514,1468,1,1,,50104086,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
515,1468,1,1,,50104087,2818,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
516,1469,1,1,,855811,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
517,1469,1,1,,11110968,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
518,1469,1,1,,11113341,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
519,1469,1,1,,26747001,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
520,1469,1,1,,26751524,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
521,1469,1,1,,50104084,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
522,1469,1,1,,50104086,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
523,1469,1,1,,50104087,2818,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
524,1471,2,1,,11110967,2818,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
525,1471,2,1,,11110968,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
526,1471,2,1,,11113341,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
527,1471,2,1,,26747001,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
528,1471,2,1,,26751524,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
529,1471,2,1,,50104086,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
530,1471,2,1,,50104087,2818,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
531,1476,2,1,,855811,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
532,1476,2,1,,11110968,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
533,1476,2,1,,11113341,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
534,1476,2,1,,26747001,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
535,1476,2,1,,50104084,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
536,1477,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
537,1477,1,1,,11110968,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
538,1477,1,1,,11113341,2818,Inconclusive,,,14.1254,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
539,1477,1,1,,26747001,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
540,1477,1,1,,26751524,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
541,1477,1,1,,50104084,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
542,1477,1,1,,50104086,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
543,1477,1,1,,50104087,2818,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
544,1478,2,1,,855811,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
545,1478,2,1,,11110968,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
546,1478,2,1,,11113341,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
547,1478,2,1,,26747001,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
548,1478,2,1,,50104084,2818,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
549,1479,1,2,,855811,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
550,1479,1,2,,11110968,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
551,1479,1,2,,11113341,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
552,1479,1,2,,26747001,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
553,1479,1,2,,26751524,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
554,1479,1,2,,50104084,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
555,1479,1,2,,50104086,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
556,1479,1,2,,50104087,2818,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
557,1481,1,2,,855811,2818,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
558,1486,1,3,,855811,2818,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
559,1487,1,1,,855811,2818,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
560,1487,1,1,,11110968,2818,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
561,1487,1,1,,26751524,2818,Inconclusive,27436948.0,4000.0,1.122,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
562,1487,1,1,,50104084,2818,Inconclusive,27436948.0,4000.0,8.9125,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
563,1490,2,1,,855811,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
564,1490,2,1,,11110968,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
565,1490,2,1,,11113341,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
566,1490,2,1,,26747001,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
567,1490,2,1,,26751524,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
568,1490,2,1,,50104086,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
569,1490,2,1,,50104087,2818,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
570,1496,1,4,,855811,2818,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
571,1496,1,4,,855811,2818,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
572,1509,1,2,,855811,2818,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
573,1510,1,3,,855811,2818,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
574,1511,1,3,,855811,2818,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
575,1515,1,2,,855811,2818,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
576,1519,1,3,,11110968,2818,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
577,1519,1,3,,11113341,2818,Inconclusive,,,28.1838,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
578,1519,1,3,,26747001,2818,Inconclusive,,,11.2202,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
579,1519,1,3,,50104084,2818,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
580,1527,1,3,,855811,2818,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
581,1529,1,1,,855811,2818,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
582,1530,1,1,,855811,2818,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
583,1531,1,1,,855811,2818,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
584,1532,1,1,,855811,2818,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
585,1554,1,1,,855811,2818,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
586,1556,1,4,,855811,2818,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
587,1565,2,2,,855811,2818,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
588,1566,2,3,,855811,2818,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
589,1578,3,2,,855811,2818,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
590,1580,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
591,1581,1,1,,8149634,2818,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
592,1582,1,1,,8149634,2818,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
593,1583,1,1,,8149634,2818,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
594,1584,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
595,1585,1,1,,8149634,2818,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
596,1586,1,1,,8149634,2818,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
597,1587,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
598,1588,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
599,1589,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
600,1590,1,1,,8149634,2818,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
601,1593,1,1,,8149634,2818,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
602,1594,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
603,1595,1,1,,8149634,2818,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
604,1596,1,1,,8149634,2818,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
605,1597,1,1,,8149634,2818,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
606,1598,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
607,1599,1,1,,8149634,2818,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
608,1600,1,1,,8149634,2818,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
609,1601,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
610,1602,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
611,1603,1,1,,8149634,2818,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
612,1604,1,1,,8149634,2818,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
613,1605,1,1,,8149634,2818,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
614,1606,1,1,,8149634,2818,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
615,1607,1,1,,8149634,2818,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
616,1608,1,1,,8149634,2818,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
617,1609,1,1,,8149634,2818,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
618,1610,1,1,,8149634,2818,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
619,1612,1,1,,8149634,2818,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
620,1613,1,1,,8149634,2818,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
621,1614,1,1,,8149634,2818,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
622,1616,1,1,,8149634,2818,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
623,1619,1,2,,855811,2818,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
624,1621,1,2,,855811,2818,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
625,1626,1,2,,855811,2818,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
626,1631,3,1,,855811,2818,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
627,1634,3,1,,855811,2818,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
628,1654,2,2,,855811,2818,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
629,1656,2,2,,855811,2818,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
630,1662,1,2,,855811,2818,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
631,1663,1,2,,855811,2818,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
632,1672,1,3,,855811,2818,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
633,1688,1,1,,855811,2818,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
634,1688,1,1,,26751524,2818,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
635,1700,1,2,,855811,2818,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
636,1705,1,2,,50104084,2818,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
637,1706,1,2,,855811,2818,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
638,1707,1,3,,50104084,2818,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
639,1708,1,3,,50104084,2818,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
640,1721,1,2,,855811,2818,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
641,1722,1,2,,855811,2818,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
642,1766,1,1,,855811,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
643,1766,1,1,,855811,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
644,1766,1,1,,11110968,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
645,1766,1,1,,11110968,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
646,1766,1,1,,11113341,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
647,1766,1,1,,11113341,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
648,1766,1,1,,26747001,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
649,1766,1,1,,26747001,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
650,1766,1,1,,26751524,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
651,1766,1,1,,26751524,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
652,1766,1,1,,50104084,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
653,1766,1,1,,50104084,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
654,1768,1,1,,855811,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
655,1768,1,1,,855811,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
656,1768,1,1,,11110968,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
657,1768,1,1,,11110968,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
658,1768,1,1,,11113341,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
659,1768,1,1,,11113341,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
660,1768,1,1,,26747001,2818,Inconclusive,18860839.0,4221.0,2.2387,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
661,1768,1,1,,26747001,2818,Inconclusive,56550039.0,4297.0,2.2387,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
662,1768,1,1,,26751524,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
663,1768,1,1,,26751524,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
664,1768,1,1,,50104084,2818,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
665,1768,1,1,,50104084,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
666,1775,1,2,,855811,2818,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
667,1776,1,2,,855811,2818,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
668,1777,3,2,,855811,2818,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
669,1778,3,3,,855811,2818,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
670,1779,2,2,,855811,2818,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
671,1789,1,2,,855811,2818,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
672,1800,1,2,,855811,2818,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
673,1813,1,2,,855811,2818,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
674,1814,1,2,,855811,2818,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
675,1815,1,1,,50104084,2818,Active,,,7.0795,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
676,1816,1,1,,50104084,2818,Active,,,7.0795,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
677,1817,2,2,,855811,2818,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
678,1822,1,3,,855811,2818,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
679,1825,1,1,,855811,2818,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
680,1828,2,1,,50104084,2818,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
681,1832,2,1,,855811,2818,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
682,1845,1,2,,855811,2818,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
683,1850,2,1,,855811,2818,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
684,1850,2,1,,56422144,2818,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
685,1851,1,2,,11110968,2818,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
686,1851,1,2,,11113341,2818,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
687,1851,1,2,1.0,11110968,2818,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
688,1851,1,2,1.0,11113341,2818,Inconclusive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
689,1851,1,2,2.0,11110968,2818,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
690,1851,1,2,2.0,11113341,2818,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
691,1851,1,2,3.0,11110968,2818,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
692,1851,1,2,3.0,11113341,2818,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
693,1851,1,2,4.0,11110968,2818,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
694,1851,1,2,4.0,11113341,2818,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
695,1851,1,2,5.0,11110968,2818,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
696,1851,1,2,5.0,11113341,2818,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
697,1861,2,1,,855811,2818,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
698,1862,1,4,,855811,2818,Inconclusive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
699,1863,2,1,,855811,2818,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
700,1863,2,1,,56422144,2818,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
701,1865,1,1,,855811,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
702,1865,1,1,,11110968,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
703,1865,1,1,,11113341,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
704,1865,1,1,,26747001,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
705,1865,1,1,,26751524,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
706,1865,1,1,,50104084,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
707,1865,1,1,,50104086,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
708,1865,1,1,,50104087,2818,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
709,1867,1,4,,855811,2818,Inconclusive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
710,1868,1,4,,855811,2818,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
711,1870,1,4,,855811,2818,Unspecified,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
712,1873,1,4,,855811,2818,Inconclusive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
713,1875,2,1,,855811,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
714,1876,1,1,,50104084,2818,Active,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
715,1877,1,1,,50104084,2818,Inconclusive,,,17.7828,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
716,1882,1,1,,50104084,2818,Inconclusive,,,5.6234,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
717,1883,1,1,,50104084,2818,Active,,,4.4668,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
718,1885,2,1,,855811,2818,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
719,1886,1,1,,50104084,2818,Active,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
720,1887,1,4,,855811,2818,Inconclusive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
721,1899,1,3,,56422144,2818,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
722,1903,2,3,,855811,2818,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
723,1903,2,3,,56422144,2818,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
724,1906,1,3,,56422144,2818,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
725,1910,1,2,,855811,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
726,1947,1,2,,56422144,2818,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
727,1948,1,1,,11110968,2818,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
728,1948,1,1,,11113341,2818,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
729,1948,1,1,,26747001,2818,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
730,1948,1,1,,50104084,2818,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
731,1950,1,3,,56422144,2818,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
732,1956,1,1,,855811,2818,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
733,1961,2,2,,855811,2818,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
734,1962,1,2,,56422144,2818,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
735,1967,1,1,,85230974,2818,Inconclusive,4505907.0,5376.0,47.7548,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
736,1974,1,2,,56422144,2818,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
737,1979,1,1,,855811,2818,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
738,1984,1,3,,855811,2818,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
739,1986,1,2,,855811,2818,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
740,1987,1,2,,56422144,2818,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
741,2006,3,2,,855811,2818,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
742,2006,3,2,,855811,2818,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
743,2006,3,2,,855811,2818,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
744,2012,3,2,,855811,2818,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
745,2013,2,2,,855811,2818,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
746,2014,3,2,,855811,2818,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
747,2016,1,3,,56422144,2818,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
748,2023,1,3,,56422144,2818,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
749,2025,1,3,,56422144,2818,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
750,2029,1,3,,56422144,2818,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
751,2052,2,1,,56422144,2818,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
752,2057,1,2,,56422144,2818,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
753,2058,3,2,,855811,2818,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
754,2062,1,2,,85209032,2818,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
755,2062,1,2,,85220237,2818,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
756,2066,1,4,,56422144,2818,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
757,2071,2,2,,855811,2818,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
758,2073,2,3,,855811,2818,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
759,2073,2,3,,855811,2818,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
760,2094,1,2,,855811,2818,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
761,2094,1,2,,855811,2818,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
762,2094,1,2,,855811,2818,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
763,2097,1,2,,855811,2818,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
764,2098,1,1,,855811,2818,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
765,2099,1,1,,855811,2818,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
766,2100,1,1,,855811,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
767,2101,1,1,,855811,2818,Inconclusive,496369.0,2629.0,8.9125,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
768,2101,1,1,,11110968,2818,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
769,2101,1,1,,11113341,2818,Inconclusive,496369.0,2629.0,3.5481,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
770,2101,1,1,,26747001,2818,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
771,2101,1,1,,26751524,2818,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
772,2101,1,1,,50104084,2818,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
773,2101,1,1,,50104086,2818,Inconclusive,496369.0,2629.0,28.1838,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
774,2101,1,1,,50104087,2818,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
775,2107,1,1,,855811,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
776,2107,1,1,,11110968,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
777,2107,1,1,,11113341,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
778,2107,1,1,,26747001,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
779,2107,1,1,,26751524,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
780,2107,1,1,,50104084,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
781,2107,1,1,,50104086,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
782,2107,1,1,,50104087,2818,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
783,2112,1,1,,855811,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
784,2112,1,1,,11110968,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
785,2112,1,1,,11113341,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
786,2112,1,1,,26747001,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
787,2112,1,1,,26751524,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
788,2112,1,1,,50104084,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
789,2112,1,1,,50104086,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
790,2112,1,1,,50104087,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
791,2129,1,2,,56422144,2818,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
792,2130,1,3,,56422144,2818,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
793,2147,1,1,,855811,2818,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
794,2147,1,1,,11110968,2818,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
795,2147,1,1,,11113341,2818,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
796,2147,1,1,,26747001,2818,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
797,2147,1,1,,50104084,2818,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
798,2156,2,2,,855811,2818,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
799,2174,1,3,,56422144,2818,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
800,2177,1,3,,56422144,2818,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
801,2205,1,1,,855811,2818,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
802,2216,1,3,,855811,2818,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
803,2221,1,2,,855811,2818,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
804,2227,1,2,,855811,2818,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
805,2234,1,2,,56422144,2818,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
806,2235,1,2,,56422144,2818,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
807,2237,1,2,,855811,2818,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
808,2239,1,2,,855811,2818,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
809,2240,1,1,,85788342,2818,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
810,2241,1,1,,85788342,2818,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
811,2242,1,1,,855811,2818,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
812,2247,1,2,,855811,2818,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
813,2275,1,1,,85788342,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
814,2280,2,3,,56422144,2818,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
815,2288,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
816,2289,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
817,2300,1,3,,56422144,2818,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
818,2313,1,1,,85788342,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
819,2314,1,2,,855811,2818,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
820,2314,1,2,,855811,2818,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
821,2315,1,2,,855811,2818,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
822,2315,1,2,,855811,2818,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
823,2322,1,1,,85788342,2818,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
824,2323,1,1,,50104084,2818,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
825,2326,1,1,,855811,2818,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
826,2326,1,1,,50104084,2818,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
827,2330,1,1,,85788342,2818,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
828,2353,1,3,,50104084,2818,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
829,2364,1,2,,50104084,2818,Inconclusive,4557365.0,641.0,0.0035,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
830,2380,1,2,,56422144,2818,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
831,2391,1,1,,56422144,2818,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
832,2417,1,1,,855811,2818,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
833,2435,1,2,,56422144,2818,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
834,2445,1,2,,56422144,2818,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
835,2451,1,2,,855811,2818,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
836,2451,1,2,,11110968,2818,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
837,2451,1,2,,11113341,2818,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
838,2451,1,2,,26747001,2818,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
839,2451,1,2,,50104084,2818,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
840,2462,1,1,,56422144,2818,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
841,2462,1,1,,56422144,2818,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
842,2472,1,2,,855811,2818,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
843,2472,1,2,,11110968,2818,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
844,2472,1,2,,11113341,2818,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
845,2472,1,2,,26747001,2818,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
846,2517,2,1,,855811,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
847,2517,2,1,,11110968,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
848,2517,2,1,,11113341,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
849,2517,2,1,,26747001,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
850,2517,2,1,,26751524,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
851,2517,2,1,,50104084,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
852,2517,2,1,,50104086,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
853,2517,2,1,,50104087,2818,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
854,2520,1,4,,56422144,2818,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
855,2521,1,3,,56422144,2818,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
856,2523,1,1,,855811,2818,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
857,2524,1,2,,56422144,2818,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
858,2528,1,2,,855811,2818,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
859,2528,1,2,,11110968,2818,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
860,2528,1,2,,11113341,2818,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
861,2528,1,2,,26747001,2818,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
862,2528,1,2,,26751524,2818,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
863,2528,1,2,,50104084,2818,Inconclusive,4557365.0,641.0,0.0035,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
864,2540,1,2,,56422144,2818,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
865,2544,1,2,,56422144,2818,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
866,2546,1,1,,855811,2818,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
867,2546,1,1,,11110968,2818,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
868,2546,1,1,,11113341,2818,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
869,2546,1,1,,26747001,2818,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
870,2546,1,1,,26751524,2818,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
871,2549,1,1,,855811,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
872,2549,1,1,,11110968,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
873,2549,1,1,,11113341,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
874,2549,1,1,,26747001,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
875,2549,1,1,,26751524,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
876,2549,1,1,,50104084,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
877,2549,1,1,,50104086,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
878,2549,1,1,,50104087,2818,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
879,2550,1,3,,855811,2818,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
880,2551,1,1,,855811,2818,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
881,2551,1,1,,11110968,2818,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
882,2551,1,1,,11113341,2818,Inconclusive,188536040.0,19885.0,39.8107,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
883,2551,1,1,,26747001,2818,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
884,2551,1,1,,26751524,2818,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
885,2553,1,2,,855811,2818,Active,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
886,2557,1,3,,56422144,2818,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
887,2563,1,1,,855811,2818,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
888,2599,1,2,,56422144,2818,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
889,2606,1,2,,56422144,2818,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
890,2629,1,1,,56422144,2818,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
891,2642,1,2,,855811,2818,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
892,2648,1,2,,855811,2818,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
893,2650,2,1,,56422144,2818,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
894,2660,1,1,,90341777,2818,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
895,2661,1,1,,56422144,2818,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
896,2662,2,1,,855811,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
897,2662,2,1,,85230974,2818,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
898,2666,1,1,,90341777,2818,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
899,2667,1,1,,90341777,2818,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
900,2668,1,1,,90341777,2818,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
901,2674,1,1,,855811,2818,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
902,2675,1,1,,855811,2818,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
903,2675,1,1,,50104084,2818,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
904,2676,1,2,,855811,2818,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
905,2685,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
906,2690,1,2,,56422144,2818,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
907,2696,1,1,,855811,2818,Active,160333370.0,22068.0,15.85,EC50,Confirmation dose response assay for compounds that inhibit transient receptor potential cation channel C6 (TRPC6).,Confirmatory,,
908,2706,1,1,,855811,2818,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
909,2716,1,1,,56422144,2818,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
910,2717,1,2,,56422144,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
911,2718,1,1,,56422144,2818,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
912,2732,1,1,,855811,2818,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
913,2732,1,1,,17404839,2818,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
914,2751,2,2,,56422144,2818,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
915,2774,1,3,,92303709,2818,Inactive,,,,,LOPAC Circadian Assay,Screening,,
916,2776,1,2,,855811,2818,Inactive,2935630.0,22066.0,,,Second specificity screen against TRPC4 for compounds that inhibit transient receptor potential cation   channel C6 (TRPC6),Screening,,
917,2777,1,2,,855811,2818,Inactive,2935630.0,22066.0,,,Specificity screen against TRPC4 for compounds that inhibit transient receptor potential   cation channel C6 (TRPC6),Screening,,
918,2779,1,1,,855811,2818,Active,,,,,Second counter screen for compounds that inhibit transient receptor potential cation   channel C6 (TRPC6),Screening,,
919,2780,1,1,,855811,2818,Inactive,,,,,Counter screen for compounds that inhibit transient receptor potential cation channel C6   (TRPC6),Screening,,
920,2796,1,4,,56422144,2818,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
921,2797,1,2,,56422144,2818,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
922,2805,2,2,,56422144,2818,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
923,2806,2,2,,56422144,2818,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
924,2825,1,2,,56422144,2818,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
925,3460,7,1,,103165765,2818,Active,,,0.15,IC50,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Confirmatory,9622542.0,
926,3656,9,1,,103165765,2818,Active,,,1.0155,IC50,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Confirmatory,7914536.0,
927,3657,7,2,,103165765,2818,Active,,,0.71,Ki,Binding affinity towards human 5-hydroxytryptamine 1 receptor,Confirmatory,11170639.0,
928,3663,7,1,,103165765,2818,Active,,,0.5870000000000001,IC50,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Confirmatory,2542551.0,
929,3669,7,2,,103165765,2818,Active,,,0.5870000000000001,IC50,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Confirmatory,2869146.0,
930,3699,7,1,,103165765,2818,Active,,,0.21,Ki,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Confirmatory,1346653.0,
931,3730,9,1,,103165765,2818,Active,,,1.01,IC50,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Confirmatory,8831770.0,
932,3736,8,5,,103165765,2818,Active,112812.0,24473.0,0.6,IC50,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Confirmatory,1676427.0,
933,3743,9,1,,103165765,2818,Active,,,0.58,IC50,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Confirmatory,1672156.0,
934,3744,7,1,,103165765,2818,Active,,,2.0,IC50,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Confirmatory,8568802.0,
935,3756,7,1,,103165765,2818,Active,,,0.2676,IC50,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Confirmatory,12361392.0,
936,3760,7,2,,103165765,2818,Active,,,2.0,IC50,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Confirmatory,7914539.0,
937,3960,7,2,,103165765,2818,Active,,,2.0,IC50,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Confirmatory,8941382.0,
938,3968,8,4,,103165765,2818,Inconclusive,,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Other,12113813.0,
939,3992,7,1,,103165765,2818,Active,,,0.247,Ki,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Confirmatory,9876110.0,
940,3995,7,1,,103165765,2818,Active,,,0.15,Ki,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Confirmatory,8691438.0,
941,4042,7,2,,103165765,2818,Active,,,0.039,Ki,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Confirmatory,7473547.0,
942,4053,9,1,,103165765,2818,Active,,,0.64,Ki,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Confirmatory,1353116.0,
943,4058,7,1,,103165765,2818,Active,,,0.111,Ki,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Confirmatory,9622541.0,
944,4067,7,1,,103165765,2818,Active,,,0.13,Ki,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Confirmatory,8709107.0,
945,4334,7,2,,103165765,2818,Active,,,0.0385,Ki,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Confirmatory,7473548.0,
946,4356,8,5,,103165765,2818,Active,112812.0,24473.0,0.111,Ki,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Confirmatory,7909336.0,
947,4357,7,1,,103165765,2818,Active,,,0.415,Ki,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Confirmatory,10464021.0,
948,4363,7,1,,103165765,2818,Active,,,0.039,Ki,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Confirmatory,1346653.0,
949,4442,7,2,,103165765,2818,Active,,,0.27,Ki,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Confirmatory,11527728.0,
950,4670,7,1,,103165765,2818,Active,,,2.5,IC50,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Confirmatory,9622542.0,
951,4782,9,1,,103165765,2818,Active,,,0.07200000000000001,IC50,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Confirmatory,8831770.0,
952,4786,7,2,,103165765,2818,Active,,,0.021,IC50,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Confirmatory,2869146.0,
953,4793,7,1,,103165765,2818,Active,,,0.024,IC50,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Confirmatory,1676427.0,
954,4803,9,1,,103165765,2818,Active,,,0.03,IC50,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Confirmatory,1672156.0,
955,4812,7,5,,103165765,2818,Active,112808.0,29595.0,0.0078,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
956,4812,7,5,,103165765,2818,Active,112817.0,25187.0,0.0078,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
957,4812,7,5,,103165765,2818,Active,398970.0,29581.0,0.0078,IC50,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Confirmatory,1348090.0,
958,4814,7,1,,103165765,2818,Active,,,0.027999999999999997,IC50,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Confirmatory,8568802.0,
959,4824,7,2,,103165765,2818,Active,,,0.027999999999999997,IC50,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Confirmatory,7914539.0,
960,5013,7,2,,103165765,2818,Active,,,0.012,Ki,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Confirmatory,9572880.0,
961,5020,7,2,,103165765,2818,Active,,,0.027999999999999997,IC50,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Confirmatory,8941382.0,
962,5042,7,2,,103165765,2818,Active,,,0.00389,Ki,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Confirmatory,7907148.0,
963,5053,7,3,,103165765,2818,Unspecified,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,Other,1348090.0,
964,5055,7,1,,103165765,2818,Active,,,0.021,IC50,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Confirmatory,2542551.0,
965,5061,7,1,,103165765,2818,Active,,,0.05,IC50,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Confirmatory,7707315.0,
966,5063,7,5,,103165765,2818,Active,112808.0,29595.0,0.02,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
967,5063,7,5,,103165765,2818,Active,112817.0,25187.0,0.02,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
968,5063,7,5,,103165765,2818,Active,398970.0,29581.0,0.02,IC50,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Confirmatory,2875184.0,
969,5090,5,1,,103165765,2818,Active,,,0.01259,Ki,pKi value for 5-hydroxytryptamine 2 receptor binding site,Confirmatory,9748351.0,
970,5123,9,2,,103165765,2818,Active,,,0.0038,Ki,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Confirmatory,8101877.0,
971,5127,4,1,,103165765,2818,Active,,,0.0050100000000000006,Ki,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Confirmatory,11392544.0,
972,5129,3,8,,103165765,2818,Active,,,,,5-hydroxytryptamine 2 receptor binding affinity,Other,,
973,5155,7,1,,103165765,2818,Active,,,0.003,IC50,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Confirmatory,9622542.0,
974,5171,9,1,,103165765,2818,Active,,,0.012,IC50,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Confirmatory,8831770.0,
975,5196,9,1,,103165765,2818,Active,,,0.005,Ki,Binding affinity towards human 5-HT2A receptor in BEK cells,Confirmatory,8831770.0,
976,5197,7,2,,103165765,2818,Active,,,0.0033,Ki,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,14998318.0,
977,5199,8,5,,103165765,2818,Active,543727.0,3356.0,0.004,Ki,Binding affinity for human 5-hydroxytryptamine 2A receptor,Confirmatory,11170639.0,
978,5205,7,2,,103165765,2818,Active,,,0.0078,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Confirmatory,14695828.0,
979,5229,7,2,,103165765,2818,Active,,,0.0018,Ki,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Confirmatory,1346653.0,
980,5231,7,1,,103165765,2818,Active,,,0.0038,Ki,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Confirmatory,8691438.0,
981,5250,7,1,,103165765,2818,Active,,,0.011000000000000001,Ki,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Confirmatory,9748351.0,
982,5255,9,1,,103165765,2818,Active,,,0.06,Ki,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Confirmatory,1353116.0,
983,5279,7,1,,103165765,2818,Active,,,0.01,Ki,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Confirmatory,2888898.0,
984,5289,7,1,,103165765,2818,Active,,,0.0036799999999999997,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Confirmatory,7901415.0,
985,5317,4,1,,103165765,2818,Active,112808.0,29595.0,0.00158,Ki,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Confirmatory,10821703.0,
986,5324,4,1,,103165765,2818,Active,112808.0,29595.0,0.02754,Ki,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,11101359.0,
987,5326,5,1,,103165765,2818,Active,,,0.01,Ki,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Confirmatory,11784139.0,
988,5328,4,1,,103165765,2818,Active,112808.0,29595.0,0.01514,Ki,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Confirmatory,8568801.0,
989,5331,5,1,,103165765,2818,Active,,,0.00759,Ki,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Confirmatory,11754579.0,
990,5335,4,1,,103165765,2818,Active,,,0.0050100000000000006,Ki,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Confirmatory,,
991,5337,4,1,,103165765,2818,Active,,,0.0050100000000000006,Ki,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Confirmatory,10425088.0,
992,5363,5,1,,103165765,2818,Active,,,0.00912,Ki,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,14741248.0,
993,5381,3,7,,103165765,2818,Unspecified,,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Other,11784139.0,
994,5447,8,4,,103165765,2818,Inconclusive,,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Other,12113813.0,
995,5479,9,1,,103165765,2818,Active,,,0.07200000000000001,IC50,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Confirmatory,7914536.0,
996,5483,7,1,,103165765,2818,Active,,,0.012,IC50,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Confirmatory,10377229.0,
997,5484,7,1,,103165765,2818,Active,,,0.0407,IC50,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Confirmatory,12361392.0,
998,5485,8,5,,103165765,2818,Active,112808.0,29595.0,0.013000000000000001,IC50,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Confirmatory,9876110.0,
999,5490,8,5,,103165765,2818,Active,112808.0,29595.0,0.0078,IC50,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Confirmatory,9406603.0,
1000,5492,7,2,,103165765,2818,Active,,,0.0078,IC50,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Confirmatory,7473566.0,
1001,5504,7,2,,103165765,2818,Active,,,0.008,Ki,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Confirmatory,7861418.0,
1002,5508,7,2,,103165765,2818,Active,,,0.008,Ki,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Confirmatory,8064797.0,
1003,5522,7,1,,103165765,2818,Active,,,0.0094,Ki,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Confirmatory,9876110.0,
1004,5554,7,2,,103165765,2818,Active,,,0.009000000000000001,Ki,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Confirmatory,10715164.0,
1005,5558,7,1,,103165765,2818,Active,,,0.017,Ki,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Confirmatory,8709107.0,
1006,5560,7,1,,103165765,2818,Active,,,0.01,Ki,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Confirmatory,11784139.0,
1007,5567,7,1,,103165765,2818,Active,,,0.0067,Ki,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Confirmatory,12408724.0,
1008,5569,7,1,,103165765,2818,Active,,,0.01,Ki,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Confirmatory,14695828.0,
1009,5573,6,8,,103165765,2818,Active,112808.0,29595.0,0.015,Ki,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Confirmatory,8568801.0,
1010,5573,6,8,,103165765,2818,Active,47117674.0,24318.0,0.015,Ki,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Confirmatory,8568801.0,
1011,5603,5,4,,103165765,2818,Active,,,0.000692,Kd,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Confirmatory,11754579.0,
1012,5614,7,2,,103165765,2818,Active,,,0.013000000000000001,Ki,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Confirmatory,14998318.0,
1013,5616,7,2,,103165765,2818,Active,,,0.005,Ki,Binding affinity towards human 5-hydroxytryptamine 2C receptor,Confirmatory,11170639.0,
1014,5686,7,1,,103165765,2818,Active,,,0.01,IC50,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Confirmatory,9622542.0,
1015,5703,7,2,,103165765,2818,Active,,,0.011000000000000001,IC50,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Confirmatory,10377229.0,
1016,5708,8,5,,103165765,2818,Active,112817.0,25187.0,0.011000000000000001,IC50,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Confirmatory,9406603.0,
1017,5714,7,2,,103165765,2818,Active,,,0.008,Ki,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Confirmatory,7861418.0,
1018,5715,7,2,,103165765,2818,Active,,,0.008,Ki,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Confirmatory,8064797.0,
1019,5735,7,2,,103165765,2818,Active,,,0.023,Ki,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Confirmatory,10715164.0,
1020,5803,5,3,,103165765,2818,Active,,,0.12589,Kd,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Confirmatory,11101359.0,
1021,5821,6,6,,103165765,2818,Active,398970.0,29581.0,0.16982,Kd,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Confirmatory,11754579.0,
1022,5831,4,1,,103165765,2818,Active,,,0.0050100000000000006,Ki,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Confirmatory,11101359.0,
1023,5835,5,1,,103165765,2818,Active,,,0.01585,Ki,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Confirmatory,11754579.0,
1024,5836,4,1,,103165765,2818,Active,,,0.01585,Ki,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Confirmatory,10425088.0,
1025,5951,5,1,,103165765,2818,Active,,,0.01047,Ki,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Confirmatory,14741248.0,
1026,6022,8,5,,103165765,2818,Active,112809.0,15561.0,0.032,Ki,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Confirmatory,8709107.0,
1027,6134,7,2,,103165765,2818,Active,,,0.053,Ki,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Confirmatory,8064797.0,
1028,6437,7,1,,103165765,2818,Active,,,0.44299999999999995,Ki,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Confirmatory,10649982.0,
1029,6480,8,5,,103165765,2818,Active,1345607.0,3361.0,1.0,Ki,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Confirmatory,12825922.0,
1030,6514,8,5,,103165765,2818,Active,1703010.0,3362.0,0.0095,Ki,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Confirmatory,12825922.0,
1031,6520,7,1,,103165765,2818,Active,,,0.0048,Ki,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Confirmatory,11055342.0,
1032,6521,7,2,,103165765,2818,Active,,,0.01,Ki,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Confirmatory,10715164.0,
1033,6563,7,2,,103165765,2818,Active,,,0.004,Ki,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Confirmatory,12825922.0,
1034,6587,8,5,,103165765,2818,Active,8488960.0,3363.0,0.04,Ki,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Confirmatory,12825922.0,
1035,6594,7,2,,103165765,2818,Active,,,0.009000000000000001,Ki,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Confirmatory,10715164.0,
1036,6648,7,2,,103165765,2818,Active,,,0.0063,Ki,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Confirmatory,12825922.0,
1037,6670,6,2,,103165765,2818,Active,,,0.01259,Ki,Binding affinity towards 5-hydroxytryptamine 7 receptor,Confirmatory,10843226.0,
1038,6685,4,1,,103165765,2818,Active,,,0.01259,Ki,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Confirmatory,14667218.0,
1039,7783,3,4,,103165765,2818,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
1040,8002,5,2,,103165765,2818,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
1041,19424,3,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
1042,20157,3,3,,103165765,2818,Unspecified,,,,,Ratio of Ki of dopamine D2 to D4 receptor,Other,8709107.0,
1043,22293,4,4,,103165765,2818,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
1044,23095,3,9,,103165765,2818,Unspecified,112808.0,29595.0,,,Ratio of pKi of 5-HT2A receptor to that of D2 receptor,Other,11101359.0,
1045,23095,3,9,,103165765,2818,Unspecified,47117674.0,24318.0,,,Ratio of pKi of 5-HT2A receptor to that of D2 receptor,Other,11101359.0,
1046,23695,3,3,,103165765,2818,Unspecified,,,,,Partition coefficient (logP),Other,10377229.0,
1047,23961,3,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1048,23964,4,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1049,23966,4,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1050,23968,4,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1051,23970,4,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1052,23971,3,3,,103165765,2818,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
1053,24452,4,3,,103165765,2818,Unspecified,,,,,logY value was determined,Other,14695828.0,
1054,26296,4,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
1055,26304,4,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
1056,26362,4,3,,103165765,2818,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
1057,26517,3,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD) (HPLC),Other,6167716.0,
1058,26522,3,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD) (HPLC),Other,6167716.0,
1059,27370,6,2,,103165765,2818,Unspecified,,,,,Lethal dose after peroral administration in mouse,Other,2869146.0,
1060,28233,3,3,,103165765,2818,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
1061,28234,3,4,,103165765,2818,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
1062,28235,3,3,,103165765,2818,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
1063,28236,3,3,,103165765,2818,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
1064,28679,3,4,,103165765,2818,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
1065,28924,3,3,,103165765,2818,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
1066,28925,3,3,,103165765,2818,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
1067,29337,3,3,,103165765,2818,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
1068,29359,3,3,,103165765,2818,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
1069,29423,3,4,,103165765,2818,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
1070,29811,4,3,,103165765,2818,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
1071,29925,5,2,,103165765,2818,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
1072,33271,7,5,,103165765,2818,Active,231461.0,25083.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1073,33271,7,5,,103165765,2818,Active,231464.0,24175.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1074,33271,7,5,,103165765,2818,Active,543734.0,24173.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1075,33271,7,5,,103165765,2818,Active,1168244.0,29413.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1076,33271,7,5,,103165765,2818,Active,1168247.0,29412.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1077,33271,7,5,,103165765,2818,Active,47117345.0,24174.0,0.017,IC50,Compound was evaluated In vitro for its activity by binding to Alpha adrenergic receptor in the rat brain using [3H]prazosin as radioligand.,Confirmatory,1676427.0,
1078,35191,7,5,,103165765,2818,Active,231461.0,25083.0,0.057999999999999996,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1079,35191,7,5,,103165765,2818,Active,231464.0,24175.0,0.057999999999999996,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1080,35191,7,5,,103165765,2818,Active,47117345.0,24174.0,0.057999999999999996,Ki,Binding affinity towards alpha-2 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1081,35270,7,2,,103165765,2818,Active,,,0.0036,Ki,Compound was tested for the binding affinity against rat cortical Alpha-1 adrenergic receptor by radioligand [3H]prazosin binding assay.,Confirmatory,8709107.0,
1082,35274,7,2,,103165765,2818,Active,,,0.0014,Ki,Evaluated for binding affinity against alpha-1 adrenergic receptor,Confirmatory,10893315.0,
1083,35276,7,5,,103165765,2818,Active,543734.0,24173.0,0.0089,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1084,35276,7,5,,103165765,2818,Active,1168244.0,29413.0,0.0089,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1085,35276,7,5,,103165765,2818,Active,1168247.0,29412.0,0.0089,Ki,Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1086,35277,7,5,,103165765,2818,Active,543734.0,24173.0,0.0056,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1087,35277,7,5,,103165765,2818,Active,1168244.0,29413.0,0.0056,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1088,35277,7,5,,103165765,2818,Active,1168247.0,29412.0,0.0056,Ki,Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain,Confirmatory,8568801.0,
1089,35285,11,1,,103165765,2818,Active,,,0.013999999999999999,Ki,In vitro binding affinity at Alpha-1 adrenergic receptor in rat cortical tissues,Confirmatory,12408724.0,
1090,35289,7,1,,103165765,2818,Active,,,0.009000000000000001,Ki,In vitro binding affinity towards alpha-1 adrenergic receptor in rat frontal cortex homogenate using of [3H]prazosin as radioligand,Confirmatory,14695828.0,
1091,35428,7,5,,103165765,2818,Active,543734.0,24173.0,0.0014,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1092,35428,7,5,,103165765,2818,Active,1168244.0,29413.0,0.0014,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1093,35428,7,5,,103165765,2818,Active,1168247.0,29412.0,0.0014,Ki,Binding affinity towards alpha-1 adrenergic receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1094,35436,7,1,,103165765,2818,Active,,,0.0232,Ki,The compound was tested for its binding affinity towards alpha-1 adrenergic receptor by displacing [3H]WB-4101 radioligand in rat cerebral cortexc,Confirmatory,1346653.0,
1095,35637,7,1,,103165765,2818,Active,,,0.019,Ki,Binding affinity measured at the Alpha-2 adrenergic receptor by the inhibition of [3H]clonidine binding to rat cortex using unlabeled NAbitartrate for nonspecific binding.,Confirmatory,9876110.0,
1096,36016,4,1,,103165765,2818,Active,543734.0,24173.0,0.00562,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1097,36016,4,1,,103165765,2818,Active,1168244.0,29413.0,0.00562,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1098,36016,4,1,,103165765,2818,Active,1168247.0,29412.0,0.00562,Ki,Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor,Confirmatory,8568801.0,
1099,36024,7,5,,103165765,2818,Active,543734.0,24173.0,0.04,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1100,36024,7,5,,103165765,2818,Active,1168244.0,29413.0,0.04,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1101,36024,7,5,,103165765,2818,Active,1168247.0,29412.0,0.04,IC50,Binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]- WB-4101,Confirmatory,2875184.0,
1102,36113,7,2,,103165765,2818,Active,,,0.023,Ki,Binding affinity towards human alpha-1 adrenergic receptor,Confirmatory,14998318.0,
1103,36116,7,2,,103165765,2818,Active,,,0.0037,Ki,Binding affinity towards human alpha-1 adrenergic receptor,Confirmatory,11170639.0,
1104,36122,7,2,,103165765,2818,Active,,,0.011000000000000001,Ki,The compound was tested against Alpha-1 adrenergic receptor for percent displacement of radioligand at 10e-6 M,Confirmatory,10464021.0,
1105,36137,7,1,,103165765,2818,Active,,,0.055999999999999994,Ki,In vitro binding affinity towards alpha-1 adrenergic receptor by using [3H]-prazosin in rat brain cortex membranes.,Confirmatory,10649982.0,
1106,36197,7,2,,103165765,2818,Active,,,0.051,Ki,Binding affinity towards human alpha-2 adrenergic receptor,Confirmatory,11170639.0,
1107,36199,7,2,,103165765,2818,Active,,,0.16,Ki,Binding affinity towards human alpha-2 adrenergic receptor,Confirmatory,14998318.0,
1108,36422,7,2,,103165765,2818,Active,,,0.03715,Kd,Inhibition of specific [3H]prazosin binding (0.2 nM) to rat brain membranes alpha-1 adrenergic receptor,Confirmatory,6142954.0,
1109,36442,6,2,,103165765,2818,Active,,,0.004,Ki,Binding affinity at Alpha-1 adrenergic receptor in rat brain homogenates by [3H]- prazosin displacement.,Confirmatory,10999484.0,
1110,36454,7,1,,103165765,2818,Active,,,0.16,IC50,Affinity towards Alpha-1A adrenergic receptor in membranes from bovine frontal cortex using [3H]prazosin,Confirmatory,9622542.0,
1111,36588,7,2,,103165765,2818,Active,,,0.062,IC50,Ability to bind at Alpha-1 adrenergic receptor by displacing [3H]WB-4101,Confirmatory,2542551.0,
1112,36593,7,2,,103165765,2818,Active,,,0.062,IC50,Ability to inhibit [3H]WB-4101 binding to rat cortical alpha-1-adrenergic receptor,Confirmatory,2894466.0,
1113,36713,7,1,,103165765,2818,Active,,,0.004,IC50,"Binding affinity to alpha-1 adrenergic receptor from rat brain homogenate, using [3H]- prazosin as the competitive ligand",Confirmatory,11052797.0,
1114,36730,9,2,,103165765,2818,Active,,,0.032,IC50,Its affinity towards alpha-1 receptor using [3H]WB-4101 as radioligand in whole brain minus cerebellum,Confirmatory,7914536.0,
1115,36769,7,2,,103165765,2818,Active,,,0.0232,Ki,Binding affinity towards Alpha-1A adrenergic receptor was determined using [3H]prazosin as radioligand,Confirmatory,7473548.0,
1116,36778,7,5,,103165765,2818,Active,231461.0,25083.0,0.04,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1117,36778,7,5,,103165765,2818,Active,231464.0,24175.0,0.04,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1118,36778,7,5,,103165765,2818,Active,47117345.0,24174.0,0.04,IC50,Binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- clonidine,Confirmatory,2875184.0,
1119,36847,7,2,,103165765,2818,Active,,,0.062,IC50,In vitro affinity for cortical alpha-1 adrenergic receptor labelled with [3H]WB-4101,Confirmatory,2869146.0,
1120,36849,7,1,,103165765,2818,Active,,,0.0092,IC50,Binding affinity towards alpha-1 adrenergic receptor from rat brain membranes using [3H]prazosin as radioligand,Confirmatory,10377229.0,
1121,36865,7,2,,103165765,2818,Active,,,0.062,IC50,In vitro inhibitory concentration against radioligand [3H]WB-4101 binding to rat cortical alpha-1 adrenergic receptor,Confirmatory,1361578.0,
1122,36890,7,1,,103165765,2818,Active,,,0.022000000000000002,Ki,Binding affinity measured at the Alpha-1A adrenergic receptor by the inhibition of [3H]prazosin binding to rat cortex using unlabeled WB-4101 for nonspecific binding.,Confirmatory,9876110.0,
1123,36922,9,2,,103165765,2818,Active,,,1.4,IC50,Inhibition of specific [3H]clonidine binding (0.4 nM) to rat brain membranes Alpha-2 adrenergic receptor,Confirmatory,6142954.0,
1124,37001,7,5,,103165765,2818,Active,543734.0,24173.0,0.0092,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1125,37001,7,5,,103165765,2818,Active,1168244.0,29413.0,0.0092,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1126,37001,7,5,,103165765,2818,Active,1168247.0,29412.0,0.0092,IC50,Inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat brain membranes,Confirmatory,9406603.0,
1127,37014,7,2,,103165765,2818,Active,,,0.0092,IC50,"Binding affinity against Alpha-1 adrenergic receptor, activity is expressed as IC50 values",Confirmatory,7473566.0,
1128,37319,7,5,,103165765,2818,Active,543734.0,24173.0,0.004,Ki,Displacement of [3H]prazosin from alpha-1 adrenergic receptor of rat brain homogenate,Confirmatory,12639562.0,
1129,37319,7,5,,103165765,2818,Active,1168244.0,29413.0,0.004,Ki,Displacement of [3H]prazosin from alpha-1 adrenergic receptor of rat brain homogenate,Confirmatory,12639562.0,
1130,37319,7,5,,103165765,2818,Active,1168247.0,29412.0,0.004,Ki,Displacement of [3H]prazosin from alpha-1 adrenergic receptor of rat brain homogenate,Confirmatory,12639562.0,
1131,37361,7,2,,103165765,2818,Active,,,0.23,Ki,Compound was tested for the binding affinity against rat cortical Alpha-2 adrenergic receptor by Radio ligand ([3H]Rx-821002) binding assay,Confirmatory,8709107.0,
1132,37370,7,5,,103165765,2818,Active,231461.0,25083.0,0.128,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1133,37370,7,5,,103165765,2818,Active,231464.0,24175.0,0.128,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1134,37370,7,5,,103165765,2818,Active,47117345.0,24174.0,0.128,Ki,Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1135,37376,7,1,,103165765,2818,Active,,,0.128,Ki,In vitro binding affinity towards alpha-2 adrenergic receptor in rat frontal cortex homogenate using of [3H]clonidine as radioligand,Confirmatory,14695828.0,
1136,37472,7,1,,103165765,2818,Active,,,0.0014,Ki,Binding affinity against Alpha-1 adrenergic receptor from rat cerebral cortex,Confirmatory,9622541.0,
1137,40399,4,10,,103165765,2818,Unspecified,114754.0,24925.0,10.0,IC50,Binding affinity against beta-1 adrenergic receptor in rat brain using [3H]DHA,Confirmatory,2875184.0,
1138,40406,7,1,,103165765,2818,Active,,,26.0,Ki,Binding affinity measured at the Beta-1 adrenergic receptor by the inhibition of [3H]DHA binding to rat cortex using unlabeled isoprenalin for nonspecific binding.,Confirmatory,9876110.0,
1139,41353,4,10,,103165765,2818,Unspecified,114768.0,24176.0,10.0,IC50,Binding affinity against beta-2 adrenergic receptor in rat brain using [3H]DHA,Confirmatory,2875184.0,
1140,41749,4,7,,103165765,2818,Unspecified,,,10.0,Ki,Compound was tested for the binding affinity against rat cortical beta receptor by radioligand [3H]dihydroalprenolol binding assay.,Confirmatory,8709107.0,
1141,51563,3,3,,103165765,2818,Unspecified,,,,,Extrapyramidal side effect test in cebus monkey,Other,2875184.0,
1142,51566,3,3,,103165765,2818,Unspecified,,,,,Minimal effective dose required for signs of EPS in cebus monkeys,Other,2866248.0,
1143,51567,3,3,,103165765,2818,Unspecified,,,,,Number of animals showing dyskinesias was determined in haloperidol sensitized 11 cebus monkeys after (po) administration of 40 mg/kg,Other,11462978.0,
1144,51570,3,3,,103165765,2818,Unspecified,,,,,Number of animals showing dyskinesias was determined in haloperidol sensitized 13 cebus monkeys after (po) administration of 10 mg/kg,Other,11462978.0,
1145,51571,3,3,,103165765,2818,Unspecified,,,,,Number of animals showing dyskinesias was determined in haloperidol sensitized 13 cebus monkeys after (po) administration of 20 mg/kg,Other,11462978.0,
1146,59386,5,2,,103165765,2818,Active,,,,,Compound was tested for inhibition of emesis test in dogs administered perorally; antiemetic,Other,2875184.0,
1147,59858,6,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine induced emesis in dogs when administered perorally,Other,2891853.0,
1148,60527,3,3,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine induced emesis in dogs at 1 mg/kg of dose.,Other,2891853.0,
1149,61024,7,1,,103165765,2818,Active,,,0.192,IC50,"Binding activity against Dopamine receptor D1 in rat brain, using [3H]SCH-23390 as the radioligand",Confirmatory,2571728.0,
1150,61027,8,5,,103165765,2818,Active,118229.0,24316.0,0.192,IC50,Binding affinity against Dopamine receptor D1 using [3H]-SCN 23390 in rat brain,Confirmatory,1967652.0,
1151,61046,7,3,,103165765,2818,Unspecified,,,,,Compound was tested in vivo for methyl phenidate-induced gnawing behavior antagonistic activity against dopamine receptor D2 in mice,Other,1348090.0,
1152,61049,8,5,,103165765,2818,Active,341940463.0,13489.0,0.29,IC50,Inhibition of mouse Dopamine receptor D2,Confirmatory,8941382.0,
1153,61079,7,2,,103165765,2818,Active,,,0.04571,Ki,Binding affinity against dopamine D2 receptor,Confirmatory,7907148.0,
1154,61148,7,1,,103165765,2818,Active,,,0.42,Ki,Ability to displace D1 selective radioligand [3H]-SCH- 23390 in bovine striatal membrane preparations was determined,Confirmatory,10450964.0,
1155,61151,7,3,,103165765,2818,Active,,,0.13,IC50,Binding affinity towards D1 CNS receptor of rat corpus striatum using [3H]SCH-23390 as radioligand,Confirmatory,10377229.0,
1156,61158,4,1,,103165765,2818,Active,,,0.16982,Ki,In vitro ability to displace [3H]SCH-23390 binding from Dopamine 1 (D1) receptor in rat striatal membrane.,Confirmatory,10425088.0,
1157,61159,3,8,,103165765,2818,Active,,,,,Dopamine D1 (SCH-23390) receptor binding affinity,Other,,
1158,61161,3,8,,103165765,2818,Active,,,,,Compound was tested for dopamine D1 (spiroperidol) receptor binding affinity,Other,,
1159,61193,8,5,,103165765,2818,Active,118229.0,24316.0,0.13,IC50,Inhibitory binding of [3H]SCH-23390 to Dopamine receptor D1 in membranes from rat corpus striatum,Confirmatory,9406603.0,
1160,61199,7,2,,103165765,2818,Active,,,0.13,IC50,"Binding affinity for dopamine receptor D1, activity is expressed as IC50 values.",Confirmatory,7473566.0,
1161,61231,6,3,,103165765,2818,Unspecified,,,,,"Compound was tested for antagonism of apomorphine-induced stereotyped behavior, after intraperitoneal dosing; 22-31",Other,2565399.0,
1162,61236,7,3,,103165765,2818,Unspecified,,,,,Compound was tested in vivo for induction of catalepsy against dopamine receptor D2 in rats,Other,1348090.0,
1163,61316,7,1,,103165765,2818,Active,,,0.155,Ki,In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.,Confirmatory,9871530.0,
1164,61317,9,5,,103165765,2818,Active,118206.0,1813.0,0.25,Ki,Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor,Confirmatory,,
1165,61326,7,2,,103165765,2818,Active,,,0.44,IC50,Compound was tested in vitro for its affinity towards rat striatal Dopamine receptor D2 labeled with [3H]- spiperone,Confirmatory,2869146.0,
1166,61365,7,2,,103165765,2818,Active,,,0.043,Ki,Affinity was evaluated as inhibition constant for dopamine receptor D1 using [3H]-SCH- 23390 as radioligand,Confirmatory,8064797.0,
1167,61375,7,3,,103165765,2818,Active,,,0.235,Ki,Binding affinity measured at the Dopamine receptor D1 by the inhibition of [3H]SCH-23390 binding to rat striatum using unlabeled apomorphine for nonspecific binding.,Confirmatory,9876110.0,
1168,61376,7,1,,103165765,2818,Active,,,0.17,Ki,"Binding affinity of [3H]SCH-23,390 towards Dopamine receptor D1 in cloned mammalian receptor expressed in cultured cells or from rat whole brain.",Confirmatory,8691438.0,
1169,61381,7,3,,103165765,2818,Active,,,0.44,IC50,Ability to bind at dopamine receptor D2 of rat corpus striatum by displacing [3H]spiperone,Confirmatory,2542551.0,
1170,61385,7,2,,103165765,2818,Active,,,0.4,IC50,Ability to inhibit [3H]spiperone binding to Dopamine receptor D2 in rat corpus striatum,Confirmatory,2894466.0,
1171,61388,7,2,,103165765,2818,Active,,,0.83,IC50,Affinity for dopamine receptor D2 binding sites by its ability to displace [3H]spiperone from rat striatum.,Confirmatory,7707315.0,
1172,61401,7,1,,103165765,2818,Active,,,2.77,IC50,"Binding activity against dopamine D2 receptor in rat brain, using [3H]spiperone as the radioligand",Confirmatory,2571728.0,
1173,61415,9,1,,103165765,2818,Active,,,1.61,IC50,Binding affinity towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand,Confirmatory,8831770.0,
1174,61502,7,1,,103165765,2818,Active,,,0.353,Ki,Binding affinity which represents concentration giving half-maximal inhibition of [3H]SCH-23390 (Dopamine receptor D1) binding to rat tissue homogenate,Confirmatory,9748351.0,
1175,61517,7,1,,103165765,2818,Active,,,0.35,Ki,Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate,Confirmatory,11784139.0,
1176,61521,9,1,,103165765,2818,Active,,,0.115,Ki,In vitro binding affinity against Dopamine receptor D1 in rat striatal tissue,Confirmatory,8101877.0,
1177,61527,8,1,,103165765,2818,Active,,,0.353,Ki,In vitro binding affinity towards Dopamine receptor D1 in rat tissue homogenate using [3H]-SCH- 23390 as radioligand,Confirmatory,14695828.0,
1178,61544,8,5,,103165765,2818,Active,47117674.0,24318.0,2.77,IC50,Binding affinity for Dopamine receptor D2 using [3H]spiperone in rat brain,Confirmatory,1967652.0,
1179,61547,7,1,,103165765,2818,Active,,,0.172,IC50,Compound was evaluated In vitro for its activity by binding to Dopamine receptor D2 in the rat brain using [3H]NPA as radioligand.,Confirmatory,1676427.0,
1180,61552,9,1,,103165765,2818,Active,,,0.25,IC50,Inhibition of [3H]spiperone binding to Dopamine receptor D2 from striatum of the rat brain,Confirmatory,2573732.0,
1181,61562,9,3,,103165765,2818,Active,,,1.0,IC50,Compound was measured for affinity at dopamine receptor D2 labeled with [3H]spiroperidol radioligand in striatum tissue,Confirmatory,1672156.0,
1182,61623,7,2,,103165765,2818,Active,,,0.359,Ki,Binding affinity to the dopamine receptor D2L in rat brain membranes,Confirmatory,10464021.0,
1183,61624,7,1,,103165765,2818,Active,,,0.96,Ki,Ability to displace [3H]spiperone from the cloned human D3 dopamine receptor stably expressed in Chinese hamster ovary (CHO) cells was determined.,Confirmatory,10450964.0,
1184,61645,8,3,,103165765,2818,Inconclusive,,,,,Tested for the effective concentration against CHO 10001 cells in human D4.2 receptor established in mitogenesis assay; ND=Not determined,Other,11844688.0,
1185,61675,5,1,,103165765,2818,Active,,,0.35481,Ki,Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate,Confirmatory,11784139.0,
1186,61679,5,1,,103165765,2818,Active,,,0.31623,Ki,pKi value for Dopamine receptor D1 binding site,Confirmatory,9748351.0,
1187,61788,7,1,,103165765,2818,Active,,,0.047,Ki,In vitro binding affinity at human D4 dopamine receptor in CHO cells by [3H]spiperone displacement.,Confirmatory,9871530.0,
1188,61789,9,3,,103165765,2818,Active,,,0.07200000000000001,Ki,Potency was measured by the displacement of [3H]-spiperone binding to human D4 dopaminergic receptor,Confirmatory,,
1189,61801,8,3,,103165765,2818,Inconclusive,,,,,Agonist effect on the Dopamine D4.2 receptor was determined by evaluating effective concentration causing stimulation of mitogenesis; ND: not determined,Other,11549463.0,
1190,61804,7,2,,103165765,2818,Active,,,0.052000000000000005,IC50,Binding affinity towards human D4.2 receptor,Confirmatory,10377229.0,
1191,61806,3,8,,103165765,2818,Unspecified,,,,,Intrinsic activity as rate of incorporation of [3H]thymidine in human D4.2 receptor established in mitogenesis assay relative to quinpirole,Other,11844688.0,
1192,61807,3,8,,103165765,2818,Unspecified,,,,,Agonist effect for Dopamine D4.2 receptor determined as rate of incorporation of [3H]- thymidine relative to quinpirole,Other,11549463.0,
1193,61808,7,2,,103165765,2818,Active,,,0.04,Ki,Binding affinity towards human dopamine-4.2 receptor,Confirmatory,14998318.0,
1194,61814,9,2,,103165765,2818,Active,,,9.0,Ki,Binding affinity towards Dopamine Receptor D4 was determined via standard competitive displacement assays using [3H]-YM 09151 as the competitive ligand,Confirmatory,12372513.0,
1195,61846,3,7,,103165765,2818,Unspecified,,,,,Selectivity ratio for Dopamine receptor D1 to Dopamine receptor D2),Other,11784139.0,
1196,62007,8,5,,103165765,2818,Active,1706283.0,,0.254,Ki,Displacement of [3H]-YM 09151 from african green monkey Dopamine receptor D2,Confirmatory,8523409.0,
1197,62009,8,1,,103165765,2818,Active,1706283.0,,0.254,Ki,Displacement of [3H]YM-09151 from recombinant African green monkey Dopamine receptor D2,Confirmatory,7783157.0,
1198,62164,9,1,,103165765,2818,Active,,,0.45,IC50,"Competition in vitro with the dopamine receptor D2 antagonist [3H]spiperone, for binding sites on calf caudate membranes.",Confirmatory,8096548.0,
1199,62168,7,1,,103165765,2818,Active,,,0.14,IC50,Affinity towards Dopamine receptor D2 in membranes from bovine striatum using [3H]raclopride,Confirmatory,9622542.0,
1200,62174,9,2,,103165765,2818,Active,,,0.25,IC50,"Inhibitory activity against dDopamine receptor D2 in calf caudate tissue, using [3H]spiperone as the radioligand",Confirmatory,2571731.0,
1201,62331,7,2,,103165765,2818,Active,,,0.69,Ki,Binding affinity was evaluated for the displacement of [3H]spiperone against bovine Dopamine receptor D2,Confirmatory,9990464.0,
1202,62443,8,2,,103165765,2818,Active,,,0.18,IC50,Inhibition of binding of 1.6 nM [3H]haloperidol to dopamine receptor by 50%,Confirmatory,7288826.0,
1203,62444,8,2,,103165765,2818,Active,,,8.0,IC50,Inhibition of binding of 5 nM [3H]dopamine to dopamine receptor by 50%,Confirmatory,7288826.0,
1204,62445,9,2,,103165765,2818,Active,,,8.0,IC50,Inhibition of [3H]dopamine binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
1205,62446,9,2,,103165765,2818,Active,,,0.18,IC50,Inhibition of [3H]haloperidol binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
1206,62465,3,8,,103165765,2818,Unspecified,,,,,Ratio of IC50 evaluated by using [3H]DA to [3H]-HP,Other,7288826.0,
1207,62581,7,1,,103165765,2818,Active,,,,,Dopamine receptor antagonist activity in the superfused rabbit ear artery preparation,Other,7252977.0,
1208,62722,7,2,,103165765,2818,Active,,,0.0606,IC50,Inhibition of [3H]haloperidol binding to dopamine receptors in rat striatal membranes.,Confirmatory,2859371.0,
1209,62768,7,2,,103165765,2818,Active,,,0.113,IC50,"Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand",Confirmatory,11052797.0,
1210,62769,7,2,,103165765,2818,Active,,,0.26,IC50,Binding affinity towards human Dopamine receptor D2,Confirmatory,10377229.0,
1211,62771,7,2,,103165765,2818,Active,,,0.23,IC50,In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.,Confirmatory,9822559.0,
1212,62868,7,2,,103165765,2818,Active,,,0.89,IC50,Inhibition of [3H]spiperone binding to dopamine receptor from rat corpus striatal membranes,Confirmatory,6131130.0,
1213,62876,7,5,,103165765,2818,Active,118211.0,29238.0,4.31,IC50,Relative affinity for dopamine receptor by displacement of [3H]spiroperidol (2.2 nM) from (in vitro) dopamine binding sites in rat caudate nuclei,Confirmatory,7288815.0,
1214,62876,7,5,,103165765,2818,Active,118229.0,24316.0,4.31,IC50,Relative affinity for dopamine receptor by displacement of [3H]spiroperidol (2.2 nM) from (in vitro) dopamine binding sites in rat caudate nuclei,Confirmatory,7288815.0,
1215,62876,7,5,,103165765,2818,Active,118251.0,25195.0,4.31,IC50,Relative affinity for dopamine receptor by displacement of [3H]spiroperidol (2.2 nM) from (in vitro) dopamine binding sites in rat caudate nuclei,Confirmatory,7288815.0,
1216,62876,7,5,,103165765,2818,Active,6226851.0,25432.0,4.31,IC50,Relative affinity for dopamine receptor by displacement of [3H]spiroperidol (2.2 nM) from (in vitro) dopamine binding sites in rat caudate nuclei,Confirmatory,7288815.0,
1217,62876,7,5,,103165765,2818,Active,47117674.0,24318.0,4.31,IC50,Relative affinity for dopamine receptor by displacement of [3H]spiroperidol (2.2 nM) from (in vitro) dopamine binding sites in rat caudate nuclei,Confirmatory,7288815.0,
1218,62882,7,5,,103165765,2818,Active,118211.0,29238.0,4.31,IC50,Displacement of 3[H]spiroperidol from Dopamine receptor in rat brain,Confirmatory,7108902.0,
1219,62882,7,5,,103165765,2818,Active,118229.0,24316.0,4.31,IC50,Displacement of 3[H]spiroperidol from Dopamine receptor in rat brain,Confirmatory,7108902.0,
1220,62882,7,5,,103165765,2818,Active,118251.0,25195.0,4.31,IC50,Displacement of 3[H]spiroperidol from Dopamine receptor in rat brain,Confirmatory,7108902.0,
1221,62882,7,5,,103165765,2818,Active,6226851.0,25432.0,4.31,IC50,Displacement of 3[H]spiroperidol from Dopamine receptor in rat brain,Confirmatory,7108902.0,
1222,62882,7,5,,103165765,2818,Active,47117674.0,24318.0,4.31,IC50,Displacement of 3[H]spiroperidol from Dopamine receptor in rat brain,Confirmatory,7108902.0,
1223,62884,7,5,,103165765,2818,Active,118211.0,29238.0,0.247,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1224,62884,7,5,,103165765,2818,Active,118229.0,24316.0,0.247,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1225,62884,7,5,,103165765,2818,Active,118251.0,25195.0,0.247,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1226,62884,7,5,,103165765,2818,Active,6226851.0,25432.0,0.247,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1227,62884,7,5,,103165765,2818,Active,47117674.0,24318.0,0.247,IC50,Displacement of [3H]spiroperidol from Dopamine receptor of rat striatum membrane,Confirmatory,6128416.0,
1228,62887,3,6,,103165765,2818,Unspecified,,,,,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate at a dose of 10E-8 M,Other,2866248.0,
1229,62888,4,7,,103165765,2818,Unspecified,,,,,Inhibition of [3H]haloperidol binding to dopamine receptors in rat striatal membranes at 10e-8 M.,Other,2859371.0,
1230,62901,7,1,,103165765,2818,Active,,,0.040999999999999995,Ki,Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells,Confirmatory,12113813.0,
1231,62903,7,1,,103165765,2818,Active,,,0.027999999999999997,Ki,Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells,Confirmatory,12113813.0,
1232,62908,7,1,,103165765,2818,Active,,,0.091,Ki,Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.,Confirmatory,9276014.0,
1233,62909,8,5,,103165765,2818,Active,118206.0,1813.0,0.07400000000000001,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells,Confirmatory,8642551.0,
1234,62910,7,1,,103165765,2818,Active,,,0.07400000000000001,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells,Confirmatory,10340615.0,
1235,62913,7,2,,103165765,2818,Active,,,0.22,Ki,Affinity was evaluated as inhibition constant for dopamine D-2 receptor,Confirmatory,8064797.0,
1236,62914,7,1,,103165765,2818,Active,,,0.07400000000000001,Ki,Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines,Confirmatory,10411491.0,
1237,62917,7,1,,103165765,2818,Active,,,0.091,Ki,Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.,Confirmatory,9406594.0,
1238,62928,7,1,,103165765,2818,Active,,,0.040999999999999995,Ki,In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.,Confirmatory,11844688.0,
1239,62929,7,1,,103165765,2818,Active,,,0.027999999999999997,Ki,In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.,Confirmatory,11844688.0,
1240,63020,7,2,,103165765,2818,Active,,,0.32,Ki,In vitro ability to displace [3H]spiroperidol from rat dopamine receptor,Confirmatory,7154006.0,
1241,63022,3,7,,103165765,2818,Unspecified,,,,,Compound was tested for its effect on dopamine receptor in rat at (10 mg/kg + 250 mg/lg of alpha-methyl-p-tyrosine ) dose after intraperitoneal administration,Other,2875184.0,
1242,63023,3,7,,103165765,2818,Unspecified,,,,,Compound was tested for its effect on dopamine receptor in rat at dose of 10 mg/kg ip,Other,2875184.0,
1243,63024,7,5,,103165765,2818,Active,118211.0,29238.0,0.03,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1244,63024,7,5,,103165765,2818,Active,118229.0,24316.0,0.03,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1245,63024,7,5,,103165765,2818,Active,118251.0,25195.0,0.03,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1246,63024,7,5,,103165765,2818,Active,6226851.0,25432.0,0.03,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1247,63024,7,5,,103165765,2818,Active,47117674.0,24318.0,0.03,IC50,Binding affinity against dopamine receptor in rat striatal membrane using [3H]haloperidol,Confirmatory,2875184.0,
1248,63028,7,5,,103165765,2818,Active,118211.0,29238.0,0.06,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1249,63028,7,5,,103165765,2818,Active,118229.0,24316.0,0.06,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1250,63028,7,5,,103165765,2818,Active,118251.0,25195.0,0.06,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1251,63028,7,5,,103165765,2818,Active,6226851.0,25432.0,0.06,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1252,63028,7,5,,103165765,2818,Active,47117674.0,24318.0,0.06,IC50,Ability to inhibit [3H]haloperidol binding to dopamine receptor in rat striatal homogenate,Confirmatory,2866248.0,
1253,63047,7,2,,103165765,2818,Active,,,0.42,Ki,"Ability to displace [3H]SCH-23,390 radioligand from bovine Dopamine receptor D1",Confirmatory,12113813.0,
1254,63053,7,3,,103165765,2818,Active,,,0.113,Ki,Displacement of [3H]-YM 09151 from D2 receptor,Confirmatory,12639562.0,
1255,63055,8,5,,103165765,2818,Active,118206.0,1813.0,0.07400000000000001,Ki,Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1256,63060,7,2,,103165765,2818,Active,,,0.15,Ki,Binding affinity towards human Dopamine receptor D2,Confirmatory,14998318.0,
1257,63064,8,5,,103165765,2818,Active,118206.0,1813.0,0.254,Ki,Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151,Confirmatory,9016321.0,
1258,63069,8,2,,103165765,2818,Active,,,0.138,Ki,Binding affinity towards Dopamine receptor D2 was determined via standard competitive displacement assays using [3H]-YM 09151 as the competitive ligand,Confirmatory,12372513.0,
1259,63070,7,2,,103165765,2818,Active,,,0.19,Ki,Binding affinity towards human D2 dopamine receptor.,Confirmatory,11170639.0,
1260,63079,7,2,,103165765,2818,Active,,,0.113,Ki,Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.,Confirmatory,10999484.0,
1261,63087,7,2,,103165765,2818,Active,,,0.13,Ki,In vitro ability to inhibit the binding of [3H]spiperone to cloned human Dopamine receptor D2 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1262,63180,8,5,,103165765,2818,Active,110832828.0,281125.0,0.42,Ki,Displacement of [3H]SCH-23390 from Dopamine receptor D1 of bovine striatal membranes,Confirmatory,11087581.0,
1263,63181,7,2,,103165765,2818,Active,,,0.42,Ki,Binding affinity against bovine dopamine receptor D1 using radioligand [3H]-SCH- 23390,Confirmatory,11495580.0,
1264,63188,7,1,,103165765,2818,Active,,,0.42,Ki,In vitro binding affinity at human cloned dopamine receptor D1 stably expressed in CHO cells by [3H]-SCH- 23390 displacement.,Confirmatory,11844688.0,
1265,63189,7,2,,103165765,2818,Active,,,0.42,Ki,Binding affinity was evaluated for the displacement of [3H]-SCH- 23390 against bovine Dopamine receptor D1,Confirmatory,9990464.0,
1266,63190,8,5,,103165765,2818,Active,110832828.0,281125.0,0.42,Ki,Displacement of [3H]SCH-23390 from bovine striatal membrane Dopamine receptor D1,Confirmatory,10560741.0,
1267,63204,7,1,,103165765,2818,Active,,,0.42,Ki,In vitro displacement of [3H]- SCH 23390 from the dopamine receptor D1 of bovine striatal membrane,Confirmatory,10987445.0,
1268,63218,7,2,,103165765,2818,Active,,,0.26,Ki,In vitro binding affinity towards Dopamine receptor D2 in human using [3H]-spiperone as radioligand,Confirmatory,14695828.0,
1269,63226,7,1,,103165765,2818,Active,,,0.07400000000000001,Ki,Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.,Confirmatory,9240352.0,
1270,63233,3,10,,103165765,2818,Unspecified,118206.0,1813.0,,,Ratio of binding affinity for D2 and D4 dopamine receptors,Other,14736232.0,
1271,63233,3,10,,103165765,2818,Unspecified,1345939.0,1815.0,,,Ratio of binding affinity for D2 and D4 dopamine receptors,Other,14736232.0,
1272,63251,3,9,,103165765,2818,Active,118206.0,1813.0,,,Displacement of [3H]spiperone from human Dopamine receptor D2,Other,14736232.0,
1273,63345,7,2,,103165765,2818,Active,,,0.053,Ki,Binding affinity against dopamine receptor D1,Confirmatory,11170639.0,
1274,63347,7,2,,103165765,2818,Active,,,0.54,Ki,Binding affinity towards human Dopamine receptor D1,Confirmatory,14998318.0,
1275,63350,7,2,,103165765,2818,Active,,,0.18,Ki,Compound was tested for the Binding affinity against Human cloned Dopamine receptor D1 by Radio ligand ([3H]SCH-23390) binding assay,Confirmatory,8709107.0,
1276,63365,4,1,,103165765,2818,Active,,,0.16982,Ki,In vitro affinity against Dopamine receptor D1,Confirmatory,11101359.0,
1277,63371,7,2,,103165765,2818,Active,,,0.11482,Ki,Binding affinity against dopamine receptor D1,Confirmatory,7907148.0,
1278,63387,4,1,,103165765,2818,Active,,,0.1349,Ki,Cataleptogenic effect against cloned human Dopamine receptor D2 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1279,63513,7,1,,103165765,2818,Active,,,0.039,Ki,Binding affinity to Human Dopamine receptor D4 expressed in CHO cells was determined using [3H]- nemonapride as radioligand,Confirmatory,8709107.0,
1280,63514,7,1,,103165765,2818,Active,,,0.016,Ki,Binding affinity to recombinant human dopamine receptor D4 expressed in CHO cells by displacement of [3H]spiperone,Confirmatory,9406594.0,
1281,63519,7,2,,103165765,2818,Active,,,0.016,Ki,Binding affinity evaluated for the displacement of [3H]spiperone against human dopamine receptor D4,Confirmatory,9990464.0,
1282,63524,7,1,,103165765,2818,Active,,,0.036000000000000004,Ki,Binding affinity measured at the Dopamine receptor D4 by the inhibition of [3H]spiperone binding to human recombinant CHO cells using unlabeled haloperidol for nonspecific binding.,Confirmatory,9876110.0,
1283,63527,7,1,,103165765,2818,Active,,,0.016,Ki,In vitro binding affinity at human cloned dopamine receptor D4 stably expressed in CHO cells by [3H]spiperone displacement.,Confirmatory,11844688.0,
1284,63529,8,5,,103165765,2818,Active,1345939.0,1815.0,0.017,Ki,Displacement of [3H]-YM 09151 from D4 receptor,Confirmatory,12639562.0,
1285,63531,8,5,,103165765,2818,Active,1345939.0,1815.0,0.01,Ki,Binding affinity towards cloned human Dopamine receptor D4 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1286,63533,7,2,,103165765,2818,Active,,,0.03,Ki,Binding affinity towards human Dopamine receptor D4 using [3H]spiroperidol as radioligand,Confirmatory,12477356.0,
1287,63534,8,5,,103165765,2818,Active,1345939.0,1815.0,0.07,Ki,Binding affinity on human Dopamine receptor D4 expressed in CHO cells using radioligand [3H]-YM 09151,Confirmatory,9016321.0,
1288,63537,7,2,,103165765,2818,Active,,,0.04,Ki,Binding affinity towards human dopamine receptor D4,Confirmatory,11170639.0,
1289,63538,8,5,,103165765,2818,Active,1345939.0,1815.0,0.071,Ki,Displacement of [3H]-YM 09151 from human Dopamine receptor D4,Confirmatory,8523409.0,
1290,63539,7,1,,103165765,2818,Active,,,0.016,Ki,Competitive binding affinity against human Dopamine receptor D4 by displacing [3H]spiperone from CHO cells,Confirmatory,11087581.0,
1291,63542,7,2,,103165765,2818,Active,,,0.017,Ki,Binding affinity at human Dopamine receptor D4 by [3H]- YM 09151 displacement.,Confirmatory,10999484.0,
1292,63544,7,1,,103165765,2818,Active,,,0.016,Ki,In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D4 expressed in CHO cells,Confirmatory,10987445.0,
1293,63547,7,2,,103165765,2818,Active,,,0.054000000000000006,Ki,In vitro ability to inhibit the binding of [3H]spiperone to cloned human dopamine receptor D4 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1294,63549,11,1,,103165765,2818,Active,,,0.018000000000000002,Ki,In vitro binding affinity at human cloned Dopamine receptor D4 expressed in Sf9 cell membranes,Confirmatory,12408724.0,
1295,63637,3,7,,103165765,2818,Unspecified,,,,,Ratio of Ki(uM) of D2 receptor to the Ki(uM) of 5-hydroxytryptamine 2 receptor,Other,1353116.0,
1296,63682,7,1,,103165765,2818,Active,,,0.01,Ki,Ability to displace [3H]spiperone from human dopamine receptor D4 (hD4) receptor stably expressed in HEK293 cells.,Confirmatory,9240352.0,
1297,63683,7,1,,103165765,2818,Active,,,0.01,Ki,compound was tested for its affinity to displace [3H]spiperone cloned human Dopamine receptor D4 stably expressed in HEK393 cell lines,Confirmatory,10411491.0,
1298,63699,3,10,,103165765,2818,Active,1345939.0,1815.0,,,Displacement of [3H]spiperone from human Dopamine receptor D4,Other,14736232.0,
1299,63701,4,1,,103165765,2818,Active,,,0.0537,Ki,Cataleptogenic effect against cloned human dopamine receptor D4 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1300,63804,4,1,,103165765,2818,Active,47117674.0,24318.0,0.26303000000000004,Ki,Affinity against Dopamine receptor D2,Confirmatory,11101359.0,
1301,63805,4,1,,103165765,2818,Active,,,0.26303000000000004,Ki,Compound was measured for the inhibition of [3H]spiperone binding to striatal membrane Dopamine receptor D2,Confirmatory,9934473.0,
1302,63809,5,1,,103165765,2818,Active,,,0.25119,Ki,Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate,Confirmatory,11784139.0,
1303,63811,4,1,,103165765,2818,Active,47117674.0,24318.0,0.08317999999999999,Ki,Displacement of [3H]NPA from rat brain Dopamine receptor D2,Confirmatory,8568801.0,
1304,63820,4,1,,103165765,2818,Active,,,0.1,Ki,Tested in vitro for its ability to inhibit [3H]spiperone binding to Dopamine receptor D2 in rat striatal membrane,Confirmatory,,
1305,63822,4,1,,103165765,2818,Active,,,0.26303000000000004,Ki,In vitro ability to displace [3H]spiperone binding from dopamine receptor D2 in rat striatal membrane.,Confirmatory,10425088.0,
1306,63824,5,1,,103165765,2818,Active,,,0.25119,Ki,pKi value for Dopamine receptor D2 binding site,Confirmatory,9748351.0,
1307,63832,8,5,,103165765,2818,Active,6226851.0,25432.0,0.032,Ki,Binding affinity of [3H]spiperone towards Dopamine receptor D4 expressed in cultured cells or from rat whole brain.,Confirmatory,8691438.0,
1308,63833,7,1,,103165765,2818,Active,,,0.028999999999999998,Ki,Binding affinity of [3H]YM-09151 towards cloned mammalian Dopamine receptor D4 expressed in cultured cells or from rat whole brain,Confirmatory,8691438.0,
1309,63834,7,1,,103165765,2818,Active,,,0.009000000000000001,Ki,Binding affinity of [3H]-spiperone towards cloned mammalian Dopamine receptor D4 expressed in cultured cells or from rat whole brain,Confirmatory,8691438.0,
1310,63842,4,1,,103165765,2818,Active,,,0.01585,Ki,In vitro binding affinity for Dopamine receptor D4,Confirmatory,11392544.0,
1311,63856,3,10,,103165765,2818,Unspecified,1345939.0,1815.0,,,Intrinsic activity at human Dopamine D4.2 receptor as stimulation of mitogenesis,Other,12113813.0,
1312,63863,5,3,,103165765,2818,Inconclusive,,,,,Effective concentration of compound required against human Dopamine D4.2 receptor; no data,Other,12113813.0,
1313,63866,9,1,,103165765,2818,Active,,,0.057999999999999996,IC50,Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells,Confirmatory,8831770.0,
1314,63971,7,2,,103165765,2818,Active,,,0.069,Ki,Binding affinity for dopamine receptor D2 determined using [3H]spiperone,Confirmatory,11527728.0,
1315,63997,5,1,,103165765,2818,Active,,,0.22386999999999999,Ki,Binding affinity towards dopamine receptor D2,Confirmatory,14741248.0,
1316,64000,4,1,,103165765,2818,Active,,,0.03162,Ki,In vitro binding affinity for Dopamine receptor D2,Confirmatory,11392544.0,
1317,64005,9,1,,103165765,2818,Active,,,0.01,Ki,Binding affinity towards human Dopamine receptor D4.2 in CHO cells,Confirmatory,8831770.0,
1318,64010,8,5,,103165765,2818,Active,1345939.0,1815.0,0.013000000000000001,Ki,Displacement of [3H]YM-09151-2 from human Dopamine receptor D4.2 expressed in baculovirus Sf9 cells,Confirmatory,,
1319,64012,3,7,,103165765,2818,Unspecified,,,,,Agonist effect was measured by the stimulation of mitogenesis at Dopamine receptor D4.2,Other,11087581.0,
1320,64019,8,3,,103165765,2818,Inconclusive,,,,,Effective concentration for [3H]thymidine uptake in growing CHO cells stably expressing the dopamine D4.2 receptor; nd =not determined,Other,12617906.0,
1321,64020,3,7,,103165765,2818,Unspecified,,,,,In vitro functional assay measuring the [3H]thymidine uptake in growing CHO cells stably expressing the dopamine D4.2 receptor was performed,Other,12617906.0,
1322,64031,7,2,,103165765,2818,Active,,,0.016,Ki,Binding affinity against human dopamine receptor D4.4 using radioligand [3H]spiperone,Confirmatory,11495580.0,
1323,64034,7,1,,103165765,2818,Active,,,0.016,Ki,Binding affinity of compound towards human cloned Dopamine receptor D4.4 expressed in CHO cells using [3H]spiperone as radioligand,Confirmatory,10450964.0,
1324,64040,8,5,,103165765,2818,Active,1345939.0,1815.0,0.016,Ki,Displacement of [3H]spiperone from human Dopamine receptor D4.4 expressed in CHO cells,Confirmatory,10560741.0,
1325,64154,9,1,,103165765,2818,Active,,,0.045,Ki,In vitro binding affinity against Dopamine D2 receptor in rat striatal tissue.,Confirmatory,8101877.0,
1326,64177,7,2,,103165765,2818,Active,,,0.03,Ki,In vitro binding affinity at human Dopamine receptor D4.4 by [3H]YM-09151-2 displacement.,Confirmatory,10649982.0,
1327,64179,3,7,,103165765,2818,Unspecified,,,,,Ability to displace [3H]spiperone from dopamine receptor D4.4 expressed in CHO-K1 cells,Other,11312915.0,
1328,64187,7,2,,103165765,2818,Active,,,0.78,Ki,Compound was tested for the Binding affinity against Human cloned Dopamine receptor D5 by Radio ligand ([3H]SCH-23390) binding assay,Confirmatory,8709107.0,
1329,64201,7,2,,103165765,2818,Active,,,0.021,Ki,Affinity was evaluated as inhibition constant for dopamine D-4 receptor,Confirmatory,8064797.0,
1330,64264,7,2,,103165765,2818,Active,,,0.41,IC50,Compound was tested for the inhibition of [3H]spiperone binding to dopamine receptor D2,Confirmatory,1348090.0,
1331,64268,7,2,,103165765,2818,Active,,,0.29,IC50,Inhibition of [3H]raclopride binding at Dopamine receptor D2 from rat striata.,Confirmatory,8568802.0,
1332,64271,7,3,,103165765,2818,Active,,,0.33,IC50,Binding affinity towards Dopamine receptor D2 of rat corpus striatum using [3H]spiperone as radioligand,Confirmatory,10377229.0,
1333,64294,7,2,,103165765,2818,Active,,,0.038,IC50,In vitro binding affinity against Dopamine receptor D2 by displacement of [3H]haloperidol from rat striatal membranes.,Confirmatory,2888897.0,
1334,64296,8,5,,103165765,2818,Active,47117674.0,24318.0,0.13,IC50,Inhibition of [3H]methylspiperone binding to rat striatal membrane Dopamine receptor D2,Confirmatory,9876110.0,
1335,64299,7,2,,103165765,2818,Active,,,2.108,IC50,In vitro binding affinity for Dopamine D2 receptor of rat using [3H]YM-09151 as radioligand,Confirmatory,12361392.0,
1336,64325,7,1,,103165765,2818,Active,,,0.039,Ki,Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.,Confirmatory,10450964.0,
1337,64327,7,1,,103165765,2818,Active,,,0.22,Ki,Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells,Confirmatory,7861418.0,
1338,64333,7,2,,103165765,2818,Active,,,0.040999999999999995,Ki,Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone,Confirmatory,11495580.0,
1339,64334,8,5,,103165765,2818,Active,118206.0,1813.0,0.040999999999999995,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells,Confirmatory,11087581.0,
1340,64426,7,2,,103165765,2818,Active,,,0.29,IC50,In vitro binding affinity was measured by displacement of [3H]- raclopride from D2 receptor isolated from the striata of male Dawley rats,Confirmatory,7914539.0,
1341,64434,7,2,,103165765,2818,Active,,,0.44,IC50,In vitro inhibitory concentration against radioligand [3H]spiperone binding to rat striatal dopamine receptor D2,Confirmatory,1361578.0,
1342,64459,7,2,,103165765,2818,Active,,,0.132,IC50,Inhibition of spiropiperidone binding at dopamine receptor D2 of rat.,Confirmatory,11462978.0,
1343,64461,8,5,,103165765,2818,Active,47117674.0,24318.0,0.33,IC50,Inhibitory binding of [3H]spiperone to Dopamine receptor D2 in membranes from rat corpus striatum,Confirmatory,9406603.0,
1344,64470,7,1,,103165765,2818,Active,,,0.039,Ki,In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells,Confirmatory,10987445.0,
1345,64471,8,5,,103165765,2818,Active,118206.0,1813.0,0.040999999999999995,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells,Confirmatory,10560741.0,
1346,64478,11,1,,103165765,2818,Active,,,0.37200000000000005,Ki,In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes,Confirmatory,12408724.0,
1347,64479,7,1,,103165765,2818,Active,,,0.8759999999999999,Ki,"In vitro binding affinity towards Dopamine receptor D2L, using [3H]spiroperidol radioligand in Sf9 baculovirus expression.",Confirmatory,10649982.0,
1348,64616,7,2,,103165765,2818,Active,,,0.33,IC50,Binding affinity against dopamine receptor D2,Confirmatory,7473566.0,
1349,64653,7,1,,103165765,2818,Active,,,0.027999999999999997,Ki,Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.,Confirmatory,10450964.0,
1350,64661,7,2,,103165765,2818,Active,,,0.027999999999999997,Ki,Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone,Confirmatory,11495580.0,
1351,64667,7,1,,103165765,2818,Active,,,0.027999999999999997,Ki,Competitive binding affinity against human Dopamine receptor D2S by displacing [3H]spiperone from CHO cells,Confirmatory,11087581.0,
1352,64668,7,1,,103165765,2818,Active,,,0.027999999999999997,Ki,In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells,Confirmatory,10987445.0,
1353,64669,8,5,,103165765,2818,Active,118206.0,1813.0,0.027999999999999997,Ki,Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells,Confirmatory,10560741.0,
1354,64802,8,5,,103165765,2818,Active,1706286.0,,0.466,Ki,Displacement of [3H]-YM 09151 from african monkey Dopamine receptor D3,Confirmatory,8523409.0,
1355,64825,7,2,,103165765,2818,Active,,,0.45,IC50,Binding affinity towards human Dopamine receptor D3,Confirmatory,10377229.0,
1356,64958,7,1,,103165765,2818,Active,,,0.96,Ki,Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D3 in CHO cells,Confirmatory,12113813.0,
1357,64962,7,1,,103165765,2818,Active,,,0.222,Ki,Ability to displace [3H]spiperone from human cloned Dopamine receptor D3 expressed in CHO K-1 cells in vitro.,Confirmatory,9276014.0,
1358,64963,8,5,,103165765,2818,Active,1169206.0,1814.0,0.2,Ki,Displacement of [3H]spiperone from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,8642551.0,
1359,64964,7,1,,103165765,2818,Active,,,0.2,Ki,Displacement of [3H]spiperone from human Dopamine receptor D3 expressed in HEK293 cells,Confirmatory,10340615.0,
1360,64974,7,1,,103165765,2818,Active,,,0.222,Ki,Binding affinity against cloned human dopamine receptor D3 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.,Confirmatory,9406594.0,
1361,64976,7,2,,103165765,2818,Active,,,0.96,Ki,Binding affinity against dopamine receptor D3 using radioligand [3H]spiperone,Confirmatory,11495580.0,
1362,64980,7,2,,103165765,2818,Active,,,0.96,Ki,Binding affinity evaluated for the displacement of [3H]-spiperone against human dopamine receptor D3,Confirmatory,9990464.0,
1363,64984,7,1,,103165765,2818,Active,,,0.513,Ki,Binding affinity measured at the Dopamine receptor D3 by the inhibition of [3H]YM-09151-2 binding to human recombinant CCL 1.3 cells using unlabeled 7-OH-DPAT for nonspecific binding.,Confirmatory,9876110.0,
1364,64991,7,1,,103165765,2818,Active,,,0.96,Ki,In vitro binding affinity at human cloned dopamine receptor D3 stably expressed in CHO cells by [3H]spiperone displacement.,Confirmatory,11844688.0,
1365,64993,8,5,,103165765,2818,Active,1169206.0,1814.0,0.2,Ki,Binding affinity towards cloned human Dopamine receptor D3 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand,Confirmatory,8642550.0,
1366,65087,7,3,,103165765,2818,Active,,,0.09300000000000001,Ki,Binding affinity measured at the Dopamine receptor D2 by the inhibition of [3H]methylspiperone binding to rat striatum using unlabeled haloperidol for nonspecific binding.,Confirmatory,9876110.0,
1367,65088,7,1,,103165765,2818,Active,,,0.055,Ki,Binding affinity of [3H]U-86170 towards Dopamine receptor D2 in cloned mammalian receptor expressed in cultured cells or from rat whole brain,Confirmatory,8691438.0,
1368,65089,7,1,,103165765,2818,Active,,,0.08199999999999999,Ki,Binding affinity of [3H]YM-09151 towards cloned mammalian Dopamine receptor D2 expressed in cultured cells or from rat whole brain,Confirmatory,8691438.0,
1369,65090,7,1,,103165765,2818,Active,,,0.138,Ki,Binding affinity of [3H]spiperone towards cloned mammalian Dopamine receptor D2 expressed in cultured cells or from rat whole brain,Confirmatory,8691438.0,
1370,65100,7,1,,103165765,2818,Active,,,0.26,Ki,Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand,Confirmatory,8709107.0,
1371,65119,8,5,,103165765,2818,Active,1169206.0,1814.0,0.45399999999999996,Ki,Binding affinity on human Dopamine receptor D3 expressed in CHO cells using radioligand [3H]-YM 09151,Confirmatory,9016321.0,
1372,65121,7,2,,103165765,2818,Active,,,0.28,Ki,Binding affinity towards human dopamine receptor D3,Confirmatory,11170639.0,
1373,65123,7,1,,103165765,2818,Active,,,0.96,Ki,Competitive binding affinity against human Dopamine receptor D3 by displacing [3H]spiperone from CHO cells,Confirmatory,11087581.0,
1374,65131,7,1,,103165765,2818,Active,,,0.96,Ki,In vitro displacement of [3H]spiperone from the cloned human dopamine receptor D3 stably expressed in CHO cells,Confirmatory,10987445.0,
1375,65133,8,5,,103165765,2818,Active,1169206.0,1814.0,0.08800000000000001,Ki,Displacement of [125I]iodosulpiride from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,14521403.0,
1376,65137,8,5,,103165765,2818,Active,1169206.0,1814.0,0.96,Ki,Displacement of [3H]spiperone from human Dopamine receptor D3 expressed in CHO cells,Confirmatory,10560741.0,
1377,65146,7,2,,103165765,2818,Active,,,0.24,Ki,In vitro ability to inhibit the binding of [3H]7-OH-DPAT to cloned human Dopamine receptor D3 using apomorphine induced climbing test in male Swiss mice,Confirmatory,14552778.0,
1378,65247,7,2,,103165765,2818,Active,,,0.0536,Ki,Binding affinity was determined against Dopamine receptor D2 using [3H]spiperone,Confirmatory,7473547.0,
1379,65248,8,5,,103165765,2818,Active,47117674.0,24318.0,0.0536,Ki,Binding affinity was determined against Dopamine receptor D2 using [3H]spiperone,Confirmatory,7473548.0,
1380,65253,7,1,,103165765,2818,Active,,,0.25,Ki,Binding affinity which represents concentration giving half-maximal inhibition of [3H]spiperone (Dopamine receptor D2) binding to rat tissue homogenate,Confirmatory,9748351.0,
1381,65271,9,2,,103165765,2818,Active,,,0.79,Ki,Compound was evaluated for in vitro binding affinity towards Dopamine receptor D2 in rat striatum using [3H]- spiperone as radioligand,Confirmatory,1353116.0,
1382,65288,7,1,,103165765,2818,Active,,,0.2,Ki,Ability to displace [3H]spiperone from human dopamine receptor D3 (hD3) receptor stably expressed in HEK293 cells.,Confirmatory,9240352.0,
1383,65289,7,1,,103165765,2818,Active,,,0.2,Ki,compound was tested for its affinity to displace [3H]spiperone cloned human Dopamine receptor D3 stably expressed in HEK393 cell lines,Confirmatory,10411491.0,
1384,65400,7,2,,103165765,2818,Active,,,0.08199999999999999,Ki,Binding affinity against Dopamine receptor D2 from rat striatum,Confirmatory,9622541.0,
1385,65437,3,9,,103165765,2818,Active,1169206.0,1814.0,,,Displacement of [3H]7-OH-DPAT from human Dopamine receptor D3,Other,14736232.0,
1386,65443,4,1,,103165765,2818,Active,,,0.23988,Ki,Cataleptogenic effect against cloned human Dopamine receptor D3 in male Sprague-Dawley rats in a bar test,Confirmatory,14552778.0,
1387,65563,7,1,,103165765,2818,Active,,,0.25,Ki,Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate,Confirmatory,11784139.0,
1388,65564,7,2,,103165765,2818,Active,,,0.034,Ki,In vitro Dopamine receptor D2 affinity by using [3H]-Spiperone as the radioligand in rat limbic system at 1 uM concentration of compound,Confirmatory,2888898.0,
1389,65566,7,2,,103165765,2818,Active,,,0.11800000000000001,Ki,In vitro Dopamine receptor D2 affinity by using [3H]spiperone as the radioligand in rat limbic system at 1 uM concentration of compound; value may range from 113 to 362,Confirmatory,2888898.0,
1390,65608,7,1,,103165765,2818,Active,,,0.28,Ki,Binding affinity to rat Dopamine receptor D3 expressed in CHO cells was determined using [125 I] iodosulpride as radioligand,Confirmatory,8691438.0,
1391,65609,7,1,,103165765,2818,Active,,,0.23,Ki,Binding affinity to rat Dopamine receptor D3 expressed in CHO cells was determined using [125 I] iodosulpride as radioligand,Confirmatory,8709107.0,
1392,65619,7,1,,103165765,2818,Active,,,0.32,Ki,Half-maximal inhibition of [3H]-7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate,Confirmatory,11784139.0,
1393,65622,7,2,,103165765,2818,Active,,,0.319,Ki,In vitro binding affinity towards Dopamine receptor D3 in Sf9 cell membranes using [3H]7-OH-DPAT as radioligand,Confirmatory,14695828.0,
1394,65713,8,5,,103165765,2818,Active,47117674.0,24318.0,0.083,Ki,Displacement of [3H]NPA from rat brain Dopamine receptor D2,Confirmatory,8568801.0,
1395,65726,11,1,,103165765,2818,Active,,,0.034,Ki,In vitro binding affinity for dopamine receptor D2 of rat nucleus accumbens labeled with [3H]spiperone,Confirmatory,2884314.0,
1396,65733,7,1,,103165765,2818,Active,,,0.25,Ki,In vitro binding affinity towards Dopamine receptor D2 in rat tissue homogenate using [3H]-spiperone as radioligand,Confirmatory,14695828.0,
1397,65740,7,1,,103165765,2818,Active,,,0.168,Ki,In vitro binding affinity towards dopamine receptor D2 in rat striatal membranes by [3H]sulpiride displacement.,Confirmatory,7901415.0,
1398,65753,8,5,,103165765,2818,Active,118211.0,29238.0,0.5,Ki,Binding affinity towards baculovirus expressed rat dopamine D3 receptors,Confirmatory,7909336.0,
1399,65767,5,1,,103165765,2818,Active,,,0.31623,Ki,Half-maximal inhibition of [3H]7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate,Confirmatory,11784139.0,
1400,65785,7,2,,103165765,2818,Active,,,0.36,Ki,Binding affinity towards human Dopamine receptor D3,Confirmatory,14998318.0,
1401,65790,3,5,,103165765,2818,Unspecified,,,,,Selectivity ratio against Dopamine receptor D3 to Dopamine receptor D1,Other,11784139.0,
1402,65815,7,2,,103165765,2818,Active,,,0.138,Ki,"Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand",Confirmatory,12372512.0,
1403,65818,7,2,,103165765,2818,Active,,,0.009000000000000001,Ki,Binding affinity towards human dopamine D4 receptor was determined via standard competitive displacement assays using [3H]-YM 09151 as radioligand,Confirmatory,12372512.0,
1404,65899,8,5,,103165765,2818,Active,47117674.0,24318.0,0.11699999999999999,Ki,Displacement of [3H]spiperone from Dopamine receptor D2 of rat corpora striata synaptic membranes,Confirmatory,,
1405,65905,8,5,,103165765,2818,Active,47117674.0,24318.0,0.08199999999999999,Ki,Binding affinity towards dopamine D2 receptors in rat brain synaptosomal preparations,Confirmatory,7909336.0,
1406,65908,7,2,,103165765,2818,Active,,,0.0536,Ki,Binding affinity towards dopamine receptor D2 by displacing [3H]spiperone radioligand in rat striatum,Confirmatory,1346653.0,
1407,65919,4,1,,103165765,2818,Active,,,0.03802,Ki,In vitro affinity against Dopamine receptor D4,Confirmatory,11101359.0,
1408,65934,7,2,,103165765,2818,Active,,,0.017,IC50,"Binding affinity to dopamine receptor D4 cloned from human, using [3H]- YM09151 as competitive ligand",Confirmatory,11052797.0,
1409,65935,7,2,,103165765,2818,Active,,,0.023,IC50,In vitro binding affinity at human cloned Dopamine receptor D4.2 by [3H]YM-09151-2 displacement.,Confirmatory,9822559.0,
1410,65946,7,1,,103165765,2818,Active,,,0.016,Ki,Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D4 in CHO cells,Confirmatory,12113813.0,
1411,65948,7,1,,103165765,2818,Active,,,0.03,Ki,Displacement of [3H]-YM-09151-2 (0.06 nM) from human Dopamine receptor D4 expressed in CHO cells,Confirmatory,12519065.0,
1412,65950,7,1,,103165765,2818,Active,,,0.016,Ki,Ability to displace [3H]spiperone from cloned human Dopamine receptor D4 expressed in CHO K-1 cells in vitro,Confirmatory,9276014.0,
1413,65951,8,5,,103165765,2818,Active,1345939.0,1815.0,0.01,Ki,Displacement of [3H]spiperone from human Dopamine receptor D4 expressed in HEK293 cells,Confirmatory,8642551.0,
1414,65952,7,1,,103165765,2818,Active,,,0.01,Ki,Displacement of [3H]spiperone from human Dopamine receptor D4 expressed in HEK293 cells,Confirmatory,10340615.0,
1415,65954,7,1,,103165765,2818,Active,,,0.021,Ki,Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D4 in COS7 cells,Confirmatory,7861418.0,
1416,71423,4,8,,103165765,2818,Unspecified,120758.0,289606.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1417,71423,4,8,,103165765,2818,Unspecified,120761.0,24947.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1418,71423,4,8,,103165765,2818,Unspecified,120763.0,140675.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1419,71423,4,8,,103165765,2818,Unspecified,120764.0,29707.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1420,71423,4,8,,103165765,2818,Unspecified,120769.0,25450.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1421,71423,4,8,,103165765,2818,Unspecified,120782.0,140674.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1422,71423,4,8,,103165765,2818,Unspecified,120788.0,29709.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1423,71423,4,8,,103165765,2818,Unspecified,120790.0,79211.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1424,71423,4,8,,103165765,2818,Unspecified,232127.0,29708.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1425,71423,4,8,,103165765,2818,Unspecified,544363.0,29689.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1426,71423,4,8,,103165765,2818,Unspecified,3023821.0,81658.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1427,71423,4,8,,103165765,2818,Unspecified,13959374.0,65191.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1428,71423,4,8,,103165765,2818,Unspecified,51317298.0,29705.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1429,71423,4,8,,103165765,2818,Unspecified,52000955.0,24922.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1430,71423,4,8,,103165765,2818,Unspecified,52000957.0,25451.0,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1431,71423,4,8,,103165765,2818,Unspecified,81902501.0,,1.0,IC50,Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor,Confirmatory,2869146.0,
1432,87237,7,2,,103165765,2818,Active,,,0.017,Ki,Binding affinity against histamine H1 receptor,Confirmatory,11170639.0,
1433,87242,7,2,,103165765,2818,Active,,,0.0021,Ki,Binding affinity towards human histamine H1 receptor,Confirmatory,14998318.0,
1434,87514,7,1,,103165765,2818,Active,,,0.023,IC50,Binding affinity towards histamine H1 receptor from rat brain membranes using [3H]mepyramine as radioligand,Confirmatory,10377229.0,
1435,87516,7,2,,103165765,2818,Active,,,0.023,IC50,Inhibitory binding of [3H]mepyramine to histamine H1 receptors in rat brain membranes,Confirmatory,9406603.0,
1436,87528,7,2,,103165765,2818,Active,,,0.005,Ki,Compound was tested for the binding affinity against rat cortical H1 receptor by radioligand [3H]-pyrilamine binding assay.,Confirmatory,8709107.0,
1437,87530,8,5,,103165765,2818,Active,399890.0,24448.0,0.013999999999999999,Ki,Half-maximal inhibition of [3H]pyrilamine binding to Histamine H1 receptor in rat frontal cortex homogenate,Confirmatory,11784139.0,
1438,87531,7,1,,103165765,2818,Active,,,0.0029,Ki,In vitro binding affinity towards Histamine H1 receptor of rat frontal cortex homogenate by using radioligand [3H]pyrilamine,Confirmatory,14695828.0,
1439,90052,6,2,,103165765,2818,Active,,,0.018000000000000002,IC50,Binding affinity against histamine receptor was measured using radioligand ([3H]-pyrilamine) binding assay,Confirmatory,2869146.0,
1440,108860,3,3,,103165765,2818,Active,,,,,Relative CNS activity of compound was measured in mice (+++ =for activity in > 6 assays),Other,6106063.0,
1441,109037,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 10 mg/kg,Other,11462978.0,
1442,109039,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 20 mg/kg,Other,11462978.0,
1443,109040,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 40 mg/kg,Other,11462978.0,
1444,109042,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 80 mg/kg,Other,11462978.0,
1445,109187,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced swimming was determined in female swiss -Wbster mice after (po) administration of 20 mg/kg,Other,11462978.0,
1446,109188,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced swimming was determined in female swiss -Wbster mice after (po) administration of 40 mg/kg,Other,11462978.0,
1447,109190,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced swimming was determined in female swiss -Wbster mice after (po) administration of 80 mg/kg,Other,11462978.0,
1448,109197,3,3,,103165765,2818,Unspecified,,,,,Antagonism of apomorphine induced swimming was determined in female swiss -Webster mice after (po) administration of 10 mg/kg,Other,11462978.0,
1449,109889,3,3,,103165765,2818,Unspecified,,,,,"Tail suspension test in mice, dose(mg/Kg ip) = 4;duration of immobility(% vs controls)",Other,9622542.0,
1450,110209,6,2,,103165765,2818,Unspecified,,,,,Ability to inhibit apomorphine (APO) induced climbing behavior in mice by intraperitoneal administration of compound.; value may range from 1 to 23,Other,2888898.0,
1451,110212,6,2,,103165765,2818,Unspecified,,,,,Ability to inhibit apomorphine (APO) induced stereotyped behavior in mice by intraperitoneal administration of compound; value may range from 22 to 31,Other,2888898.0,
1452,110213,6,2,,103165765,2818,Unspecified,,,,,Ability to inhibit apomorphine-induced climbing behavior in mice.,Other,7707315.0,
1453,111333,4,2,,103165765,2818,Unspecified,,,,,Relative central nervous system(CNS) activity was measured in mice; Activity in >=6 assays,Other,7288826.0,
1454,112271,7,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine induced climbing affects in mice by administering the compound perorally in mice,Other,10377229.0,
1455,112272,6,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine induced climbing affects in mice by administering the compound subcutaneously in mice,Other,10377229.0,
1456,112508,6,2,,103165765,2818,Unspecified,,,,,In vivo Antipsychotic activity was quantified by induction of catalepsy in mice,Other,10425088.0,
1457,112509,6,2,,103165765,2818,Unspecified,,,,,In vivo Antipsychotic activity was quantified by inhibition of apomorphine-induced climbing(CL 95%) by mice,Other,10425088.0,
1458,112671,6,2,,103165765,2818,Unspecified,,,,,In vivo inhibition of apomorphine-induced climbing response in mice.,Other,8568802.0,
1459,112708,4,3,,103165765,2818,Unspecified,,,,,Hypothermia in mice after perorla administration,Other,6105217.0,
1460,112713,3,3,,103165765,2818,Unspecified,,,,,Tested for the apomorphine climbing behavior in mice after oral administration,Other,8096548.0,
1461,112818,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of Apomorphine induced climbing in Mice,Other,8709107.0,
1462,112949,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of apomorphine-induced climbing in mice after intraperitoneal administration,Other,2875184.0,
1463,112950,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of locomotor activity and ataxia in mice after intraperitoneal administration,Other,2875184.0,
1464,112952,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of norepinephrine lethality in mouse when administered perorally,Other,2869146.0,
1465,112953,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of physostigmine lethality in mouse when administered perorally,Other,2869146.0,
1466,112955,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in mouse when administered perorally,Other,2869146.0,
1467,112977,7,2,,103165765,2818,Unspecified,,,,,Anticholinergic activity in mice.,Other,2876098.0,
1468,113116,7,2,,103165765,2818,Unspecified,,,,,Antagonism of methyl phenidate-induced gnawing behavior in mice,Other,7473566.0,
1469,113122,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for the neuroleptic activity as measured by it's antagonism of d-amphetamine induced lethality in grouped mice(GAL) when administered perorally; 3.2-5.5,Other,6110781.0,
1470,113128,7,2,,103165765,2818,Unspecified,,,,,Sedative activity in mice,Other,2876098.0,
1471,113139,6,2,,103165765,2818,Unspecified,,,,,Compound was tested in vivo for its ability to antagonize apomorphine-induced climbing response in mice upon intraperitoneal administration,Other,9464359.0,
1472,113189,6,2,,103165765,2818,Unspecified,,,,,In vivo antipsychotic activity measured by the inhibition of apomorphine-induced climbing behavior in mice after 30 min po administration.,Other,9876110.0,
1473,113351,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose for inhibition of apomorphine-induced climbing in mice after intraperitoneal administration at a dose 20 mg/kg,Other,7914536.0,
1474,113515,9,1,,103165765,2818,Unspecified,,,,,In vivo inhibitory activity tested in apomorphine climbing mice after oral administration,Other,14695828.0,
1475,113685,6,2,,103165765,2818,Unspecified,,,,,Inhibition of ataxia in mice by intraperitoneal administration.,Other,2888897.0,
1476,113686,6,2,,103165765,2818,Unspecified,,,,,Inhibition of grooming-induced by SKF 38393 in mice.,Other,9876110.0,
1477,113687,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of head twitches-induced by 2,5-dimethoxy-4-iodoamphetamine in mice.",Other,9876110.0,
1478,113689,6,2,,103165765,2818,Unspecified,,,,,Inhibition of locomotor activity (LMA) and motor coordination in mice by intraperitoneal administration.,Other,2888897.0,
1479,113690,6,2,,103165765,2818,Unspecified,,,,,Inhibition of p-chloroamphetamine-induced hyperactivity in mice.,Other,9876110.0,
1480,113872,6,2,,103165765,2818,Unspecified,,,,,Intraperitoneal effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1481,113874,6,2,,103165765,2818,Unspecified,,,,,Intraperitoneal dose required for antagonism of d-amphetamine lethality in grouped mice (GAL),Other,6103960.0,
1482,114064,8,7,,103165765,2818,Unspecified,543728.0,15558.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1483,114064,8,7,,103165765,2818,Unspecified,341940154.0,15560.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1484,114064,8,7,,103165765,2818,Unspecified,341940463.0,13489.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1485,114064,8,7,,103165765,2818,Unspecified,550544258.0,15559.0,,,Oral effective dose required for inhibition of apomorphine-induced climbing in mice,Other,8831770.0,
1486,115620,5,2,,103165765,2818,Inactive,,,,,Inhibition of tetrabenazine induced depression in mice was following p.o. administration; Inactive.,Other,6110781.0,
1487,115755,5,2,,103165765,2818,Inactive,,,,,Minimum effective dose was measured orally by antagonism of tetrabenazine-induced depression in mice(po); inact means compound is inactive.,Other,6103960.0,
1488,115764,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity using locomotor activity (LMA)-inverted screen test in mice (i.p. admin.),Other,2866248.0,
1489,116536,4,3,,103165765,2818,Unspecified,,,,,"Lowest active dose for the inhibition of locomotor screen falloff test, ip",Other,2859371.0,
1490,116898,7,2,,103165765,2818,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105217.0,
1491,118021,4,3,,103165765,2818,Unspecified,,,,,Anticholinergic activity relative with respect to clozapine.,Other,2876098.0,
1492,118022,4,3,,103165765,2818,Unspecified,,,,,Sedative activity relative with respect to clozapine.,Other,2876098.0,
1493,119053,3,3,,103165765,2818,Unspecified,,,,,Compound was tested for the anticholinergic activity against tetrabenazine-treated mice; activity expressed as the pupil size at the dose of 100 mg/kg sc,Other,3941416.0,
1494,122934,3,3,,103165765,2818,Unspecified,,,,,"Compound was evaluated in vivo antagonism of mescaline-induced scratching(% vs controls), dose(mg/Kg ip)=4, p<0.001",Other,9622542.0,
1495,123345,3,3,,103165765,2818,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 16 (mg\\kg) in porsolt's test,Other,12408724.0,
1496,123348,3,3,,103165765,2818,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 4 (mg\\kg) in porsolt's test,Other,12408724.0,
1497,123351,3,3,,103165765,2818,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 8 (mg\\kg) in porsolt's test,Other,12408724.0,
1498,125148,3,3,,103165765,2818,Unspecified,,,,,Induction of convulsions in mice evaluated in IRWIN-test,Other,11392544.0,
1499,125149,3,3,,103165765,2818,Unspecified,,,,,Induction of sedation in mice evaluated in IRWIN-test,Other,11392544.0,
1500,125299,3,3,,103165765,2818,Unspecified,,,,,Lethality in mice evaluated in IRWIN-test,Other,11392544.0,
1501,125935,3,3,,103165765,2818,Unspecified,,,,,Anticholinergic effect evaluated in mice using oxotremorine induced salivation(ip),Other,11392544.0,
1502,126066,3,3,,103165765,2818,Unspecified,,,,,Anticholinergic effect evaluated in mice using oxotremorine induced tremors(ip),Other,11392544.0,
1503,128815,6,2,,103165765,2818,Unspecified,,,,,Antagonistic activity against amphetamine-induced Hypermobility in mouse by administering perorally,Other,2571727.0,
1504,128818,6,2,,103165765,2818,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 1 hour of peroral administration in mouse",Other,2571727.0,
1505,128819,6,2,,103165765,2818,Unspecified,,,,,"Antagonistic activity against amphetamine-induced hypermotility, after 5 hour of peroral administration in mouse",Other,2571727.0,
1506,128987,6,2,,103165765,2818,Unspecified,,,,,"Anticonvulsant activity against tryptamine-induced convulsions, after 1 hour of peroral administration in mouse",Other,2571727.0,
1507,129286,6,2,,103165765,2818,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, when administered perorally",Other,2891853.0,
1508,129759,3,3,,103165765,2818,Unspecified,,,,,Decrease in number of avoidance responses in mice at a dose ~10 mg/kg,Other,11392544.0,
1509,129762,3,3,,103165765,2818,Unspecified,,,,,Decrease in number of avoidance responses in mice at a dose ~25 mg/kg,Other,11392544.0,
1510,129763,3,3,,103165765,2818,Unspecified,,,,,Decrease in number of avoidance responses in mice at a dose ~50 mg/kg,Other,11392544.0,
1511,129967,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced climbing in mouse after intraperitoneal administration.,Other,1353116.0,
1512,129968,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced climbing in mouse after peroral administration.,Other,1353116.0,
1513,130264,4,3,,103165765,2818,Unspecified,,,,,Dose below which no catalepsy was observed at any time period (following p.o. dosing),Other,2573732.0,
1514,130265,3,3,,103165765,2818,Unspecified,,,,,Compound administered perorally was evaluated for the hypothermia (rectal temperature ) in mice,Other,2573732.0,
1515,130391,4,3,,103165765,2818,Unspecified,,,,,Hypothermia in mice after peroral administration,Other,6105216.0,
1516,130393,3,3,,103165765,2818,Unspecified,,,,,Effective dose required to evoke catalepsy in mouse when administered perorally,Other,2571731.0,
1517,130395,3,3,,103165765,2818,Unspecified,,,,,Effective dose required to produce hypothermia in mouse when administered peroral,Other,2571731.0,
1518,130696,9,1,,103165765,2818,Unspecified,,,,,In vivo inhibitory activity against 5-MeO-DMT-Induced Head-Twitches in mouse after oral administration,Other,14695828.0,
1519,130711,6,2,,103165765,2818,Unspecified,,,,,In vivo inhibition of the apomorphine-induced climbing behavior in mice,Other,11527728.0,
1520,130850,3,3,,103165765,2818,Inactive,,,,,Induction of catalepsy up to a dose of 160 mg/kg when administered po in mice; No induction,Other,11392544.0,
1521,130860,4,2,,103165765,2818,Unspecified,,,,,"3,4 -Dihydroxy phenylacetic acid (DOPAC) levels in mouse brain at 10 mg/kg dose.",Other,2891853.0,
1522,130864,7,2,,103165765,2818,Unspecified,,,,,In vivo the ability to antagonize the apomorphine induced climbing response in mice,Other,7914539.0,
1523,130873,6,2,,103165765,2818,Unspecified,,,,,"Inhibition against apomorphine-induced climbing, after 1 hour of peroral administration in mouse",Other,2571727.0,
1524,130877,6,2,,103165765,2818,Unspecified,,,,,"Inhibition against apomorphine-induced turning, after 1 hr of peroral administration in mouse",Other,2571727.0,
1525,130881,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of apomorphine induced mouse climbing, administered intraperitoneally",Other,1672156.0,
1526,130885,6,2,,103165765,2818,Unspecified,,,,,Inhibition of conditioned avoidance response in mice when administered perorally,Other,2891853.0,
1527,130911,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of spontaneous motor activity in mouse, by administering perorally",Other,2571727.0,
1528,131045,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of spontaneous motor activity, after 1 hour of peroral administration in mouse",Other,2571727.0,
1529,131046,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of spontaneous motor activity, after 5 hour of peroral administration in mouse",Other,2571727.0,
1530,131051,6,2,,103165765,2818,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 1 hour of peroral administration in mouse",Other,2571727.0,
1531,131052,7,2,,103165765,2818,Unspecified,,,,,"Inhibitory activity against tremorine-induced salivation, after 5 hour of peroral administration in mouse",Other,2571727.0,
1532,131053,6,2,,103165765,2818,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 1 hour of peroral administration in mouse",Other,2571727.0,
1533,131054,6,2,,103165765,2818,Unspecified,,,,,"Inhibitory activity against tremorine-induced tremors, after 5 hour of peroral administration in mouse",Other,2571727.0,
1534,131198,6,2,,103165765,2818,Unspecified,,,,,Concentration of compound that causes catalepsy in the mice when administered perorally,Other,2891853.0,
1535,131199,6,2,,103165765,2818,Unspecified,,,,,Concentration of compound that causes ptosis in the mice when administered perorally,Other,2891853.0,
1536,131204,6,3,,103165765,2818,Unspecified,,,,,"Contractile activity in skeletal muscles, after 1 hour of peroral administration in mouse",Other,2571727.0,
1537,131364,6,3,,103165765,2818,Unspecified,,,,,"Effect on skeletal muscle tone, after 1 hour of peroral administration in mouse",Other,2571727.0,
1538,131365,6,3,,103165765,2818,Unspecified,,,,,"Effect on skeletal muscle tone, after 5 hour of peroral administration in mouse",Other,2571727.0,
1539,131419,6,2,,103165765,2818,Unspecified,,,,,"Potentiation against pentobarbital-induced sleeping, after 1 hour of peroral administration in mouse",Other,2571727.0,
1540,131588,6,2,,103165765,2818,Unspecified,,,,,"Suppression of aggressive behavior, after 1 hour of peroral administration in mouse",Other,2571727.0,
1541,131722,6,2,,103165765,2818,Unspecified,,,,,Effective dose for inhibition of norepinephrine induced lethality in mouse,Other,1361578.0,
1542,131723,6,2,,103165765,2818,Unspecified,,,,,Effective dose for inhibition of physostigmine induced lethality in mouse,Other,1361578.0,
1543,131872,7,2,,103165765,2818,Unspecified,,,,,Effective dose required for inhibition of DOI-induced head-twitches in mice on ip administration,Other,11392544.0,
1544,131873,7,2,,103165765,2818,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced climbing in mice on ip administration",Other,11392544.0,
1545,131874,7,2,,103165765,2818,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced climbing in mice on po administration",Other,11392544.0,
1546,131875,7,2,,103165765,2818,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced stereotypy in mice on ip administration",Other,11392544.0,
1547,131876,7,2,,103165765,2818,Unspecified,,,,,"Effective dose required for inhibition of apomorphine(sc, 2.5 mg/kg ) induced stereotypy in mice on op administration",Other,11392544.0,
1548,132128,6,2,,103165765,2818,Unspecified,,,,,Tested in vivo for their ability to antagonize the apomorphine induced stereotypy response in mice,Other,7914539.0,
1549,132130,6,2,,103165765,2818,Unspecified,,,,,Tested in vivo for their ability to induction of catalepsy in mice,Other,7914539.0,
1550,132469,6,2,,103165765,2818,Unspecified,,,,,"The compound was tested for antagonistic activity against apomorphine induced climbing in the mouse, percentages are for reduction in climbing after peroral administration",Other,10464021.0,
1551,133184,3,3,,103165765,2818,Unspecified,,,,,Tested for physostigmine lethality at a dose of 15 mg/kg after oral administration in mice,Other,6128416.0,
1552,133230,3,3,,103165765,2818,Unspecified,,,,,"Suppression of aggressive behavior, after 5 hour of peroral administration in mouse at a dose of 10 mg/kg",Other,2571727.0,
1553,133400,4,2,,103165765,2818,Unspecified,,,,,The homovanillic acid (HVA)levels in mouse brain at 10 mg/kg of dose.,Other,2891853.0,
1554,133401,4,2,,103165765,2818,Unspecified,,,,,The homovanillic acid (HVA)levels in mouse brain at 50 mg/kg of dose.,Other,2891853.0,
1555,133656,4,2,,103165765,2818,Unspecified,,,,,"3,4 -Dihydroxy phenylacetic acid (DOPAC) levels in mouse brain at 50 mg/kg dose.",Other,2891853.0,
1556,133677,3,3,,103165765,2818,Unspecified,,,,,"Activity of inclined screen in mouse, after 1 hour of peroral administration in mouse",Other,2571727.0,
1557,133679,3,3,,103165765,2818,Unspecified,,,,,"Activity of inclined screen in mouse, after 5 hour of peroral administration in mouse",Other,2571727.0,
1558,133844,3,3,,103165765,2818,Unspecified,,,,,"Anticonvulsant activity against electroshock-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 26 mg/kg",Other,2571727.0,
1559,133855,3,3,,103165765,2818,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 40 mg/kg",Other,2571727.0,
1560,133859,3,3,,103165765,2818,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 5 hour of peroral administration in mouse at a dose of 40 mg/kg",Other,2571727.0,
1561,133863,3,3,,103165765,2818,Unspecified,,,,,"Anticonvulsant activity against tryptamine-induced convulsions, after 5 hour of peroral administration in mouse at a dose of 40 mg/kg",Other,2571727.0,
1562,133865,3,3,,103165765,2818,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, 10 mg/kg of dose was administered perorally",Other,2891853.0,
1563,134001,3,3,,103165765,2818,Unspecified,,,,,"Antiexploratory activity (EXPL) of mice determined by an antimex activity meter, 50 mg/kg of dose was administered perorally",Other,2891853.0,
1564,134417,7,2,,103165765,2818,Unspecified,,,,,Lethal dose in mice after perorla administration,Other,6105216.0,
1565,134515,3,4,,103165765,2818,Unspecified,,,,,"Contractile activity in skeletal muscles, after 5 hour of peroral administration in mouse at a dose of 40 mg/kg",Other,2571727.0,
1566,134580,6,2,,103165765,2818,Unspecified,,,,,Lethal dose in mice (LD50) following i.p. dosing,Other,2571727.0,
1567,140974,10,1,,103165765,2818,Active,,,0.025,Ki,In vitro binding affinity against Muscarinic acetylcholine receptors in rat brain.,Confirmatory,8101877.0,
1568,141053,7,1,,103165765,2818,Active,,,0.0094,IC50,Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells,Confirmatory,10377229.0,
1569,141055,8,5,,103165765,2818,Active,113118.0,1128.0,0.0094,IC50,Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells,Confirmatory,9406603.0,
1570,141100,7,2,,103165765,2818,Active,,,0.034,Ki,Binding affinity towards human muscarinic receptor,Confirmatory,14998318.0,
1571,141154,8,5,,103165765,2818,Inconclusive,,,,,Binding affinity measured at the Muscarinic acetylcholine receptor by the inhibition of [3H]pyrilamine binding to guinea pig cerebellum using unlabeled Triprolidine for nonspecific binding.; ND = 'Not determined',Other,9876110.0,
1572,141173,7,2,,103165765,2818,Active,,,0.00098,Ki,Binding affinity towards human M1 muscarinic receptor.,Confirmatory,11170639.0,
1573,141422,7,1,,103165765,2818,Active,,,0.051,IC50,Binding activity against muscarinic receptor in rat brain using [3H]QNB as the radioligand,Confirmatory,2571728.0,
1574,141423,7,5,,103165765,2818,Active,113121.0,25229.0,0.02,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1575,141423,7,5,,103165765,2818,Active,113127.0,24260.0,0.02,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1576,141423,7,5,,103165765,2818,Active,113130.0,25111.0,0.02,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1577,141423,7,5,,103165765,2818,Active,113132.0,53949.0,0.02,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1578,141423,7,5,,103165765,2818,Active,12643977.0,81645.0,0.02,IC50,Binding affinity against Muscarinic acetylcholine receptor in rat brain using [3H]- QNB,Confirmatory,2875184.0,
1579,141527,7,5,,103165765,2818,Active,113121.0,25229.0,0.051,IC50,Binding affinity was determined against Muscarinic acetylcholine receptor using [3H]QNB as radioligand in rat brain.,Confirmatory,1967652.0,
1580,141527,7,5,,103165765,2818,Active,113127.0,24260.0,0.051,IC50,Binding affinity was determined against Muscarinic acetylcholine receptor using [3H]QNB as radioligand in rat brain.,Confirmatory,1967652.0,
1581,141527,7,5,,103165765,2818,Active,113130.0,25111.0,0.051,IC50,Binding affinity was determined against Muscarinic acetylcholine receptor using [3H]QNB as radioligand in rat brain.,Confirmatory,1967652.0,
1582,141527,7,5,,103165765,2818,Active,113132.0,53949.0,0.051,IC50,Binding affinity was determined against Muscarinic acetylcholine receptor using [3H]QNB as radioligand in rat brain.,Confirmatory,1967652.0,
1583,141527,7,5,,103165765,2818,Active,12643977.0,81645.0,0.051,IC50,Binding affinity was determined against Muscarinic acetylcholine receptor using [3H]QNB as radioligand in rat brain.,Confirmatory,1967652.0,
1584,141548,7,5,,103165765,2818,Active,113121.0,25229.0,0.012,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to Muscarinic acetylcholine receptor in rat brain,Confirmatory,7288815.0,
1585,141548,7,5,,103165765,2818,Active,113127.0,24260.0,0.012,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to Muscarinic acetylcholine receptor in rat brain,Confirmatory,7288815.0,
1586,141548,7,5,,103165765,2818,Active,113130.0,25111.0,0.012,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to Muscarinic acetylcholine receptor in rat brain,Confirmatory,7288815.0,
1587,141548,7,5,,103165765,2818,Active,113132.0,53949.0,0.012,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to Muscarinic acetylcholine receptor in rat brain,Confirmatory,7288815.0,
1588,141548,7,5,,103165765,2818,Active,12643977.0,81645.0,0.012,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to Muscarinic acetylcholine receptor in rat brain,Confirmatory,7288815.0,
1589,141671,9,1,,103165765,2818,Active,,,0.18,IC50,"Inhibitory activity against Muscarinic acetylcholine receptor in male olac rat brain, using [3H]-QNB as the radioligand",Confirmatory,2571731.0,
1590,141680,7,1,,103165765,2818,Active,,,0.012,IC50,Tested in vitro for its ability to displace 3[H] clozapine from Muscarinic acetylcholine receptor in rat brain,Confirmatory,7108902.0,
1591,141681,7,5,,103165765,2818,Active,113121.0,25229.0,0.179,IC50,Displacement of [3H]QNB from Muscarinic acetylcholine receptor of rat brain membrane,Confirmatory,6128416.0,
1592,141681,7,5,,103165765,2818,Active,113127.0,24260.0,0.179,IC50,Displacement of [3H]QNB from Muscarinic acetylcholine receptor of rat brain membrane,Confirmatory,6128416.0,
1593,141681,7,5,,103165765,2818,Active,113130.0,25111.0,0.179,IC50,Displacement of [3H]QNB from Muscarinic acetylcholine receptor of rat brain membrane,Confirmatory,6128416.0,
1594,141681,7,5,,103165765,2818,Active,113132.0,53949.0,0.179,IC50,Displacement of [3H]QNB from Muscarinic acetylcholine receptor of rat brain membrane,Confirmatory,6128416.0,
1595,141681,7,5,,103165765,2818,Active,12643977.0,81645.0,0.179,IC50,Displacement of [3H]QNB from Muscarinic acetylcholine receptor of rat brain membrane,Confirmatory,6128416.0,
1596,141682,7,2,,103165765,2818,Active,,,0.048,IC50,The compound was tested for inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor,Confirmatory,2866248.0,
1597,141833,7,2,,103165765,2818,Active,,,0.0021,Ki,Compound was tested for the binding affinity against rat cortical Muscarinic acetylcholine receptor M1 by radioligand [3H]pirenzepine binding assay.,Confirmatory,8709107.0,
1598,141837,7,1,,103165765,2818,Active,,,0.055,Ki,Half-maximal inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor M1 in rat frontal cortex homogenate,Confirmatory,11784139.0,
1599,141838,7,1,,103165765,2818,Active,,,0.054000000000000006,Ki,In vitro binding affinity towards M1 receptor of rat frontal cortex homogenate by using radioligand [3H]QNB,Confirmatory,14695828.0,
1600,142486,6,2,,103165765,2818,Active,,,0.091,IC50,Binding affinity against Muscarinic acetylcholine receptor was measured using radioligand ([3H]QNB) binding assay,Confirmatory,2869146.0,
1601,142508,9,1,,103165765,2818,Active,,,0.18,IC50,Compound was evaluated for the inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor from male Olac rat brain.,Confirmatory,2573732.0,
1602,142687,7,2,,103165765,2818,Active,,,0.02512,Ki,Binding affinity against muscarinic (M) receptor,Confirmatory,7907148.0,
1603,142953,7,2,,103165765,2818,Active,,,0.046,Ki,Compound was tested for the binding affinity against rat heart Muscarinic acetylcholine receptor M2 by Radio ligand [3H]quinuclidinyl binding assay.,Confirmatory,8709107.0,
1604,145553,3,10,,103165765,2818,Unspecified,81907603.0,,,,Compound was tested for its effect on norepinephrine receptor in rat at (10 mg/kg + 250 mg/lg of alpha-methyl-p-tyrosine ) dose after intraperitoneal administration,Other,2875184.0,
1605,145554,3,10,,103165765,2818,Unspecified,81907603.0,,,,Compound was tested for its effect on norepinephrine receptor in rat at dose of 10 mg/kg ip,Other,2875184.0,
1606,147425,4,3,,103165765,2818,Active,,,0.013000000000000001,IC50,Tested in vitro for its ability to displace 3[H] clozapine from non-muscarinic receptor in rat brain,Confirmatory,7108902.0,
1607,147427,4,4,,103165765,2818,Active,,,0.013000000000000001,IC50,Concentration required (in vitro) to displace 50% specific binding of [3H]clozapine to non-muscarinic sites in rat brain in presence of 1 uM atropine,Confirmatory,7288815.0,
1608,161281,10,5,,103165765,2818,Active,7531135.0,3757.0,0.32359,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
1609,166854,3,7,,103165765,2818,Unspecified,,,,,Antagonist activity against norepinephrine-induced alpha-2-adrenoceptor-mediated vasoconstriction of rabbit isolated pulmonary artery.,Other,6142954.0,
1610,167198,9,2,,103165765,2818,Active,,,0.125,IC50,Inhibition of specific [3H]-prazosin binding (0.2 nM) to rat brain membranes alpha1 adrenoceptor.,Confirmatory,6142954.0,
1611,167450,7,2,,103165765,2818,Unspecified,,,,,Compound was tested for the muscle-relaxing activity in rabbits,Other,2876098.0,
1612,167992,3,3,,103165765,2818,Inactive,,,,,Effective dose for reversal of trifluoperazine-induced catalepsy in rats; I=Inactive (ED50 mg/Kg),Other,1361578.0,
1613,168347,3,3,,103165765,2818,Unspecified,,,,,Social interaction of rats was determined after 1 hr of intraperitoneal administration at 10 mg/kg,Other,7707315.0,
1614,169420,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon ip administration; value ranges from 6.5-7.5,Other,2884314.0,
1615,169426,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon po administration; value ranges from 8-17,Other,2884314.0,
1616,169429,3,3,,103165765,2818,Unspecified,,,,,Potential antipsychotic activity was assessed by measuring the ability to block the conditioned avoidance response(CAR) in rats on oral administration,Other,2888898.0,
1617,169473,3,3,,103165765,2818,Unspecified,,,,,Compound behavior in rat,Other,2573732.0,
1618,169608,3,5,,103165765,2818,Unspecified,,,,,Compound at an intraperitoneal dose of 40 mg/Kg was tested for the inhibition of apomorphine-induced stereotypy in rat,Other,8831770.0,
1619,169818,3,3,,103165765,2818,Unspecified,,,,,Compound was assessed for its ability to block a conditioned avoidance response; Dose administered perorally is 30 mg/kg; 51-75%block,Other,6105216.0,
1620,169968,3,3,,103165765,2818,Unspecified,,,,,Compound was assessed for its ability to produce catalepsy in rats; Dose administered perorally is 80; Group score is 8-15,Other,6105216.0,
1621,170121,3,3,,103165765,2818,Unspecified,,,,,Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 20 mg/kg; 51-75% block,Other,6105217.0,
1622,170880,3,3,,103165765,2818,Unspecified,,,,,Percentage change in Social interaction when compound administered at a doe of 10 mg/kg ip in rats,Other,8831770.0,
1623,170882,3,3,,103165765,2818,Unspecified,,,,,Percentage change in Social interaction when compound administered at a doe of 5 mg/kg ip in rats,Other,8831770.0,
1624,170886,3,3,,103165765,2818,Unspecified,,,,,Percentage change in Total activity (anti psychotic) when compound administered at a doe of 10 mg/kg ip in rats,Other,8831770.0,
1625,170888,3,3,,103165765,2818,Unspecified,,,,,Percentage change in Total activity (anti psychotic) when compound administered at a doe of 5 mg/kg ip in rats,Other,8831770.0,
1626,170900,3,3,,103165765,2818,Unspecified,,,,,Percentage change in chronic single unit sampling when compound given at a dose of 20 mg/kg ip in rats,Other,8831770.0,
1627,170901,3,3,,103165765,2818,Unspecified,,,,,Percentage change in chronic single unit sampling when compound given at a dose of 20 mg/kg ip in rats (Expt-2),Other,8831770.0,
1628,171232,3,3,,103165765,2818,Unspecified,,,,,Side effect liability of compound at intraperitoneal dose of 20 mg/kg on 13.7 (A9 units)dopamine neurons in the nigrostriatal in rat,Other,7707315.0,
1629,171693,3,3,,103165765,2818,Unspecified,,,,,Catalytic action on male Wistar rats after subcutaneous administration of 100 mg/kg dose of compound,Other,9406603.0,
1630,171694,3,3,,103165765,2818,Unspecified,,,,,Catalytic action on male Wistar rats after subcutaneous administration of 10 mg/kg dose of compound,Other,9406603.0,
1631,171877,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic efficacy of compound at intraperitoneal dose of 20 mg/kg on 1.8 (A10 units) dopamine neurons in the mesolimbic region of rat,Other,7707315.0,
1632,171953,3,3,,103165765,2818,Unspecified,,,,,compound was evaluated for its ability to produce catalepsy activity in rats.,Other,6105217.0,
1633,173070,3,3,,103165765,2818,Unspecified,,,,,Percent change in serum prolactin in adult male Dawley rats after intraperitoneal administration.,Other,8096548.0,
1634,173415,3,3,,103165765,2818,Unspecified,,,,,Rotarod response in rat to assess muscular incoordination (following p.o. dosing),Other,2573732.0,
1635,173417,3,3,,103165765,2818,Unspecified,,,,,Compound administered perorally was evaluated for the conditioned avoidance response in rats,Other,2573732.0,
1636,174225,3,4,,103165765,2818,Unspecified,,,,,Decrease in arterial blood pressure by the compound at a dose of 32.7 mg/kg in rats 0.5-2.5h after administration,Other,11392544.0,
1637,176178,6,2,,103165765,2818,Unspecified,,,,,Compound was tested in vivo for its ability to antagonize extrapolatory behavior impairment induced by DOPA in rats upon intraperitoneal administration,Other,9464359.0,
1638,176222,7,2,,103165765,2818,Unspecified,,,,,Effective in vivo peroral dose against induction of catalepsy in rats,Other,1361578.0,
1639,176225,7,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine-induced stereotypy in rats via peroral route,Other,1361578.0,
1640,176231,6,2,,103165765,2818,Unspecified,,,,,Effective peroral dose for inhibition of conditioned avoidance response in rats,Other,1361578.0,
1641,176251,6,2,,103165765,2818,Unspecified,,,,,Intracranial self stimulation in rat was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1642,176322,6,2,,103165765,2818,Unspecified,,,,,Blockade of apomorphine-induced stereotypy in rats when administered perorally,Other,2542551.0,
1643,176325,6,2,,103165765,2818,Unspecified,,,,,"Body weight gain, after 1 hour of peroral administration in rats",Other,2571727.0,
1644,176339,6,2,,103165765,2818,Unspecified,,,,,Compound was tested in vivo for its ability to induce catalepsy in rats upon intraperitoneal administration,Other,9464359.0,
1645,176349,7,2,,103165765,2818,Unspecified,,,,,Compound was tested or the anti-tryptamine activity in rats,Other,2876098.0,
1646,176368,6,2,,103165765,2818,Unspecified,,,,,Conditioned avoidance response (CAR) when administered perorally,Other,2542551.0,
1647,176370,6,2,,103165765,2818,Unspecified,,,,,Conditioned avoidance response activity was determined by the ability to block the conditioned avoidance of a foot shock (ip),Other,7473547.0,
1648,176371,6,2,,103165765,2818,Unspecified,,,,,Conditioned avoidance response activity was determined by the ability to block the conditioned avoidance of a foot shock (ip),Other,7473548.0,
1649,176457,6,2,,103165765,2818,Unspecified,,,,,Pole climb avoiding activity in rats was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1650,176458,6,2,,103165765,2818,Unspecified,,,,,Pole climb escape failures of rats was determined after 1 hr of intraperitoneal administration of the compound,Other,7707315.0,
1651,176478,7,2,,103165765,2818,Unspecified,,,,,Cataleptogenic effect in rats,Other,7473566.0,
1652,176499,6,2,,103165765,2818,Unspecified,,,,,Compound is measured for inhibition of catalepsy in rat by peroral administration of compound,Other,10377229.0,
1653,176500,6,2,,103165765,2818,Unspecified,,,,,Inhibition of catalepsy in rat by subcutaneous administration of compound,Other,10377229.0,
1654,176644,5,2,,103165765,2818,Inactive,,,,,"Reversal of trifluoperazine-induced catalepsy in rats when administered perorally; Inactive, maximum dose examined was 20 mg/Kg",Other,2542551.0,
1655,176733,6,2,,103165765,2818,Unspecified,,,,,Dose (administered orally) inhibiting amphetamine-induced locomotor behavior in rats,Other,8568801.0,
1656,176734,6,2,,103165765,2818,Unspecified,,,,,Dose (administered orally) inhibiting apomorphine-induced stereotypy in rats,Other,8568801.0,
1657,176735,6,2,,103165765,2818,Unspecified,,,,,Dose (administered orally) inhibiting spontaneous locomotor behavior in rats,Other,8568801.0,
1658,176743,6,2,,103165765,2818,Unspecified,,,,,Dose inducing catalepsy in rats after oral administration,Other,8568801.0,
1659,176744,6,2,,103165765,2818,Unspecified,,,,,Dose inhibiting conditioned avoidance response in rats after oral administration,Other,8568801.0,
1660,176803,6,2,,103165765,2818,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by intracranial self stimulation in rat,Other,1672156.0,
1661,176804,6,2,,103165765,2818,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by pole climb avoidance in rat,Other,1672156.0,
1662,176805,6,2,,103165765,2818,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by pole climb escape failures in rat,Other,1672156.0,
1663,177081,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for inhibition of apomorphine-induced stereotypy behavior in rats after intraperitoneal administration.,Other,1353116.0,
1664,177106,6,2,,103165765,2818,Unspecified,,,,,ED50 value for catalepsy indicates the dose required to produce a 50% of maximum catalepsy score.,Other,1346653.0,
1665,177133,6,2,,103165765,2818,Unspecified,,,,,In vivo antipsychotic activity measured by the induction of catalepsy in rats after po administration.,Other,9876110.0,
1666,177227,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for intracranial self-stimulation in rat after intraperitoneal administration.,Other,1353116.0,
1667,177251,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for pole-climb avoidance in rat after peroral administration.,Other,1353116.0,
1668,177252,6,2,,103165765,2818,Unspecified,,,,,Compound was evaluated for pole-climb avoidance (escape failures) in rat after peroral administration.,Other,1353116.0,
1669,177350,8,1,,103165765,2818,Inconclusive,,,,,In vivo inhibition against MK-801 induced hyperactivity in rats after oral administration; No data,Other,14695828.0,
1670,177351,9,1,,103165765,2818,Unspecified,,,,,In vivo inhibition against catalepsy in rats after oral administration evaluated by metal bar,Other,14695828.0,
1671,177353,9,1,,103165765,2818,Unspecified,,,,,In vivo inhibition against conditioned avoidance response in rats after oral administration,Other,14695828.0,
1672,177505,7,2,,103165765,2818,Unspecified,,,,,In vivo inhibition of apomorphine (APO) induced stereotypy in rats (po),Other,2894466.0,
1673,177509,5,2,,103165765,2818,Inactive,,,,,In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as ED50 (mg/kg); Inactive,Other,8101877.0,
1674,177555,6,2,,103165765,2818,Unspecified,,,,,Ability to block apomorphine-induced stereotypy in rats.,Other,7707315.0,
1675,177575,5,2,,103165765,2818,Inactive,,,,,Ability to reverse trifluoperazine-induced catalepsy in rat (po); IA = Compound induced catalepsy,Other,2894466.0,
1676,177623,5,3,,103165765,2818,Unspecified,,,,,Selectivity for mesolimbic over nigrostriatal dopamine system in rat brain as ventral tegmental area infusion of muscimol induced locomotor activity (LMA) by sc dose,Other,,
1677,177692,9,1,,103165765,2818,Unspecified,,,,,In vivo inhibition of spontaneous locomotory activity tested in rats after oral administration,Other,14695828.0,
1678,177715,6,2,,103165765,2818,Unspecified,,,,,In vivo suppression of the conditioned avoidance response (CAR) in rats after po administration of the compound,Other,11527728.0,
1679,177716,6,4,,103165765,2818,Unspecified,118211.0,29238.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1680,177716,6,4,,103165765,2818,Unspecified,118229.0,24316.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1681,177716,6,4,,103165765,2818,Unspecified,118251.0,25195.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1682,177716,6,4,,103165765,2818,Unspecified,6226851.0,25432.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1683,177716,6,4,,103165765,2818,Unspecified,47117674.0,24318.0,,,Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals),Other,6131130.0,
1684,177722,4,1,,103165765,2818,Unspecified,,,,,Induction of catalepsy in rats was determined after 1 hr of intraperitoneal administration at 80 mg/kg,Other,7707315.0,
1685,177726,6,2,,103165765,2818,Unspecified,,,,,Induction of catalepsy in rats when administered perorally,Other,2542551.0,
1686,177731,6,2,,103165765,2818,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 1 hour of peroral administration in rats",Other,2571727.0,
1687,177741,6,2,,103165765,2818,Unspecified,,,,,"Activity to evoke catalepsy, after 1 hour of peroral administration in rats",Other,2571727.0,
1688,177879,6,2,,103165765,2818,Unspecified,,,,,Inhibition of Sidman avoidance in rats after peroral administration,Other,2892936.0,
1689,177887,6,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine-induced stereotypy in rats.,Other,9876110.0,
1690,177895,6,2,,103165765,2818,Unspecified,,,,,Inhibition of conditioned avoidance response (CAR) in fasted male Sprague-Dawley rats.,Other,6131130.0,
1691,177928,7,4,,103165765,2818,Unspecified,118229.0,24316.0,,,Antagonism of SKF 38393-induced circling behavior in rats with unilateral 6-OHDA generated lesions,Other,7473566.0,
1692,177939,7,4,,103165765,2818,Unspecified,47117674.0,24318.0,,,Antagonism of pergolide-induced circling behavior in rats with unilateral 6-OHDA generated lesions,Other,7473566.0,
1693,177958,6,2,,103165765,2818,Unspecified,,,,,Antagonistic activity administered intraperitoneally on head twitches induced by 5- HTP,Other,7707315.0,
1694,177983,5,3,,103165765,2818,Unspecified,,,,,Compound was tested for functional dopamine antagonism in normalization assay (i.e. AS: reversal of apomorphine induced swimming ED50s in mg/kg orally),Other,,
1695,178009,7,2,,103165765,2818,Unspecified,,,,,Effective dose determined by catalepsy test in rat,Other,2859371.0,
1696,178010,7,2,,103165765,2818,Unspecified,,,,,Effective dose determined by suppression of high base-line self-stimulation in adult male hooded rats,Other,2859371.0,
1697,178150,6,2,,103165765,2818,Unspecified,,,,,"Compound was tested for antagonism of apomorphine-induced climbing behavior, after intraperitoneal dosing; 1-23",Other,2565399.0,
1698,178197,6,2,,103165765,2818,Unspecified,,,,,Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally,Other,2565400.0,
1699,178235,6,2,,103165765,2818,Unspecified,,,,,Inhibition of self stimulation response in rats when administered perorally.,Other,2891853.0,
1700,178395,6,2,,103165765,2818,Unspecified,,,,,Effective dose for ethanol potentiation in rats,Other,1361578.0,
1701,178397,6,2,,103165765,2818,Unspecified,,,,,Effective dose for inhibition of spontaneous motor activity in rats,Other,1361578.0,
1702,178399,6,2,,103165765,2818,Unspecified,,,,,Effective dose for motor incoordination in rats was determined by rotarod method,Other,1361578.0,
1703,178515,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of conditional avoid in rats after peroral administration,Other,2875184.0,
1704,178517,6,2,,103165765,2818,Unspecified,,,,,Inhibition of conditioned avoidance response (CAR),Other,2869146.0,
1705,178536,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of sidman avoid in rats after peroral administration,Other,2875184.0,
1706,178537,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of spontaneous motor activity in rat when administered perorally,Other,2869146.0,
1707,178541,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for its ability to induce catalepsy in rats.,Other,2869146.0,
1708,178681,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity determined in vivo by inhibition of amphetamine induced locomotor behavior in rats by the sc administration.,Other,1676427.0,
1709,178716,7,2,,103165765,2818,Unspecified,,,,,Compound was tested for the apomorphine antagonistic activity in rats.,Other,2876098.0,
1710,178868,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for the inhibition of apomorphine-induced stereotype,Other,2869146.0,
1711,178872,7,2,,103165765,2818,Unspecified,,,,,Compound was tested for the inhibition of quipazine-induced head twitches 24 hours after subcutaneous administration,Other,1348090.0,
1712,178987,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of the rat conditioned avoidance response, CAR (Tranquilizing activity, peroral)",Other,2894466.0,
1713,180162,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity at a dose 10 times the ED50 value for CAR block for production of catalepsy in the rat (following i.p. dosing),Other,1346653.0,
1714,180185,6,2,,103165765,2818,Unspecified,,,,,The compound was evaluated for the conditioned avoidance response data (CAR) in rat intra peritoneally,Other,7909336.0,
1715,180343,9,1,,103165765,2818,Unspecified,,,,,The compound was measured at a dose 10 times the ED50 value for CAR block for production of catalepsy in the rat via oral administration.,Other,1346653.0,
1716,180345,6,3,,103165765,2818,Unspecified,,,,,Activity against the suppression of high base line self stimulation with electrodes in the medial forebrain of the posterior hypothalamus of male hooded rats (Peroral admin.),Other,2866248.0,
1717,180347,6,2,,103165765,2818,Unspecified,,,,,The compound was tested (after peroral administration) for its ability to induce catalepsy in rats,Other,2866248.0,
1718,180521,6,2,,103165765,2818,Unspecified,,,,,The compound was tested for inhibition of sidman avoidance in rat,Other,2866248.0,
1719,180526,6,2,,103165765,2818,Unspecified,,,,,The compound was tested for its ability to induced catalepsy in rats,Other,2866248.0,
1720,180551,6,2,,103165765,2818,Unspecified,,,,,The compound was tested in vivo for induction of catalepsy in rat after ip administration,Other,10464021.0,
1721,180930,6,2,,103165765,2818,Unspecified,,,,,The percentage production of catalepsy in rat at a dose of 70 mg/kg ip.,Other,1346653.0,
1722,181083,6,2,,103165765,2818,Unspecified,,,,,compound was tested for antipsychotic activity by conditioned avoidance response(CAR) assay in rats with a pretreatment period of 30 min upon intra peritoneal administration at a concentration of 5 mg/kg.,Other,9622541.0,
1723,181085,6,2,,103165765,2818,Unspecified,,,,,compound was tested for antipsychotic activity by conditioned avoidance response(CAR) assay in rats with a pretreatment period of 30 min upon peroral administration,Other,9622541.0,
1724,181422,3,3,,103165765,2818,Unspecified,,,,,Conditioned avoidance response in rats after oral administration,Other,8096548.0,
1725,181424,3,3,,103165765,2818,Unspecified,,,,,Tested for the amphetamine induced stereotyped behavior in rats after oral administration,Other,8096548.0,
1726,181425,3,3,,103165765,2818,Unspecified,,,,,Compound was tested for the presence of catalepsy (CAT) in rats after oral administration,Other,8096548.0,
1727,181428,3,3,,103165765,2818,Unspecified,,,,,Effective dose against muscular in coordination in rats determined by rotarod test when administered peroral,Other,2571731.0,
1728,181436,3,3,,103165765,2818,Unspecified,,,,,"Inhibition of conditioned avoidance response in rats, peroral dose",Other,2571731.0,
1729,181986,3,4,,103165765,2818,Unspecified,,,,,Increase in heart rate by the compound at a dose of 10.5 mg/kg in rats,Other,11392544.0,
1730,182005,3,3,,103165765,2818,Unspecified,,,,,Compound was evaluated in vivo for its antipsychotic activity for inhibition of apomorphine-induced stereotypy in rat after intraperitoneal administration of a dose of 40 mg/kg,Other,7914536.0,
1731,182039,3,3,,103165765,2818,Unspecified,,,,,In vivo inhibition of amphetamine induced stereotypy in rat by the compound administered intraperitoneally at 50 uM,Other,1672156.0,
1732,182040,3,3,,103165765,2818,Unspecified,,,,,In vivo inhibition of apomorphine induced stereotypy in rat by the compound administered intraperitoneally at 40 uM,Other,1672156.0,
1733,182043,3,3,,103165765,2818,Unspecified,,,,,In vivo inhibition of apomorphine-mediated stereotypy in rats administered subcutaneously at 20 mg/kg expressed as percent inhibition,Other,8101877.0,
1734,182849,3,3,,103165765,2818,Unspecified,,,,,"Activity to evoke catalepsy in rats, by administering perorally at a dose of 26 mg/kg",Other,2571727.0,
1735,182856,3,3,,103165765,2818,Unspecified,,,,,"Activity to evoke catalepsy, after 5 hours of peroral administration in rats at a dose of 40 mg/kg",Other,2571727.0,
1736,183058,3,3,,103165765,2818,Unspecified,,,,,"Inhibition against conditioned avoidance response, after 5 hour of peroral administration in rats at a dose of 20 mg/kg",Other,2571727.0,
1737,183164,3,3,,103165765,2818,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 1 hour of peroral administration in rats at a dose of 20 mg/kg",Other,2571727.0,
1738,183166,3,3,,103165765,2818,Unspecified,,,,,"Antagonistic activity against amphetamine-induced stereotypy, after 5 hour of peroral administration in rats at a dose of 20 mg/kg",Other,2571727.0,
1739,183168,3,3,,103165765,2818,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 5 hour of peroral administration in rats at a dose of 80 mg/kg",Other,2571727.0,
1740,183178,3,3,,103165765,2818,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy in rats, by administering perorally at a dose of 80 mg/kg",Other,2571727.0,
1741,183180,3,3,,103165765,2818,Unspecified,,,,,"Antagonistic activity against apomorphine-induced stereotypy, after 1 hour of peroral administration in rats at a dose of 80 mg/kg",Other,2571727.0,
1742,183724,3,4,,103165765,2818,Unspecified,,,,,"Inhibitory activity in apomorphine antagonism test at a dose of 20 mg/kg, sc",Other,7907148.0,
1743,184032,3,3,,103165765,2818,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by induction of catalepsy in rat,Other,1672156.0,
1744,184035,4,2,,103165765,2818,Unspecified,,,,,In vivo activity administered intraperitoneally was determined by social interaction of rat at 5.0 uM,Other,1672156.0,
1745,184473,3,3,,103165765,2818,Unspecified,,,,,Reduction in motor activity in rats following p.o. administration.,Other,6110781.0,
1746,184476,3,3,,103165765,2818,Unspecified,,,,,Estimated oral dose depressing motor activity by 50% in rats(po),Other,6103960.0,
1747,184656,4,3,,103165765,2818,Unspecified,,,,,Compound was evaluated for the inhibition of apomorphine induced stereotypy behavior in rats after sc administration.,Other,1676427.0,
1748,184659,3,3,,103165765,2818,Inactive,,,,,Compound was evaluated for the inhibition of haloperidol induced catalepsy behavior in rats after sc administration; Inactive,Other,1676427.0,
1749,185022,3,3,,103165765,2818,Unspecified,,,,,Minimum effective dose required for significant dose dependent reduction of amphetamine-induced locomotor activity in male Sprague-Dawley rats on subcutaneous administration (30 min prior to receiving amphetamine 0.5 mg/kg),Other,12372513.0,
1750,185024,3,3,,103165765,2818,Unspecified,,,,,Minimum effective dose required in the catalepsy experiment in rats; showed no significant effect at this dose,Other,12372513.0,
1751,185044,3,3,,103165765,2818,Unspecified,,,,,Minimum effective dose that produced a significant effect relative to the amphetamine alone control using a Fisher's LSD post hoc test (P<0.05),Other,11052797.0,
1752,185207,3,3,,103165765,2818,Unspecified,,,,,Blockade of Sidman-avoidance activity in rats when administered perorally,Other,2542551.0,
1753,185209,3,3,,103165765,2818,Unspecified,,,,,Blockade of apomorphine-induced climbing in mice when administered perorally,Other,2542551.0,
1754,186188,3,3,,103165765,2818,Unspecified,,,,,"Locomotor activity in male Wistar rats after a dose of 10 uM/kg, 30 min before 1 mg/kg of apomorphine administration",Other,9406603.0,
1755,186189,3,3,,103165765,2818,Unspecified,,,,,"Locomotor activity in male Wistar rats after a dose of 100 uM/kg, 30 min before 1 mg/kg of apomorphine administration",Other,9406603.0,
1756,189694,3,3,,103165765,2818,Unspecified,,,,,Compound was tested for the apomorphine antagonistic activity in rats expressed as relative activity,Other,2876098.0,
1757,189697,4,3,,103165765,2818,Unspecified,,,,,Compound was tested or the anti-tryptamine activity in rats relative with respect to clozapine.,Other,2876098.0,
1758,190821,3,3,,103165765,2818,Unspecified,,,,,Total activity (anti psychotic) when compound administered at a doe of 10 mg/kg ip in rats,Other,8831770.0,
1759,190823,3,3,,103165765,2818,Unspecified,,,,,Total activity (anti psychotic) when compound administered at a doe of 5 mg/kg ip in rats,Other,8831770.0,
1760,191613,3,3,,103165765,2818,Unspecified,,,,,Anti psychotic effect Social interaction when compound administered at a doe of 10 mg/kg ip in rats,Other,8831770.0,
1761,191615,3,3,,103165765,2818,Unspecified,,,,,Anti psychotic effect Social interaction when compound administered at a doe of 5 mg/kg ip in rats,Other,8831770.0,
1762,192861,3,3,,103165765,2818,Unspecified,,,,,Minimal inhibitory activity tested in rats after intraperitoneal administration,Other,14695828.0,
1763,193241,4,2,,103165765,2818,Unspecified,,,,,Cataleptic effect over the dose range tested (1-40 mg/kg) in rat,Other,11052797.0,
1764,194153,3,4,,103165765,2818,Unspecified,,,,,The percent loss of escape responding was determined for the estimated effective dose 50 values for CAR block,Other,2565400.0,
1765,195964,3,3,,103165765,2818,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of Avoidance performance(% change from control) p<0.001 dose(mg/Kg po) =32",Other,9622542.0,
1766,196013,3,3,,103165765,2818,Unspecified,,,,,Compound was evaluated in paw test for the forelimb retraction in rat at effective dose of 20 (mg\\kg),Other,12408724.0,
1767,196014,3,3,,103165765,2818,Unspecified,,,,,Compound was evaluated in paw test for the hindlimb retraction at effective dose of 5 (mg\\kg),Other,12408724.0,
1768,196115,3,4,,103165765,2818,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of escape failure (absolute change from control), p<0.01, dose(mg/Kg po) =32",Other,9622542.0,
1769,196118,3,3,,103165765,2818,Unspecified,,,,,"effects on sidiman Avoidance performance in rats, number of shocks (absolute change from control), p<0.001, dose(mg/Kg po) =32",Other,9622542.0,
1770,196771,6,3,,103165765,2818,Unspecified,,,,,In vivo accumulation of L-DOPA was measured in striatum of rats,Other,10377229.0,
1771,196984,5,8,,103165765,2818,Active,543734.0,24173.0,0.51286,Kd,Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats.,Confirmatory,6142954.0,
1772,196984,5,8,,103165765,2818,Active,1168244.0,29413.0,0.51286,Kd,Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats.,Confirmatory,6142954.0,
1773,196984,5,8,,103165765,2818,Active,1168247.0,29412.0,0.51286,Kd,Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats.,Confirmatory,6142954.0,
1774,196987,5,8,,103165765,2818,Active,231461.0,25083.0,20.4174,Kd,Antagonist activity against B-HT 933-induced alpha-2-adrenoceptor-mediated vasoconstriction in pithed normotensive rats,Confirmatory,6142954.0,
1775,196987,5,8,,103165765,2818,Active,231464.0,24175.0,20.4174,Kd,Antagonist activity against B-HT 933-induced alpha-2-adrenoceptor-mediated vasoconstriction in pithed normotensive rats,Confirmatory,6142954.0,
1776,196987,5,8,,103165765,2818,Active,47117345.0,24174.0,20.4174,Kd,Antagonist activity against B-HT 933-induced alpha-2-adrenoceptor-mediated vasoconstriction in pithed normotensive rats,Confirmatory,6142954.0,
1777,197165,5,3,,103165765,2818,Active,,,0.000692,Kd,pA2 value was evaluated by measuring the inhibition of the 5-HT-induced contraction of rat aorta.,Confirmatory,10425088.0,
1778,203698,7,1,,103165765,2818,Active,,,8.5,Ki,Compound was tested for its binding affinity towards sigma 1 receptor using [3H](+)-pentazocine from guinea pig brain,Confirmatory,9572880.0,
1779,203829,4,4,,103165765,2818,Unspecified,,,10.0,Ki,Binding affinity towards sigma 2 receptor using [3H]DTG in the presence of 200 nM (+)-NANM from guinea pig brain,Confirmatory,9572880.0,
1780,204461,7,3,,103165765,2818,Active,,,8.5,Ki,Binding affinity measured at the sigma receptor by the inhibition of [3H]-3-PPP binding to guinea pig cerebellum using unlabeled 3-PPP for nonspecific binding.,Confirmatory,9876110.0,
1781,204615,8,5,,103165765,2818,Unspecified,81882051.0,29336.0,1.0,IC50,Compound was tested in vitro for its ability to displace radioligand (+)-[3H]-3-PPP from rat cortical sigma receptor,Confirmatory,1361578.0,
1782,205031,7,5,,103165765,2818,Active,112812.0,24473.0,8.7,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1783,205031,7,5,,103165765,2818,Active,112815.0,25075.0,8.7,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1784,205031,7,5,,103165765,2818,Active,112820.0,25323.0,8.7,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1785,205031,7,5,,103165765,2818,Active,398968.0,60448.0,8.7,IC50,Binding affinity against serotonin-1 receptor in rat brain using [3H]5-HT,Confirmatory,2875184.0,
1786,205143,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of sidman avoid in squirrel monkeys after peroral administration,Other,2875184.0,
1787,205150,6,2,,103165765,2818,Unspecified,,,,,The compound was tested for its ability to induced catalepsy in squirrel monkeys,Other,2866248.0,
1788,205174,6,2,,103165765,2818,Unspecified,,,,,The compound was tested for inhibition of sidman avoidance in squirrel monkeys,Other,2866248.0,
1789,214939,7,3,,103165765,2818,Unspecified,,,62.0,Km,Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4),Confirmatory,12699380.0,
1790,218670,7,1,,103165765,2818,Active,,,0.02,IC50,The compound was tested for inhibition of [3H]WB-4101 binding to alpha-1 adrenergic receptor of rat frontal cortex,Confirmatory,2866248.0,
1791,218904,9,3,,103165765,2818,Active,,,1.61,IC50,In vitro affinity towards D2 receptor using [3H]spiroperidol as radioligand in striatum,Confirmatory,7914536.0,
1792,221060,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of apomorphine-induced climbing behavior in mice, after Intraperitoneal administration",Other,8709130.0,
1793,221062,6,2,,103165765,2818,Unspecified,,,,,"Inhibition of apomorphine-induced climbing behavior in mice, after peroral administration",Other,8709130.0,
1794,222148,5,6,,103165765,2818,Active,7531135.0,3757.0,0.191,IC50,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Confirmatory,12190308.0,
1795,222975,7,2,,103165765,2818,Unspecified,,,,,Ability to antagonize 5-MeO-DMT-induced head twitches in mice after administration of 0.33 mg/kg dose subcutaneously,Other,11784139.0,
1796,222976,7,2,,103165765,2818,Unspecified,,,,,Ability to antagonize apomorphine-induced climbing in mice after administration of 0.93 mg/kg dose subcutaneously,Other,11784139.0,
1797,223305,6,2,,103165765,2818,Unspecified,,,,,Effective dose administered in apomorphine induced climbing test in mice (in vivo)value in parentheses represents 95% confidence limit,Other,11101359.0,
1798,223306,6,2,,103165765,2818,Unspecified,,,,,Effective dose administered in catalepsy test in mice(in vivo) value in parentheses represents 95% confidence limit,Other,11101359.0,
1799,225148,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of ethanol potentiation in rat when administered perorally,Other,2869146.0,
1800,225150,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for inhibition of hexobarbatial potentiation in rat when administered perorally,Other,2869146.0,
1801,225270,8,1,,103165765,2818,Unspecified,,,,,Dose required to induce 50% maximum catalepsy in rat,Other,8709130.0,
1802,225446,6,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine-induced stereotypy in rat after peroral administration,Other,8709130.0,
1803,225491,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for antagonist activity against apomorphine-induced mouse climbing(intraperitoneally - ip). using in vivo method,Other,8941382.0,
1804,225492,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for antagonist activity against apomorphine-induced mouse climbing(per orally - po). using in vivo method,Other,8941382.0,
1805,225495,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for antagonist activity against apomorphine-induced mouse stereotypy(per orally - po). using in vivo method,Other,8941382.0,
1806,225497,6,2,,103165765,2818,Unspecified,,,,,Compound was tested for induction of catalepsy in mouse.,Other,8941382.0,
1807,226201,3,5,,103165765,2818,Unspecified,,,,,Rate of incorporation of [3H]thymidine as evidence of mitogenetic activity,Other,11495580.0,
1808,226426,3,8,,103165765,2818,Unspecified,,,,,In vitro binding affinity for D2 receptor compared to that of 5-HT2 receptor,Other,11392544.0,
1809,226576,3,8,,103165765,2818,Unspecified,,,,,In vitro binding affinity for D2 receptor compared to that of D4 receptor,Other,11392544.0,
1810,227557,3,10,,103165765,2818,Unspecified,112808.0,29595.0,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain,Other,8568801.0,
1811,227559,3,5,,103165765,2818,Unspecified,,,,,Relative binding affinity for dopamine D2 and alpha receptors,Other,8568801.0,
1812,227718,7,1,,103165765,2818,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1813,228343,3,11,,103165765,2818,Unspecified,118206.0,1813.0,,,"Relative binding to dopamine D2 and D4 receptor, ratio of Ki",Other,9276014.0,
1814,228343,3,11,,103165765,2818,Unspecified,1345939.0,1815.0,,,"Relative binding to dopamine D2 and D4 receptor, ratio of Ki",Other,9276014.0,
1815,228677,3,3,,103165765,2818,Unspecified,,,,,Delta ED50 value by Subcutaneous administration (ED50 catalepsy-ED50 Climbing),Other,10377229.0,
1816,228678,3,3,,103165765,2818,Unspecified,,,,,Delta ED50 value by peroral administration (ED50 catalepsy-ED50 Climbing),Other,10377229.0,
1817,229000,5,4,,103165765,2818,Active,,,0.0024,Kd,Compound was tested for Antagonistic activity against denuded rat aorta,Confirmatory,9934473.0,
1818,229002,4,1,,103165765,2818,Active,,,0.00759,Ki,Compound was measured for the inhibition of [3H]ketanserin binding to rat frontal cortex membrane (5-HT2A receptor),Confirmatory,9934473.0,
1819,229516,3,6,,103165765,2818,Unspecified,,,,,Ratio of IC50 value against dopamine receptor D2 to that of 5-hydroxytryptamine 3 receptor.,Other,7707315.0,
1820,229628,4,7,,103165765,2818,Unspecified,,,,,Selectivity ratio for serotonin 5-HT2A to that of dopamine D2 receptors,Other,14741248.0,
1821,229631,4,6,,103165765,2818,Unspecified,,,,,Selectivity ratio for serotonin 5-HT2C to that of serotonin 5-HT2A receptors,Other,14741248.0,
1822,229637,3,7,,103165765,2818,Unspecified,,,,,Selectivity ratio towards D4 receptor to that of D2 receptor,Other,,
1823,230009,3,7,,103165765,2818,Unspecified,,,,,Ratio of Ki value towards dopamine D2L receptor to that of D-4 receptor.,Other,7861418.0,
1824,230011,3,5,,103165765,2818,Unspecified,,,,,Ratio of Ki value towards dopamine D2L receptor to that of serotonin S-2A receptor.,Other,7861418.0,
1825,230094,4,4,,103165765,2818,Unspecified,,,,,Ratio of pKi of compound towards 5-HT2 receptor to that of D1 receptor,Other,9748351.0,
1826,230095,4,4,,103165765,2818,Unspecified,,,,,Ratio of pKi of compound towards 5-HT2 receptor to that of D2 receptor,Other,9748351.0,
1827,230096,4,7,,103165765,2818,Unspecified,,,,,Ratio of pKi of compound towards D1 receptor to that of D2 receptor,Other,9748351.0,
1828,230492,3,10,,103165765,2818,Unspecified,543728.0,15558.0,,,Relative receptor binding affinities for dopamine D2 and serotonin 5-HT2,Other,8941382.0,
1829,230492,3,10,,103165765,2818,Unspecified,341940154.0,15560.0,,,Relative receptor binding affinities for dopamine D2 and serotonin 5-HT2,Other,8941382.0,
1830,230492,3,10,,103165765,2818,Unspecified,341940463.0,13489.0,,,Relative receptor binding affinities for dopamine D2 and serotonin 5-HT2,Other,8941382.0,
1831,230492,3,10,,103165765,2818,Unspecified,550544258.0,15559.0,,,Relative receptor binding affinities for dopamine D2 and serotonin 5-HT2,Other,8941382.0,
1832,230935,3,3,,103165765,2818,Unspecified,,,,,Ratio of the catalepsy to that of conditioned avoidance response in rats,Other,14695828.0,
1833,231159,3,8,,103165765,2818,Unspecified,,,,,Ratio of the potency for displacement of of [3H]spiperone binding to human D2 dopaminergic receptor/human D4 dopaminergic receptor,Other,,
1834,231369,3,3,,103165765,2818,Unspecified,,,,,Ratio representing inhibitory activity against catalepsy to inhibitory activity against amphetamine-induced locomotor behavior in rats,Other,8568801.0,
1835,231370,3,3,,103165765,2818,Unspecified,,,,,Ratio representing inhibitory activity against spontaneous locomotor behavior to inhibitory activity against amphetamine-induced stereotypy in rats,Other,8568801.0,
1836,231459,4,10,,103165765,2818,Unspecified,112808.0,29595.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1837,231459,4,10,,103165765,2818,Unspecified,112817.0,25187.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1838,231459,4,10,,103165765,2818,Unspecified,398970.0,29581.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1839,231459,4,10,,103165765,2818,Unspecified,47117674.0,24318.0,,,Ratio between D2 receptor and 5-HT2 receptor binding affinities.,Other,7901415.0,
1840,231522,3,6,,103165765,2818,Unspecified,,,,,Ratio of binding affinity towards 5-HT2 to D2 receptor was measured,Other,7907148.0,
1841,231526,3,6,,103165765,2818,Unspecified,,,,,Ratio of binding affinity towards D2 to D1 receptor was measured,Other,7907148.0,
1842,231527,4,6,,103165765,2818,Unspecified,,,,,Ratio of binding affinity towards D2 to D1 receptor.,Other,7473566.0,
1843,231528,3,5,,103165765,2818,Unspecified,,,,,Ratio of binding affinity towards D2 to muscarinic receptor (M) was measured,Other,7907148.0,
1844,231649,3,7,,103165765,2818,Unspecified,,,,,"Binding affinity ratio against human dopamine D2L versus D4.2, calculated using pKi (-logKi) values",Other,12408724.0,
1845,231650,3,5,,103165765,2818,Unspecified,,,,,"Binding affinity ratio against rat cortical tissue 5-HT2 versus human D2, calculated using pKi (-logKi) values",Other,12408724.0,
1846,231653,3,10,,103165765,2818,Unspecified,112808.0,29595.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1847,231653,3,10,,103165765,2818,Unspecified,112817.0,25187.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1848,231653,3,10,,103165765,2818,Unspecified,398970.0,29581.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1849,231653,3,10,,103165765,2818,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between 5-HT2 and D2 receptors,Other,8101877.0,
1850,231654,3,9,,103165765,2818,Unspecified,118229.0,24316.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
1851,231654,3,9,,103165765,2818,Unspecified,47117674.0,24318.0,,,Binding ratio of -log Ki between D2 and D1 receptors,Other,8101877.0,
1852,231655,3,5,,103165765,2818,Unspecified,,,,,Binding ratio of -log Ki between D2 and M receptors,Other,8101877.0,
1853,231681,4,7,,103165765,2818,Unspecified,,,,,Ratio between Ki values of D2 and D4 receptors,Other,8064797.0,
1854,231682,4,5,,103165765,2818,Unspecified,,,,,Ratio between Ki values of D2 and S-2A receptors,Other,8064797.0,
1855,231683,3,5,,103165765,2818,Unspecified,,,,,Ratio between Ki values of D2 and S-3 receptors,Other,8064797.0,
1856,231707,3,7,,103165765,2818,Unspecified,,,,,Ratio between binding affinities of dopamine D2 and serotonin 5-HT 2A receptors,Other,9934473.0,
1857,232152,3,7,,103165765,2818,Unspecified,,,,,Ratio of 5-HT2A receptor to that of dopamine 2 (D2) receptor in human,Other,14695828.0,
1858,232153,4,6,,103165765,2818,Unspecified,,,,,Ratio of 5-HT2A receptor to that of dopamine 2 (D2) receptor in rat tissue homogenate,Other,14695828.0,
1859,232372,4,7,,103165765,2818,Unspecified,,,,,Ratio of affinity for D2 and D4 receptors,Other,9871530.0,
1860,232438,4,5,,103165765,2818,Unspecified,,,,,Ratio of inhibition of rat circling behaviors induced by pergolide (D2 receptor) and SKF 38393 (D1 receptor),Other,7473566.0,
1861,232553,3,3,,103165765,2818,Unspecified,,,,,Ratio of ED50 for antagonism of apomorphine induced stereotypy to ED50 for antagonism of apomorphine induced climbing,Other,7914539.0,
1862,232554,3,3,,103165765,2818,Unspecified,,,,,Ratio of ED50 for antagonism of apomorphine-induced stereotypy to ED50 for antagonism of apomorphine-induced climbing.,Other,8941382.0,
1863,232559,3,3,,103165765,2818,Unspecified,,,,,Ratio of ED50 for induction of catalepsy to ED50 for antagonism of apomorphine induced climbing.,Other,7914539.0,
1864,232560,3,3,,103165765,2818,Unspecified,,,,,Ratio of ED50 for induction of catalepsy to ED50 for antagonism of apomorphine-induced climbing.,Other,8941382.0,
1865,233293,3,7,,103165765,2818,Unspecified,,,,,Selectivity ratio is Ki of human dopamine D2 receptor to that of human dopamine D4 receptor.,Other,9406594.0,
1866,233507,4,1,,103165765,2818,Unspecified,,,15488200.0,Ki,Ratio of inhibition constant of 5-HT2A receptor to that of D2 receptor,Confirmatory,,
1867,233807,4,6,,103165765,2818,Unspecified,,,,,The ratio of the IC50 value of Dopamine D2 receptor to that of serotonergic 5-HT2 receptor,Other,7914539.0,
1868,235773,3,3,,103165765,2818,Unspecified,,,,,Therapeutic ratio by Peroral dose of administration (quotient ED50 catalepsy/ED50 climbing),Other,10377229.0,
1869,235774,3,3,,103165765,2818,Unspecified,,,,,Therapeutic ratio by Subcutaneous dose of administration (quotient ED50 catalepsy/ED50 climbing),Other,10377229.0,
1870,235864,3,6,,103165765,2818,Unspecified,,,,,Index of alpha1/alpha2 adrenoceptor antagonist selectivity at post junctional vascular sites in vivo.,Other,6142954.0,
1871,235865,3,5,,103165765,2818,Unspecified,,,,,Index of alpha1/alpha2 adrenoceptor antagonist selectivity at pre and postsynaptic sites in vitro.,Other,6142954.0,
1872,235866,3,7,,103165765,2818,Unspecified,,,,,Index of alpha1/alpha2 adrenoceptor binding selectivity.,Other,6142954.0,
1873,238747,4,9,,103165765,2818,Active,1703010.0,3362.0,0.05,Ki,Binding affinity for human 5-hydroxytryptamine 6 receptor,Confirmatory,15771424.0,
1874,238778,8,5,,103165765,2818,Active,1345939.0,1815.0,0.0304,Ki,In vitro ability to inhibit [3H]6b binding to human Dopamine receptor D4.4,Confirmatory,15380206.0,
1875,238855,8,1,,103165765,2818,Active,118229.0,24316.0,0.539,Ki,Inhibition of [3H]SCH-23390 binding to rat Dopamine receptor D1,Confirmatory,15771415.0,
1876,238882,8,1,,103165765,2818,Active,112808.0,29595.0,0.01,Ki,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2A receptor,Confirmatory,15771414.0,
1877,238889,8,5,,103165765,2818,Active,1345939.0,1815.0,0.0284,Ki,In vitro ability to inhibit [3H]spiperone binding to human Dopamine receptor D4.4,Confirmatory,15380206.0,
1878,238933,5,6,,103165765,2818,Active,17367264.0,11255.0,0.631,Ki,Antagonist potency against human H3 receptor in GTPgamma-S-Assay,Confirmatory,15634025.0,
1879,238940,8,1,,103165765,2818,Active,118229.0,24316.0,0.353,Ki,Inhibition of [3H]-SCH- 23390 binding to rat dopamine D1 receptor,Confirmatory,15771414.0,
1880,238941,8,1,,103165765,2818,Active,47117674.0,24318.0,0.25,Ki,Inhibition of [3H]spiperone binding to rat dopamine D2 receptor,Confirmatory,15771414.0,
1881,238962,8,5,,103165765,2818,Active,81907603.0,,0.6970000000000001,Ki,Inhibition of [3H]nisoxetine binding to rat Norepinephrine transporter,Confirmatory,15771415.0,
1882,238989,8,5,,103165765,2818,Active,1351829.0,150.0,0.024,Ki,Inhibition of [3H]rauwolscine binding to Alpha-2A adrenergic receptor,Confirmatory,15771415.0,
1883,238990,8,5,,103165765,2818,Active,20141211.0,152.0,0.0029,Ki,Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor,Confirmatory,15771415.0,
1884,238991,7,5,,103165765,2818,Active,543734.0,24173.0,0.022000000000000002,Ki,Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor,Confirmatory,15771415.0,
1885,238991,7,5,,103165765,2818,Active,1168244.0,29413.0,0.022000000000000002,Ki,Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor,Confirmatory,15771415.0,
1886,238991,7,5,,103165765,2818,Active,1168247.0,29412.0,0.022000000000000002,Ki,Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor,Confirmatory,15771415.0,
1887,239010,8,5,,103165765,2818,Active,543727.0,3356.0,0.0063,Ki,Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor,Confirmatory,15771415.0,
1888,239052,8,5,,103165765,2818,Active,118206.0,1813.0,0.14400000000000002,Ki,Inhibition of [3H]-spiperone binding to human Dopamine receptor D2,Confirmatory,15771415.0,
1889,239069,8,5,,103165765,2818,Active,112816.0,3358.0,0.021,Ki,Inhibition of [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor,Confirmatory,15771415.0,
1890,239091,8,5,,103165765,2818,Active,547645.0,3269.0,0.0011,Ki,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor,Confirmatory,15771415.0,
1891,239149,8,5,,103165765,2818,Active,8488960.0,3363.0,0.048,Ki,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 7 receptor,Confirmatory,15771415.0,
1892,239150,8,5,,103165765,2818,Active,1169206.0,1814.0,0.242,Ki,Inhibition of [125I]iodosulpiride binding to human Dopamine receptor D3,Confirmatory,15771415.0,
1893,239151,7,2,,103165765,2818,Active,,,0.319,Ki,Inhibition of [3H]7-OH-DPAT binding to Dopamine D3 receptor expressed in Sf9 cells,Confirmatory,15771414.0,
1894,239902,4,1,,103165765,2818,Active,,,0.03162,Ki,Binding affinity against Dopamine D1 receptor,Confirmatory,15261283.0,
1895,239904,4,1,,103165765,2818,Active,,,0.07762000000000001,Ki,Binding affinity against Dopamine receptor D2,Confirmatory,15261283.0,
1896,239905,4,1,,103165765,2818,Active,,,0.22386999999999999,Ki,Inhibitory constant towards dopamine D2 receptor was determined,Confirmatory,15878662.0,
1897,239910,4,1,,103165765,2818,Active,,,0.04786,Ki,Binding affinity against Alpha-1 adrenergic receptor,Confirmatory,15261283.0,
1898,239911,4,1,,103165765,2818,Active,,,0.00912,Ki,Inhibitory constant towards 5-hydroxytryptamine 2A receptor (5-HT2A),Confirmatory,15878662.0,
1899,239912,4,1,,103165765,2818,Active,,,0.01047,Ki,Inhibitory constant towards 5-hydroxytryptamine 2C receptor (5-HT2C),Confirmatory,15878662.0,
1900,239913,4,1,,103165765,2818,Active,,,0.18621,Ki,Binding affinity against 5-Hydroxytryptamine 3 receptor,Confirmatory,15261283.0,
1901,239915,4,1,,103165765,2818,Active,,,0.41686999999999996,Ki,Binding affinity against 5-Hydroxytryptamine 1A receptor,Confirmatory,15261283.0,
1902,239916,4,1,,103165765,2818,Active,,,0.0026899999999999997,Ki,Binding affinity against 5-Hydroxytryptamine 2A receptor,Confirmatory,15261283.0,
1903,239917,4,1,,103165765,2818,Active,,,0.00288,Ki,Binding affinity against 5-Hydroxytryptamine 2C receptor,Confirmatory,15261283.0,
1904,243050,3,7,,103165765,2818,Unspecified,,,,,Ratio of binding affinity against 5-Hydroxytryptamine 2A receptor to that of Dopamine receptor D2,Other,15261283.0,
1905,243053,3,5,,103165765,2818,Unspecified,,,,,Ratio of inhibitory constant for 5-hydroxytryptamine 2A receptor to that of dopamine receptor D2,Other,15878662.0,
1906,243151,7,2,,103165765,2818,Active,,,0.32359,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
1907,243189,7,4,,103165765,2818,Active,7531135.0,3757.0,5.7544,IC50,Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel),Confirmatory,15745831.0,
1908,243422,3,10,,103165765,2818,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
1909,244496,5,7,,103165765,2818,Inconclusive,1345939.0,1815.0,,,Efficacy in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and G-alpha-qo5 relative to 10 uM dopamine; ND denotes not determined,Other,15380206.0,
1910,246673,8,7,,103165765,2818,Inconclusive,1345939.0,1815.0,,,Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5; ND denotes not determined,Other,15380206.0,
1911,246835,10,1,,103165765,2818,Unspecified,,,,,In vivo effective dose against catalepsy response was determined in rats,Other,15771414.0,
1912,246836,10,1,,103165765,2818,Unspecified,,,,,In vivo effective dose was determined against apomorphine climbing in rats,Other,15771414.0,
1913,246858,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose of compound against 5-MeO-DMT induced head twitches in rats,Other,15771414.0,
1914,246864,10,1,,103165765,2818,Unspecified,,,,,In vivo effective dose against conditioned avoidance response was determined in rats,Other,15771414.0,
1915,246865,10,1,,103165765,2818,Unspecified,,,,,In vivo effective dose against spontaneous locomotor activity was determined in rats,Other,15771414.0,
1916,246870,8,2,,103165765,2818,Unspecified,,,,,In vivo effective dose against 5-MeO-DMT-induced head twitches in rats was determined,Other,15771414.0,
1917,246883,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose for reversal of tryptamine-induced cyanosis in rats,Other,15771415.0,
1918,246894,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose for reversal of RO-4-1284 induced hypothermia in mouse,Other,15771415.0,
1919,246918,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose to inhibit tryptamine-induced bilateral convulsions in rats,Other,15771415.0,
1920,246931,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose for reversal of tryptamine-induced backward locomotion in rats,Other,15771415.0,
1921,246985,6,2,,103165765,2818,Unspecified,,,,,Effective dose for antagonistic activity against m-chlorophenyl-piperazine induced anxiety in rats,Other,15771415.0,
1922,247009,6,2,,103165765,2818,Unspecified,,,,,In vivo effective dose to inhibit apomorphine induced agitation in rats upon subcutaneous administration,Other,15771415.0,
1923,247986,7,1,,103165765,2818,Unspecified,400629.0,25553.0,10.0,IC50,Inhibitory concentration against reuptake of 5-HT from rat synaptosomes,Confirmatory,15261283.0,
1924,251584,3,9,,103165765,2818,Unspecified,112808.0,29595.0,,,Relative binding affinity against 5-hydroxytryptamine 2A and dopamine D2 receptors,Other,15771414.0,
1925,251584,3,9,,103165765,2818,Unspecified,47117674.0,24318.0,,,Relative binding affinity against 5-hydroxytryptamine 2A and dopamine D2 receptors,Other,15771414.0,
1926,254688,8,5,,103165765,2818,Active,118206.0,1813.0,0.009000000000000001,IC50,Inhibitory concentration against dopamine receptor D2,Confirmatory,16220969.0,
1927,254689,8,5,,103165765,2818,Active,1345939.0,1815.0,0.138,IC50,Inhibitory concentration against dopamine receptor D4,Confirmatory,16220969.0,
1928,255079,8,5,,103165765,2818,Active,803374855.0,140.0,0.156,IC50,Inhibitory concentration against human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA,Confirmatory,16250647.0,
1929,265753,6,2,,103165765,2818,Unspecified,,,,,Inhibition of apomorphine-induced climbing in ip dosed Swiss Webster mouse,Other,16621538.0,
1930,266654,12,1,,103165765,2818,Unspecified,14194819.0,59340.0,,Ki,Displacement of [3H]histamine from human histamine H4 receptor transfected in SK-N-MC cells,Confirmatory,16854056.0,
1931,266663,11,1,,103165765,2818,Unspecified,14194819.0,59340.0,,Kd,Displacement of [3H]Histamine from human histamine H4 receptor transfected in SK-N-MC cells at 100 nM,Confirmatory,16854056.0,
1932,266664,12,1,,103165765,2818,Unspecified,14194819.0,59340.0,,Kd,Displacement of [3H]histamine from human histamine H4 receptor transfected in SK-N-MC cells at 300 nM,Confirmatory,16854056.0,
1933,266665,12,1,,103165765,2818,Unspecified,14194819.0,59340.0,,Kd,Displacement of [3H]histamine from human histamine H4 receptor transfected in SK-N-MC cells at 1 uM,Confirmatory,16854056.0,
1934,266772,8,5,,103165765,2818,Active,1706296.0,100144487.0,0.42,Ki,Displacement of [3H]SCH 23990 from dopamine receptor D1 in porcine striatal membrane,Confirmatory,16789750.0,
1935,266773,8,5,,103165765,2818,Active,118206.0,1813.0,0.040999999999999995,Ki,Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane,Confirmatory,16789750.0,
1936,266774,8,5,,103165765,2818,Active,118206.0,1813.0,0.027999999999999997,Ki,Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane,Confirmatory,16789750.0,
1937,266775,8,5,,103165765,2818,Active,1169206.0,1814.0,0.96,Ki,Displacement of [3H]spiperone from human dopamine receptor D3 in CHO cell membrane,Confirmatory,16789750.0,
1938,266776,8,5,,103165765,2818,Active,1345939.0,1815.0,0.016,Ki,Displacement of [3H]spiperone from human dopamine receptor D4.4 in CHO cell membrane,Confirmatory,16789750.0,
1939,266777,7,1,,103165765,2818,Inconclusive,,,,Ki,Displacement of [3H]8-OH-DPAT from 5HT1A receptor in porcine cortical membrane,Confirmatory,16789750.0,
1940,266778,8,5,,103165765,2818,Inconclusive,1703009.0,397432.0,,Ki,Displacement of [3H]ketanserin from 5HT2 receptor in porcine cortical membrane,Confirmatory,16789750.0,
1941,266779,7,1,,103165765,2818,Inconclusive,,,,Ki,Displacement of [3H]prazosin from porcine Adrenergic alpha-1 receptor in porcine brain,Confirmatory,16789750.0,
1942,266790,6,1,,103165765,2818,Unspecified,,,,,"Reduction of sc dosed 20 ug/kg 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]-pyridine-induced penile erection in Sprague-Dawley rat at 1 mg/kg, ip",Other,16789750.0,
1943,266791,6,1,,103165765,2818,Unspecified,,,,,"Reduction of icv dosed 1 ug 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]-pyridine-induced penile erection in Sprague-Dawley rat at 1 mg/kg, ip",Other,16789750.0,
1944,269017,3,3,,103165765,2818,Active,,,,,"Inhibition of (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime-induced erectogenic effect in Wistar rat at 3 umol/kg, ip",Other,16913699.0,
1945,270037,8,5,,103165765,2818,Active,118228.0,1812.0,0.132,Ki,Displacement of [3H]SCH 23390 from human dopamine D1 receptor expressed in CHO cells,Confirmatory,16809034.0,
1946,270038,8,5,,103165765,2818,Active,118206.0,1813.0,0.20800000000000002,Ki,Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells,Confirmatory,16809034.0,
1947,270039,3,9,,103165765,2818,Unspecified,118206.0,1813.0,,,Selectivity for D1 receptor over D2 receptor,Other,16809034.0,
1948,270039,3,9,,103165765,2818,Unspecified,118228.0,1812.0,,,Selectivity for D1 receptor over D2 receptor,Other,16809034.0,
1949,270275,8,5,,103165765,2818,Active,118228.0,1812.0,0.132,Ki,Displacement of [3H]SCH 23390 from dopamine D1 receptor expressed in CHO cells,Confirmatory,16806922.0,
1950,270276,8,5,,103165765,2818,Active,118206.0,1813.0,0.20800000000000002,Ki,Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells,Confirmatory,16806922.0,
1951,270277,3,9,,103165765,2818,Unspecified,118206.0,1813.0,,,Selectivity for D1 receptor over D2 receptor,Other,16806922.0,
1952,270277,3,9,,103165765,2818,Unspecified,118228.0,1812.0,,,Selectivity for D1 receptor over D2 receptor,Other,16806922.0,
1953,274504,3,3,,103165765,2818,Active,,,,,"Blockade of ABT-670-induced erctogenic activity in rat at 3 umol/kg, ip",Other,17149874.0,
1954,274704,3,3,,103165765,2818,Active,,,,,"Antipsychotic activity in Sprague-Dawley rat assessed as ability to reverse apomorphine effect on prepulse inhibition of the startle response at 1 mg/kg, sc",Other,17149881.0,
1955,290939,8,5,,103165765,2818,Active,7531135.0,3757.0,3.08,Ki,Displacement of [3H]dofetilide from hERG expressed in HEK293 cells by SPA,Confirmatory,17536794.0,
1956,290940,8,5,,103165765,2818,Active,7531135.0,3757.0,4.06,Ki,Binding affinity at hERG expressed in HEK293 cells by fluorescence polarization assay,Confirmatory,17536794.0,
1957,290941,3,10,,103165765,2818,Unspecified,7531135.0,3757.0,,,Ratio of Ki for hERG by SPA to Ki for hERG by fluorescence polarization assay in HEK293 cells,Other,17536794.0,
1958,298031,3,5,,103165765,2818,Unspecified,,,,,"Lipophilicity, log D at pH7.4",Other,17725338.0,
1959,298032,3,3,,103165765,2818,Unspecified,,,,,"Acid dissociation constant, pKa of the compound",Other,17725338.0,
1960,298478,4,1,,103165765,2818,Active,118206.0,1813.0,0.12589,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells,Confirmatory,17880057.0,
1961,298479,4,1,,103165765,2818,Active,1169206.0,1814.0,0.1,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,17880057.0,
1962,298480,4,1,,103165765,2818,Active,1345939.0,1815.0,0.039810000000000005,Ki,Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells,Confirmatory,17880057.0,
1963,298481,4,1,,103165765,2818,Active,231454.0,3350.0,0.1,Ki,Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells,Confirmatory,17880057.0,
1964,298482,4,1,,103165765,2818,Active,543727.0,3356.0,0.0050100000000000006,Ki,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells,Confirmatory,17880057.0,
1965,298483,4,1,,103165765,2818,Active,1168220.0,3357.0,0.00316,Ki,Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells,Confirmatory,17880057.0,
1966,298485,4,1,,103165765,2818,Active,112816.0,3358.0,0.007940000000000001,Ki,Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells,Confirmatory,17880057.0,
1967,298486,4,1,,103165765,2818,Active,1703010.0,3362.0,0.007940000000000001,Ki,Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1968,298487,4,1,,103165765,2818,Active,8488960.0,3363.0,0.01995,Ki,Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells,Confirmatory,17880057.0,
1969,298488,4,1,,103165765,2818,Active,1168222.0,3359.0,0.39810999999999996,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1970,298488,4,1,,103165765,2818,Active,74705987.0,9177.0,0.39810999999999996,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1971,298488,4,1,,103165765,2818,Active,162416113.0,285242.0,0.39810999999999996,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1972,298488,4,1,,103165765,2818,Active,166198366.0,170572.0,0.39810999999999996,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1973,298488,4,1,,103165765,2818,Active,338817899.0,200909.0,0.39810999999999996,Ki,Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells,Confirmatory,17880057.0,
1974,298489,4,1,,103165765,2818,Inactive,400630.0,6532.0,,Ki,Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells,Confirmatory,17880057.0,
1975,298490,4,1,,103165765,2818,Active,113118.0,1128.0,0.0063100000000000005,Ki,Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells,Confirmatory,17880057.0,
1976,298491,4,1,,103165765,2818,Active,23503039.0,1132.0,0.01259,Ki,Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells,Confirmatory,17880057.0,
1977,298492,4,1,,103165765,2818,Active,543734.0,24173.0,0.01,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1978,298492,4,1,,103165765,2818,Active,1168244.0,29413.0,0.01,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1979,298492,4,1,,103165765,2818,Active,1168247.0,29412.0,0.01,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1980,298493,4,1,,103165765,2818,Active,231461.0,25083.0,0.07943,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1981,298493,4,1,,103165765,2818,Active,231464.0,24175.0,0.07943,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1982,298493,4,1,,103165765,2818,Active,47117345.0,24174.0,0.07943,Ki,Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex,Confirmatory,17880057.0,
1983,298494,4,1,,103165765,2818,Active,399889.0,100730517.0,0.007940000000000001,Ki,Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum,Confirmatory,17880057.0,
1984,301900,6,2,,103165765,2818,Unspecified,,,56.0,EC50,Cytotoxicity against CHO cells by MTT assay,Confirmatory,17870534.0,
1985,301901,4,1,,103165765,2818,Active,47117674.0,24318.0,0.14454,Ki,Binding affinity at dopamine D2 receptor in rat striatal membranes,Confirmatory,17870534.0,
1986,301902,4,1,,103165765,2818,Active,112808.0,29595.0,0.01318,Ki,Binding affinity at 5HT2A receptor in rat striatal membranes,Confirmatory,17870534.0,
1987,301903,4,1,,103165765,2818,Active,112812.0,24473.0,0.0955,Ki,Binding affinity at 5HT1A receptor in rat striatal membranes,Confirmatory,17870534.0,
1988,301904,4,1,,103165765,2818,Active,,,0.02239,Ki,Binding affinity at adrenergic alpha 1 receptor in rat striatal membranes,Confirmatory,17870534.0,
1989,301905,4,1,,103165765,2818,Unspecified,,,14125400.0,Ki,Selectivity for 5HT2A receptor over dopamine D2 receptor,Confirmatory,17870534.0,
1990,301906,3,3,,103165765,2818,Inactive,,,,,Induction of catalepsy in Mill Hill hooded rat at 1 mg/kg after 30-180 min,Other,17870534.0,
1991,301907,3,3,,103165765,2818,Inactive,,,,,Induction of catalepsy in Mill Hill hooded rat at 10 mg/kg after 30-180 min,Other,17870534.0,
1992,308685,4,1,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Displacement of [3H]ketanserin human cloned serotonin 5HT2A receptor,Confirmatory,17588750.0,
1993,308686,4,1,,103165765,2818,Active,112816.0,3358.0,0.01047,Ki,Displacement of [3H]mesulergine human cloned serotonin 5HT2C receptor,Confirmatory,17588750.0,
1994,308687,4,1,,103165765,2818,Active,118206.0,1813.0,0.22386999999999999,Ki,Displacement of [3H]spiperone human cloned dopamine D2 receptor,Confirmatory,17588750.0,
1995,308688,3,3,,103165765,2818,Unspecified,,,,,Ratio of pKi for human 5HT2A receptor to pKi for human D2 receptor,Other,17588750.0,
1996,311524,4,3,,103165765,2818,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1997,311933,3,3,,103165765,2818,Unspecified,,,,,Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM,Other,18027916.0,
1998,311934,3,3,,103165765,2818,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
1999,311935,3,4,,103165765,2818,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
2000,324372,3,4,,103165765,2818,Unspecified,,,,,Induction of light chain 3-GFP level in human H4 cells at 7.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
2001,324424,3,4,,103165765,2818,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 7.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
2002,324476,3,4,,103165765,2818,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 7.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
2003,324528,3,4,,103165765,2818,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 7.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
2004,324576,3,4,,103165765,2818,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control,Other,18024584.0,
2005,324577,3,4,,103165765,2818,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control,Other,18024584.0,
2006,324578,3,4,,103165765,2818,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control,Other,18024584.0,
2007,324582,3,4,,103165765,2818,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control,Other,18024584.0,
2008,324583,3,4,,103165765,2818,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control,Other,18024584.0,
2009,324584,3,4,,103165765,2818,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control,Other,18024584.0,
2010,324585,3,4,,103165765,2818,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control,Other,18024584.0,
2011,330537,3,4,,103165765,2818,Active,,,,,Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices at 500 nM after 30 mins by Western blotting,Other,17360666.0,
2012,330538,3,3,,103165765,2818,Active,,,,,Orexigenic activity in H1RKO mouse,Other,17360666.0,
2013,330539,3,5,,103165765,2818,Unspecified,,,,,Increase in alpha-2AMPK activity in H1RKO mouse hyphalamic slices,Other,17360666.0,
2014,330540,3,4,,103165765,2818,Active,,,,,Increase in phospho-AMPK levels in intact H1RKO mouse hypothalamus at 1 mg/kg after 3 hrs,Other,17360666.0,
2015,330541,3,5,,103165765,2818,Active,,,,,Increase in alpha-2AMPK levels in intact H1RKO mouse hypothalamus at 1 mg/kg after 3 hrs,Other,17360666.0,
2016,330542,3,4,,103165765,2818,Unspecified,,,,,Increase in phospho-AMPK levels in intact H1RKO mouse hypothalamus at 5 mg/kg after 3 hrs,Other,17360666.0,
2017,330543,3,5,,103165765,2818,Unspecified,,,,,Increase in alpha-2AMPK levels in intact H1RKO mouse hypothalamus at 5 mg/kg after 3 hrs,Other,17360666.0,
2018,330544,3,4,,103165765,2818,Inactive,,,,,"Increase in phospho-AMPK levels in intact H1RKO mouse cerebellum at 1 mg/kg, ip after 3 hrs by Western blotting",Other,17360666.0,
2019,330545,3,3,,103165765,2818,Inactive,,,,,"Increase in phospho-AMPK levels in intact H1RKO mouse liver at 1 mg/kg, ip after 3 hrs by Western blotting",Other,17360666.0,
2020,330546,3,4,,103165765,2818,Unspecified,,,,,Increase in cortical alpha-2AMPK levels in intact H1RKO mouse at 5 mg/kg after 3 hrs,Other,17360666.0,
2021,330547,3,5,,103165765,2818,Inactive,,,,,Increase in alpha-2AMPK levels in intact H1RKO mouse cerebellum at 5 mg/kg after 3 hrs,Other,17360666.0,
2022,330548,3,3,,103165765,2818,Active,,,,,Reversal of leptin-induced reduction in hyphalamic phospho-AMPK in H1RKO mouse at 5 mg/kg after 3 hrs by Western blotting,Other,17360666.0,
2023,330549,3,4,,103165765,2818,Active,,,,,Reversal of leptin-induced reduction in hyphalamic alpha-2AMPK activity in H1RKO mouse at 5 mg/kg,Other,17360666.0,
2024,330550,3,3,,103165765,2818,Active,,,,,Increase in phospho-AMPK level in arcuate hyphalamic nuclei intact H1RKO mouse at 1 mg/kg after 3 hrs by immunohistochemistry,Other,17360666.0,
2025,330551,4,3,,103165765,2818,Active,,,,EC50,Increase in phospho-AMPK level in arcuate hyphalamic nuclei intact H1RKO mouse at 5 mg/kg after 3 hrs by immunohistochemistry,Confirmatory,17360666.0,
2026,330552,3,3,,103165765,2818,Active,,,,,Increase in phospho-AMPK level in paraventricular hyphalamic nuclei intact H1RKO mouse at 1 mg/kg after 3 hrs by immunohistochemistry,Other,17360666.0,
2027,330553,3,3,,103165765,2818,Active,,,,,Increase in phospho-AMPK level in paraventricular hyphalamic nuclei intact H1RKO mouse at 5 mg/kg after 3 hrs by immunohistochemistry,Other,17360666.0,
2028,330555,3,8,,103165765,2818,Inactive,,,,,Binding affinity to leptin receptor at 10 nM,Other,17360666.0,
2029,330556,3,8,,103165765,2818,Inactive,,,,,Binding affinity to leptin receptor at 100 nM,Other,17360666.0,
2030,330557,3,3,,103165765,2818,Inactive,,,,,Binding affinity to alphaMSH receptor at 10 nM,Other,17360666.0,
2031,330558,3,3,,103165765,2818,Inactive,,,,,Binding affinity to alphaMSH receptor at 100 nM,Other,17360666.0,
2032,330559,3,7,,103165765,2818,Inactive,,,,,Binding affinity to neuropeptide Y receptor at 10 nM,Other,17360666.0,
2033,330560,3,7,,103165765,2818,Inactive,,,,,Binding affinity to neuropeptide Y receptor at 100 nM,Other,17360666.0,
2034,330561,8,5,,103165765,2818,Active,399890.0,24448.0,0.009000000000000001,IC50,Displacement of [3H]mepyramine from H1R in rat brain,Confirmatory,17360666.0,
2035,330563,3,3,,103165765,2818,Inactive,,,,,Increase in phospho-AMPK in H1R knockout mouse at 3 mg/kg by immunohistochemistry,Other,17360666.0,
2036,330564,4,4,,103165765,2818,Active,,,0.01,EC50,Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices after 30 mins by Western blotting,Confirmatory,17360666.0,
2037,330565,3,5,,103165765,2818,Inactive,,,,,Increase in alpha-2AMPK levels in intact H1RKO mouse cerebral cortex at 1 mg/kg after 3 hrs,Other,17360666.0,
2038,330566,3,5,,103165765,2818,Inactive,,,,,Increase in alpha-2AMPK levels in intact H1RKO mouse cerebellum at 1 mg/kg after 3 hrs,Other,17360666.0,
2039,330567,3,3,,103165765,2818,Active,,,,,Reversal of leptin-induced reduction in hyphalamic phospho-AMPK level in H1RKO mouse at 50 nM after 30 mins by Western blotting,Other,17360666.0,
2040,330568,3,3,,103165765,2818,Active,,,,,Reversal of insulin-induced reduction in hyphalamic phospho-AMPK level in H1RKO mouse at 50 nM after 30 mins by Western blotting,Other,17360666.0,
2041,330569,3,3,,103165765,2818,Active,,,,,Reversal of histamine-induced reduction in hyphalamic phospho-AMPK level in H1RKO mouse at 200 nM after 30 mins by Western blotting,Other,17360666.0,
2042,342773,8,5,,103165765,2818,Active,1703010.0,3362.0,0.011000000000000001,Ki,Binding affinity to human cloned 5HT6 receptor,Confirmatory,18595716.0,
2043,342774,8,5,,103165765,2818,Active,113118.0,1128.0,0.0018,Ki,Binding affinity to human cloned muscarinic M1 receptor,Confirmatory,18595716.0,
2044,342775,8,5,,103165765,2818,Active,118228.0,1812.0,0.29,Ki,Binding affinity to human cloned dopamine D1 receptor,Confirmatory,18595716.0,
2045,342777,8,5,,103165765,2818,Active,118206.0,1813.0,0.13,Ki,Binding affinity to human cloned dopamine D2 receptor,Confirmatory,18595716.0,
2046,342778,8,5,,103165765,2818,Active,1169206.0,1814.0,0.24,Ki,Binding affinity to human cloned dopamine D3 receptor,Confirmatory,18595716.0,
2047,342779,8,5,,103165765,2818,Active,1345939.0,1815.0,0.054000000000000006,Ki,Binding affinity to human cloned dopamine D4 receptor,Confirmatory,18595716.0,
2048,342780,4,3,,103165765,2818,Unspecified,,,,,Ratio of Ki for human cloned dopamine D2 receptor to Ki for human cloned dopamine D4 receptor,Other,18595716.0,
2049,342781,8,5,,103165765,2818,Active,112816.0,3358.0,0.017,Ki,Binding affinity to human cloned 5HT2C receptor,Confirmatory,18595716.0,
2050,342782,8,5,,103165765,2818,Active,547645.0,3269.0,0.0018,Ki,Binding affinity to human cloned histamine H1 receptor,Confirmatory,18595716.0,
2051,342783,8,5,,103165765,2818,Active,231454.0,3350.0,0.14,Ki,Binding affinity to human cloned 5HT1A receptor,Confirmatory,18595716.0,
2052,342784,8,5,,103165765,2818,Active,543727.0,3356.0,0.0089,Ki,Binding affinity to human cloned 5HT2A receptor,Confirmatory,18595716.0,
2053,342786,8,5,,103165765,2818,Active,81890335.0,,0.39,Ki,Binding affinity to rat NET,Confirmatory,18595716.0,
2054,342787,8,5,,103165765,2818,Active,400630.0,6532.0,3.9,Ki,Binding affinity to human SERT,Confirmatory,18595716.0,
2055,342788,7,2,,103165765,2818,Unspecified,,,,,Blockade of apomorphine-induced climbing stereotypy in Swiss Webster mouse after 30 mins,Other,18595716.0,
2056,346415,6,2,,103165765,2818,Active,,,0.11,IC50,Displacement of radiolabeled clozapine from human dopamine D4.4 receptor,Confirmatory,18983139.0,
2057,374351,6,2,,103165765,2818,Active,,,23.26,EC50,Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
2058,374353,6,3,,103165765,2818,Active,,,40.0,CC50,Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
2059,374355,3,3,,103165765,2818,Unspecified,,,,,"Selectivity index, ratio of CC50 for human WI38 cells preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay to EC50 for BKV Gardner ATCC VR837",Other,17893158.0,
2060,382243,4,3,,103165765,2818,Active,,,0.0014,Ki,Binding affinity to adrenergic alpha1 receptor,Confirmatory,18378462.0,
2061,386623,4,8,,103165765,2818,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
2062,391273,8,5,,103165765,2818,Active,118206.0,1813.0,0.22386999999999999,Ki,Displacement of [3H]spiperone from human cloned dopamine D2 receptor,Confirmatory,18783204.0,
2063,391274,8,5,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,Confirmatory,18783204.0,
2064,391275,8,5,,103165765,2818,Active,112816.0,3358.0,0.01047,Ki,Displacement of [3H]mesulergine from human cloned 5HT2C receptor,Confirmatory,18783204.0,
2065,391277,3,3,,103165765,2818,Unspecified,,,,,Ratio of pKi for human cloned 5HT2A receptor to pKi for human cloned dopamine D2 receptor,Other,18783204.0,
2066,392463,8,5,,103165765,2818,Unspecified,17367264.0,11255.0,1.0,Ki,Displacement of [125I]iodoproxyfan from human histamine H3 receptor expressed in CHO/HEK293 cells,Confirmatory,19091563.0,
2067,392464,8,5,,103165765,2818,Active,547645.0,3269.0,0.00238,Ki,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Confirmatory,19091563.0,
2068,392465,8,5,,103165765,2818,Active,118228.0,1812.0,0.08900000000000001,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK cells,Confirmatory,19091563.0,
2069,392466,8,5,,103165765,2818,Active,118214.0,1816.0,0.198,Ki,Displacement of [3H]SCH23390 from human dopamine D5 receptor expressed in HEK cells,Confirmatory,19091563.0,
2070,392467,8,5,,103165765,2818,Active,118206.0,1813.0,0.083,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells,Confirmatory,19091563.0,
2071,392468,8,5,,103165765,2818,Active,1169206.0,1814.0,0.295,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,19091563.0,
2072,395324,3,4,,103165765,2818,Unspecified,,,,,"Lipophilicity, log D at pH 7.4 by liquid chromatography",Other,19256501.0,
2073,395325,3,3,,103165765,2818,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
2074,395327,3,3,,103165765,2818,Unspecified,,,,,"Dissociation constant, pKa by capillary electrophoresis",Other,19256501.0,
2075,395328,3,3,,103165765,2818,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
2076,395329,3,3,,103165765,2818,Unspecified,,,,,"Dissociation constant, pKa by mass spectrometry",Other,19256501.0,
2077,397743,11,2,,103165765,2818,Active,7531135.0,3757.0,0.32,IC50,Inhibition of human ERG channel,Confirmatory,19534531.0,
2078,408340,8,5,,103165765,2818,Active,7531135.0,3757.0,0.32359,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
2079,410331,8,5,,103165765,2818,Active,118229.0,24316.0,0.353,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,19072656.0,
2080,410332,8,5,,103165765,2818,Active,47117674.0,24318.0,0.21,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,19072656.0,
2081,410333,7,1,,103165765,2818,Active,,,0.319,Ki,Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry,Confirmatory,19072656.0,
2082,410334,8,5,,103165765,2818,Active,112812.0,24473.0,0.16,Ki,Displacement of [3H]8OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus by scintillation spectrometry,Confirmatory,19072656.0,
2083,410335,8,5,,103165765,2818,Active,112808.0,29595.0,0.01,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry,Confirmatory,19072656.0,
2084,410336,4,3,,103165765,2818,Active,,,0.0048,Ki,Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry,Confirmatory,19072656.0,
2085,410338,9,5,,103165765,2818,Active,7531135.0,3757.0,17.0,Ki,Binding affinity to human ERG expressed in HEK293 cells by whole cell patch clamp method,Confirmatory,19072656.0,
2086,410339,6,2,,103165765,2818,Unspecified,,,,,Sedative activity in NMRI mouse assessed as reduction in spontaneous locomotor activity administered 30 mins prior to testing,Other,19072656.0,
2087,410529,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,19072656.0,
2088,410532,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in NMRI mouse assessed as reduction in phencyclidine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,19072656.0,
2089,410535,6,2,,103165765,2818,Unspecified,,,,,Toxicity in sc dosed NMRI mouse assessed as cataleptogenic potential administered 30 mins prior to testing measured every 15 mins for 60 mins by horizontal bar test,Other,19072656.0,
2090,416911,8,5,,103165765,2818,Active,112808.0,29595.0,0.00605,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in rat cortical membrane,Confirmatory,18603331.0,
2091,419436,3,3,,103165765,2818,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19398330.0,
2092,420668,8,5,,103165765,2818,Active,7531135.0,3757.0,0.19055,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
2093,420669,3,4,,103165765,2818,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
2094,425652,7,2,,103165765,2818,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2095,425653,7,2,,103165765,2818,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2096,427638,8,5,,103165765,2818,Active,110832828.0,281125.0,0.42,Ki,Displacement of [3H]SCH23390 from bovine dopamine D1 receptor,Confirmatory,19481941.0,
2097,427639,8,5,,103165765,2818,Active,118206.0,1813.0,0.040999999999999995,Ki,Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells,Confirmatory,19481941.0,
2098,427640,8,5,,103165765,2818,Active,118206.0,1813.0,0.027999999999999997,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells,Confirmatory,19481941.0,
2099,427641,8,5,,103165765,2818,Active,1169206.0,1814.0,0.96,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D3 receptor expressed in CHO cells,Confirmatory,19481941.0,
2100,427642,4,4,,103165765,2818,Active,,,0.016,Ki,Displacement of [3H]spiroperidol from human cloned dopamine D4.4 receptor expressed in CHO cells,Confirmatory,19481941.0,
2101,434955,1,2,,56422144,2818,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
2102,434959,1,1,,85788342,2818,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2103,434962,1,2,,56422144,2818,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
2104,434973,1,3,,56422144,2818,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
2105,434989,1,1,,56422144,2818,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2106,435003,1,3,,56422144,2818,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
2107,435005,1,1,,56422144,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
2108,435022,2,2,,56422144,2818,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
2109,435030,1,2,,56422144,2818,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2110,435030,1,2,,56422144,2818,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2111,439064,8,5,,103165765,2818,Active,118206.0,1813.0,0.22386999999999999,Ki,Displacement of [3H]spiperone from human cloned dopamine D2 receptor,Confirmatory,19796944.0,
2112,439066,8,5,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Displacement of [3H]ketanserin from human cloned 5HT2A receptor,Confirmatory,19796944.0,
2113,439067,3,3,,103165765,2818,Unspecified,,,,,Ratio of pKi for human cloned dopamine D2 receptor to pKi for human cloned 5HT2A receptor,Other,19796944.0,
2114,439068,8,5,,103165765,2818,Active,118228.0,1812.0,0.02138,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor,Confirmatory,19796944.0,
2115,439069,8,5,,103165765,2818,Active,1169206.0,1814.0,0.91201,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor,Confirmatory,19796944.0,
2116,439070,8,5,,103165765,2818,Active,112816.0,3358.0,0.01047,Ki,Displacement of [3H]mesulergine from human 5HT2C receptor,Confirmatory,19796944.0,
2117,444050,7,1,,103165765,2818,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
2118,444051,6,2,,103165765,2818,Unspecified,,,,,Total clearance in human,Other,20070106.0,
2119,444052,6,2,,103165765,2818,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
2120,444053,6,2,,103165765,2818,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
2121,444054,6,1,,103165765,2818,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
2122,444055,3,3,,103165765,2818,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
2123,444056,3,3,,103165765,2818,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
2124,444057,3,3,,103165765,2818,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
2125,444058,6,2,,103165765,2818,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
2126,449728,1,2,,56422144,2818,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
2127,449739,1,2,,855811,2818,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
2128,449762,1,2,,56422144,2818,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
2129,449763,1,3,,56422144,2818,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2130,449768,1,1,,855811,2818,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
2131,457687,5,3,,103165765,2818,Active,,,0.12,Ki,Displacement of [3H]nemonapride from D2-like receptor in Wistar rat striatum homogenate,Confirmatory,20153652.0,
2132,457688,8,5,,103165765,2818,Active,112812.0,24473.0,0.38,Ki,Displacement of [3H]-8-OH-DPAT from 5HT1A receptor in Wistar rat hippocampus homogenate,Confirmatory,20153652.0,
2133,457689,8,5,,103165765,2818,Active,112808.0,29595.0,0.013999999999999999,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in Wistar rat cortex homogenate,Confirmatory,20153652.0,
2134,457690,3,3,,103165765,2818,Unspecified,,,,,"Selectivity index, ratio of Ki for Wistar rat striatum D2-like receptor to Ki for Wistar rat hippocampus 5HT1A receptor",Other,20153652.0,
2135,457691,3,3,,103165765,2818,Unspecified,,,,,"Selectivity index, ratio of Ki for Wistar rat striatum D2-like receptor to Ki for Wistar rat cortex 5HT2A receptor",Other,20153652.0,
2136,457692,3,3,,103165765,2818,Unspecified,,,,,"Selectivity index, ratio of Ki for Wistar rat hippocampus 5HT1A receptor to Ki for Wistar rat cortex 5HT2A receptor",Other,20153652.0,
2137,457697,3,3,,103165765,2818,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 15 mg/kg, po after 30 mins (Rvb = 1.8 +/- 1.1 sec)",Other,20153652.0,
2138,457698,3,3,,103165765,2818,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 15 mg/kg, po after 60 mins (Rvb = 2.7 +/- 2.9 sec)",Other,20153652.0,
2139,457699,3,3,,103165765,2818,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of catalepsy by measuring time spent on elevated wood bar at 15 mg/kg, po after 90 mins (Rvb = 2.4 +/- 2.6 sec)",Other,20153652.0,
2140,457706,3,3,,103165765,2818,Unspecified,,,,,"Toxicity in CF1 mouse assessed as induction of motor impairment by measuring permanence time at 15 mg/kg, po by rotarod test (Rvb = 241.4 +/- 18.0 sec)",Other,20153652.0,
2141,458778,3,3,,103165765,2818,Unspecified,,,,,Displacement of [125I]CCL5 from HCMV US28 receptor at 10 uM,Other,20031418.0,
2142,458779,3,3,,103165765,2818,Unspecified,,,,,Activity at HCMV US28 receptor assessed as receptor-mediated inositol phosphate response at 10 uM,Other,20031418.0,
2143,463073,1,2,,855811,2818,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
2144,463075,1,1,,855811,2818,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
2145,463079,1,2,,56422144,2818,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
2146,463082,1,1,,56422144,2818,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
2147,463096,1,1,,50104084,2818,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
2148,463097,1,1,,50104084,2818,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
2149,463104,1,2,,56422144,2818,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2150,463106,1,2,,90341777,2818,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2151,463111,1,1,,855811,2818,Active,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
2152,463115,1,1,,855811,2818,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
2153,463141,1,2,,56422144,2818,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
2154,463165,1,1,,855811,2818,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
2155,463187,1,1,,855811,2818,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
2156,463189,1,1,,855811,2818,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2157,463189,1,1,,53777382,2818,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2158,463190,1,2,,56422144,2818,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
2159,463193,1,1,,855811,2818,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
2160,463195,1,2,,56422144,2818,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
2161,463210,1,2,,56422144,2818,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
2162,463212,1,1,,56422144,2818,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
2163,463254,1,1,,855811,2818,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2164,467611,3,6,,103165765,2818,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
2165,467612,3,6,,103165765,2818,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
2166,467613,5,3,,103165765,2818,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
2167,474877,11,1,,103165765,2818,Active,,,0.039810000000000005,Ki,Displacement of [3H]5CT from 5HT7 receptor,Confirmatory,20346662.0,
2168,478680,6,2,,103165765,2818,Active,,,0.3723,Ki,Binding affinity to dopamine D3 receptor,Confirmatory,20408551.0,
2169,484805,10,2,,103165765,2818,Inactive,7993747.0,10846.0,,IC50,Inhibition of human recombinant PDE10A expressed in baculovirus-SF21 cell system assessed as hydrolysis of [3H]cAMP after 1 hr by liquid scintillation counting,Confirmatory,20450197.0,
2170,484807,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK-801-induced hyperactivity administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,20450197.0,
2171,484808,3,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK-801-induced stereotyped sniffing administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,20450197.0,
2172,485270,1,1,,56422144,2818,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2173,485272,1,1,,56422144,2818,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
2174,485273,2,1,,56422144,2818,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
2175,485275,1,3,,56422144,2818,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
2176,485281,1,1,,855811,2818,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2177,485281,1,1,,11110968,2818,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2178,485290,1,1,,855811,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2179,485290,1,1,,11110968,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2180,485290,1,1,,11113341,2818,Inactive,20150581.0,,1.2589,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2181,485290,1,1,,26747001,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2182,485290,1,1,,26751524,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2183,485290,1,1,,50104084,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2184,485290,1,1,,50104086,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2185,485290,1,1,,50104087,2818,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2186,485294,1,1,,855811,2818,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
2187,485295,1,2,,90341777,2818,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
2188,485297,1,1,,855811,2818,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2189,485297,1,1,,90341777,2818,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2190,485298,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2191,485298,1,1,,90341777,2818,Inactive,,,8.1995,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2192,485313,1,2,,855811,2818,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2193,485313,1,2,,90341777,2818,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2194,485314,1,1,,855811,2818,Inconclusive,4505931.0,5423.0,79.4328,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2195,485314,1,1,,50104084,2818,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2196,485341,1,1,,855811,2818,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
2197,485342,1,2,,90341777,2818,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2198,485344,1,1,,855811,2818,Active,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
2199,485345,1,2,,90341777,2818,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2200,485346,1,1,,56422144,2818,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2201,485346,1,1,,56422144,2818,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2202,485347,1,2,,855811,2818,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
2203,485349,1,1,,855811,2818,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
2204,485350,1,2,,92124300,2818,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2205,485350,1,2,,92125385,2818,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2206,485350,1,2,,99300918,2818,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2207,485353,2,1,,855811,2818,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
2208,485358,1,1,,855811,2818,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
2209,485360,1,1,,855811,2818,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
2210,485364,1,1,,855811,2818,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
2211,485366,1,2,,90341777,2818,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2212,485367,1,2,,855811,2818,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2213,485368,1,2,,90341777,2818,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2214,488745,1,4,,85230974,2818,Inconclusive,,,14.7157,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2215,488752,1,4,,85230974,2818,Inconclusive,,,18.526,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2216,488772,1,1,,90341777,2818,Inconclusive,8659577.0,58819.0,33.5875,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2217,488773,1,2,,90341777,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2218,488806,1,2,,855811,2818,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
2219,488816,1,1,,90341777,2818,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
2220,488837,1,1,,855811,2818,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2221,488837,1,1,,90341777,2818,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2222,488839,1,1,,56422144,2818,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2223,488839,1,1,,56422144,2818,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2224,488847,1,3,,56422144,2818,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
2225,488862,1,1,,56422144,2818,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2226,488890,1,2,,56422144,2818,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
2227,488895,1,2,,56422144,2818,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2228,488896,1,1,,56422144,2818,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2229,488899,1,1,,56422144,2818,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2230,488922,1,2,,855811,2818,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
2231,488949,1,2,,85230974,2818,Inconclusive,41055989.0,54737.0,35.4813,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2232,488949,1,2,,90341777,2818,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2233,488953,1,1,,90341777,2818,Active,187960037.0,10951.0,79.4328,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2234,488960,1,1,,855811,2818,Inactive,160333370.0,22068.0,,,Confirmatory screen for identification of compounds that inhibit transient receptor potential cation channel C6 (TRPC6),Screening,,
2235,488961,1,1,,855811,2818,Inactive,160333370.0,22068.0,,,Confirmatory screen for identification of compounds that activate transient receptor potential cation channel C6 (TRPC6),Screening,,
2236,488965,1,2,,56422144,2818,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2237,488966,1,1,,56422144,2818,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
2238,488975,1,2,,56422144,2818,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
2239,488977,1,2,,56422144,2818,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
2240,488978,1,1,,90341777,2818,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
2241,488979,1,1,,50104084,2818,Inconclusive,74315350.0,7442.0,12.5893,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
2242,488980,1,1,,85230974,2818,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
2243,488981,1,1,,90341777,2818,Inconclusive,4503383.0,1812.0,12.5893,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
2244,488982,1,1,,90341777,2818,Inactive,4503383.0,1812.0,0.1836,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
2245,488983,1,1,,90341777,2818,Active,4503383.0,1812.0,0.631,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
2246,489030,2,1,,56422144,2818,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
2247,489031,2,1,,56422144,2818,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
2248,492631,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,20481570.0,
2249,492634,6,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed NMRI mouse assessed as reduction in spontaneous exploratory locomotor activity administered 30 mins prior to testing measured for 60 mins,Other,20481570.0,
2250,492638,8,5,,103165765,2818,Active,7531135.0,3757.0,17.0,Ki,Binding affinity to human ERG expressed in HEK293 cells,Confirmatory,20481570.0,
2251,492639,3,3,,103165765,2818,Active,,,0.0048,Ki,Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry,Confirmatory,20481570.0,
2252,492640,7,5,,103165765,2818,Active,112808.0,29595.0,0.01,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry,Confirmatory,20481570.0,
2253,492641,7,5,,103165765,2818,Active,112812.0,24473.0,0.16,Ki,Displacement of [3H]8OH-DPAT from 5HT1A receptor in rat CRL:CD(SD)BR-COBS hippocampus by scintillation spectrometry,Confirmatory,20481570.0,
2254,492642,7,5,,103165765,2818,Active,47117674.0,24318.0,0.319,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,20481570.0,
2255,492643,7,5,,103165765,2818,Active,118229.0,24316.0,0.21,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry,Confirmatory,20481570.0,
2256,492645,3,3,,103165765,2818,Active,,,,,"Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 10 mg/kg, ip administered 30 mins prior to testing measured for 60 mins",Other,20481570.0,
2257,492646,3,3,,103165765,2818,Active,,,,,"Antipsychotic activity in NMRI mouse assessed as increase of PCP-induced locomotor activity at 3 mg/kg, ip administered 30 mins prior to testing measured for 60 mins",Other,20481570.0,
2258,492947,1,1,,855811,2818,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2259,492953,1,1,,56422144,2818,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
2260,492956,1,1,,56422144,2818,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
2261,492967,1,2,,92125385,2818,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2262,492967,1,2,,99301431,2818,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2263,492972,1,1,,56422144,2818,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
2264,493005,1,1,,56422144,2818,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2265,493008,1,1,,56422144,2818,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2266,493008,1,1,,56422144,2818,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2267,493008,1,1,,56422144,2818,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2268,493008,1,1,,56422144,2818,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2269,493011,1,1,,56422144,2818,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2270,493012,1,1,,56422144,2818,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2271,493014,1,1,,855811,2818,Inconclusive,,,35.4813,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2272,493017,1,1,,103857966,2818,Unspecified,,1813.0,,,Wombat Data for BeliefDocking,Other,7914536.0,
2273,493027,1,2,,56422144,2818,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2274,493027,1,2,,56422144,2818,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2275,493033,1,2,,92124300,2818,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2276,493033,1,2,,92125385,2818,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2277,493033,1,2,,99300918,2818,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2278,493035,1,2,,56422144,2818,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2279,493035,1,2,,56422144,2818,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2280,493036,1,2,,56422144,2818,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
2281,493056,1,1,,855811,2818,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2282,493084,1,1,,855811,2818,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2283,493087,1,1,,56422144,2818,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
2284,493091,1,1,,56422144,2818,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
2285,493098,1,1,,56422144,2818,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
2286,493106,1,1,,90341777,2818,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2287,493107,1,1,,90341777,2818,Inconclusive,116283940.0,79915.0,2.31,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2288,493127,1,1,,50104084,2818,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
2289,493131,1,1,,56422144,2818,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
2290,493140,1,1,,103914138,2818,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
2291,493153,1,1,,90341777,2818,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2292,493153,1,1,,90341777,2818,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2293,493160,1,1,,56422144,2818,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
2294,493162,1,2,,99301431,2818,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2295,493162,1,2,,99302438,2818,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2296,493164,1,2,,90341777,2818,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2297,493164,1,2,,90341777,2818,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2298,493164,1,2,,90341777,2818,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2299,493187,1,2,,56422144,2818,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
2300,493189,1,1,,50104084,2818,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
2301,493244,1,1,,56422144,2818,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2302,493244,1,1,,56422144,2818,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2303,493244,1,1,,56422144,2818,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2304,493244,1,1,,56422144,2818,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2305,496817,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
2306,496818,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
2307,496819,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
2308,496820,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
2309,496821,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
2310,496823,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
2311,496824,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
2312,496825,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
2313,496826,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
2314,496827,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
2315,496828,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
2316,496829,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
2317,496830,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
2318,496831,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
2319,496832,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
2320,497005,4,2,,103165765,2818,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
2321,503306,2,5,,103165765,2818,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
2322,504326,1,2,,56422144,2818,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2323,504326,1,2,,56422144,2818,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2324,504327,1,1,,855811,2818,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2325,504327,1,1,,11110968,2818,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2326,504327,1,1,,90341777,2818,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2327,504329,1,1,,56422144,2818,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
2328,504332,1,1,,855811,2818,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2329,504332,1,1,,11110968,2818,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2330,504332,1,1,,50104084,2818,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2331,504332,1,1,,90341777,2818,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2332,504333,1,1,,855811,2818,Inconclusive,6683500.0,29994.0,79.4328,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2333,504339,1,1,,56422144,2818,Inconclusive,162330054.0,,79.4328,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
2334,504357,1,1,,56422144,2818,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2335,504357,1,1,,56422144,2818,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2336,504364,1,1,,85230974,2818,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
2337,504406,1,1,,56422144,2818,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
2338,504408,2,1,,855811,2818,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
2339,504411,1,1,,56422144,2818,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
2340,504414,1,1,,56422144,2818,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2341,504414,1,1,,56422144,2818,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2342,504423,1,1,,56422144,2818,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2343,504441,1,1,,56422144,2818,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2344,504444,1,1,,56422144,2818,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
2345,504454,1,3,,56422144,2818,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
2346,504459,1,3,,855811,2818,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
2347,504462,1,1,,56422144,2818,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
2348,504466,1,1,,855811,2818,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2349,504467,1,1,,855811,2818,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2350,504490,1,2,,56422144,2818,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
2351,504523,1,1,,56422144,2818,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2352,504523,1,1,,56422144,2818,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2353,504536,1,1,,90341777,2818,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
2354,504541,1,1,,855811,2818,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
2355,504547,1,1,,90341777,2818,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2356,504548,1,2,,90341777,2818,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
2357,504558,1,1,,56422144,2818,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2358,504577,2,2,,56422144,2818,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2359,504582,2,1,,56422144,2818,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2360,504594,1,1,,56422144,2818,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2361,504600,1,2,,855811,2818,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2362,504621,1,1,,56422144,2818,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2363,504634,1,1,,56422144,2818,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2364,504648,1,1,,56422144,2818,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
2365,504651,1,1,,855811,2818,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2366,504652,1,1,,855811,2818,Active,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2367,504660,1,1,,855811,2818,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2368,504690,1,3,,56422144,2818,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
2369,504692,2,2,,56422144,2818,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2370,504700,1,1,,56422144,2818,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2371,504700,1,1,,56422144,2818,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2372,504706,1,1,,855811,2818,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
2373,504707,1,1,,56422144,2818,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2374,504707,1,1,,56422144,2818,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2375,504720,1,1,,56422144,2818,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2376,504734,1,1,,56422144,2818,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2377,504749,1,3,,26751524,2818,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2378,504749,1,3,,104171134,2818,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2379,504749,1,3,1.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2380,504749,1,3,2.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2381,504749,1,3,3.0,104171134,2818,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2382,504749,1,3,4.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2383,504749,1,3,5.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2384,504749,1,3,6.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2385,504749,1,3,7.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2386,504749,1,3,8.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2387,504749,1,3,9.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2388,504749,1,3,10.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2389,504749,1,3,11.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2390,504749,1,3,12.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2391,504749,1,3,13.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2392,504749,1,3,14.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2393,504749,1,3,15.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2394,504749,1,3,16.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2395,504749,1,3,17.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2396,504749,1,3,18.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2397,504749,1,3,19.0,26751524,2818,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2398,504749,1,3,20.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2399,504749,1,3,21.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2400,504749,1,3,22.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2401,504749,1,3,23.0,104171134,2818,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2402,504749,1,3,24.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2403,504749,1,3,25.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2404,504749,1,3,26.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2405,504749,1,3,27.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2406,504749,1,3,28.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2407,504749,1,3,29.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2408,504749,1,3,30.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2409,504749,1,3,31.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2410,504749,1,3,32.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2411,504749,1,3,33.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2412,504749,1,3,34.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2413,504749,1,3,35.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2414,504749,1,3,36.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2415,504749,1,3,37.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2416,504749,1,3,38.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2417,504749,1,3,39.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2418,504749,1,3,40.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2419,504749,1,3,41.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2420,504749,1,3,42.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2421,504749,1,3,43.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2422,504749,1,3,44.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2423,504749,1,3,45.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2424,504749,1,3,46.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2425,504749,1,3,47.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2426,504749,1,3,48.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2427,504749,1,3,49.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2428,504749,1,3,50.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2429,504749,1,3,51.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2430,504749,1,3,52.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2431,504749,1,3,53.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2432,504749,1,3,54.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2433,504749,1,3,55.0,104171134,2818,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2434,504749,1,3,56.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2435,504749,1,3,57.0,26751524,2818,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2436,504749,1,3,58.0,26751524,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2437,504749,1,3,59.0,104171134,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2438,504749,1,3,60.0,104171134,2818,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2439,504749,1,3,61.0,26751524,2818,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2440,504766,2,1,,56422144,2818,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2441,504770,1,2,,92124300,2818,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2442,504775,1,1,,56422144,2818,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2443,504803,1,1,,56422144,2818,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2444,504810,1,2,,855811,2818,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2445,504810,1,2,,90341777,2818,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2446,504812,1,2,,855811,2818,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2447,504812,1,2,,90341777,2818,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2448,504821,1,1,,85230974,2818,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2449,504832,1,1,,855811,2818,Inconclusive,,,20.7865,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2450,504832,1,1,,104171134,2818,Active,,,16.9441,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2451,504834,1,1,,855811,2818,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2452,504834,1,1,,104171134,2818,Inconclusive,,,13.4591,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2453,504836,1,2,,90341777,2818,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2454,504842,1,1,,855811,2818,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2455,504845,1,1,,56422144,2818,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2456,504845,1,1,,90341777,2818,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2457,504845,1,1,,104171134,2818,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2458,504847,1,1,,11110968,2818,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2459,504847,1,1,,56422144,2818,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2460,504847,1,1,,90341777,2818,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2461,504847,1,1,,104171134,2818,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2462,504865,1,1,,11110968,2818,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2463,504865,1,1,,90341777,2818,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2464,504865,1,1,,104171134,2818,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2465,504884,1,2,,56422144,2818,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2466,504891,1,1,,56422144,2818,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2467,504894,1,1,,56422144,2818,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2468,504937,1,2,,56422144,2818,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2469,515780,5,1,,103165765,2818,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
2470,521220,3,3,,103165765,2818,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2471,524790,7,2,,103165765,2818,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2472,524791,7,2,,103165765,2818,Active,,,7.943280000000001,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2473,524794,7,1,,103165765,2818,Active,,,7.943280000000001,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2474,524795,7,2,,103165765,2818,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2475,524796,7,1,,103165765,2818,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2476,539464,4,2,,103165765,2818,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
2477,540209,4,3,,103165765,2818,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2478,540210,4,3,,103165765,2818,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2479,540211,2,5,,103165765,2818,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2480,540212,4,3,,103165765,2818,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2481,540213,4,3,,103165765,2818,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2482,540234,2,5,,103165765,2818,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
2483,540237,2,3,,103165765,2818,Active,,,,,Phospholipidosis-positive literature compound observed in rat,Other,17428028.0,
2484,540253,1,1,,56422144,2818,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2485,540253,1,1,,56422144,2818,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2486,540253,1,1,,56422144,2818,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2487,540256,1,2,,855811,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2488,540256,1,2,,50104084,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2489,540256,1,2,,90341777,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2490,540263,1,1,,56422144,2818,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2491,540263,1,1,,56422144,2818,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2492,540267,1,1,,56422144,2818,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2493,540275,1,1,,855811,2818,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2494,540276,1,2,,855811,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2495,540276,1,2,,11110967,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2496,540276,1,2,,11110968,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2497,540276,1,2,,11113341,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2498,540276,1,2,,26747001,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2499,540276,1,2,,26747002,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2500,540276,1,2,,26751523,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2501,540276,1,2,,26751524,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2502,540276,1,2,,50100204,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2503,540276,1,2,,50104084,2818,Active,420597.0,,12.5893,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2504,540276,1,2,,50104085,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2505,540276,1,2,,50104086,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2506,540276,1,2,,50104087,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2507,540276,1,2,,85230974,2818,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2508,540276,1,2,,90341777,2818,Inconclusive,420597.0,,23.0999,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2509,540277,1,1,,855811,2818,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2510,540295,1,1,,56422144,2818,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2511,540299,1,2,,92124300,2818,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2512,540299,1,2,,92125385,2818,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2513,540299,1,2,,99302438,2818,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2514,540303,1,1,,56422144,2818,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2515,540303,1,1,,56422144,2818,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2516,540303,1,1,,56422144,2818,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2517,540308,1,1,,56422144,2818,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2518,540317,1,1,,56422144,2818,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2519,540336,1,1,,56422144,2818,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2520,540336,1,1,,56422144,2818,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2521,540364,1,2,,56422144,2818,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2522,540370,1,3,,855811,2818,Inactive,6325022.0,855842.0,,,"Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin, Single Point, Cherry Pick 1",Other,,
2523,566251,2,4,,103165765,2818,Active,,,0.12,IC50,Inhibition of human dopamine D4.4 receptor,Confirmatory,20875743.0,
2524,576612,7,5,,103165765,2818,Active,7531135.0,3757.0,3.98107,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
2525,588208,2,3,,103165765,2818,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
2526,588209,2,3,,103165765,2818,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2527,588210,2,4,,103165765,2818,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2528,588211,2,3,,103165765,2818,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2529,588212,2,3,,103165765,2818,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2530,588213,2,3,,103165765,2818,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2531,588214,2,3,,103165765,2818,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2532,588215,2,3,,103165765,2818,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2533,588216,2,3,,103165765,2818,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2534,588217,2,3,,103165765,2818,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2535,588218,2,3,,103165765,2818,Active,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2536,588219,2,3,,103165765,2818,Active,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2537,588220,2,3,,103165765,2818,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2538,588334,1,1,,56422144,2818,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2539,588335,1,1,,56422144,2818,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2540,588342,1,1,,855811,2818,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2541,588349,1,1,,90341777,2818,Inconclusive,,,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2542,588352,1,2,,56422144,2818,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2543,588354,1,1,,56422144,2818,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2544,588358,1,2,,56422144,2818,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2545,588368,1,2,,855811,2818,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2546,588378,1,1,,90341777,2818,Inconclusive,171543895.0,6311.0,19.9526,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2547,588379,1,2,,124879684,2818,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2548,588391,1,1,,56422144,2818,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2549,588405,1,1,,56422144,2818,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2550,588413,1,2,,56422144,2818,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2551,588436,1,1,,56422144,2818,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2552,588453,1,1,,56422144,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2553,588453,1,1,,85230974,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2554,588453,1,1,,90341777,2818,Inactive,8659577.0,58819.0,1.7783,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2555,588453,1,1,,124879688,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2556,588456,1,1,,56422144,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2557,588456,1,1,,90341777,2818,Inconclusive,8659577.0,58819.0,33.5875,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2558,588456,1,1,,124879688,2818,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2559,588458,1,1,,56422144,2818,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2560,588459,1,2,,855811,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2561,588459,1,2,,855811,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2562,588459,1,2,,855811,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2563,588460,1,2,,855811,2818,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2564,588460,1,2,,855811,2818,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2565,588460,1,2,,855811,2818,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2566,588461,1,2,,855811,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2567,588461,1,2,,855811,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2568,588461,1,2,,855811,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2569,588473,1,1,,56422144,2818,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2570,588473,1,1,,56422144,2818,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2571,588475,1,2,,56422144,2818,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2572,588475,1,2,,56422144,2818,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2573,588478,1,2,,124801149,2818,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2574,588489,1,1,,56422144,2818,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2575,588492,1,1,,56422144,2818,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2576,588493,1,2,,56422144,2818,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2577,588497,1,2,,56422144,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2578,588497,1,2,,56422144,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2579,588497,1,2,,56422144,2818,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2580,588499,1,3,,56422144,2818,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2581,588499,1,3,,56422144,2818,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2582,588499,1,3,,56422144,2818,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2583,588501,1,2,,56422144,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2584,588501,1,2,,56422144,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2585,588501,1,2,,56422144,2818,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2586,588506,1,2,,855811,2818,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2587,588511,1,2,,56422144,2818,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2588,588519,1,2,,92124300,2818,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2589,588519,1,2,,92125385,2818,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2590,588519,1,2,,99300918,2818,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2591,588519,1,2,,99302438,2818,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2592,588549,1,1,,56422144,2818,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2593,588550,1,1,,855811,2818,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2594,588579,1,1,,11110968,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2595,588579,1,1,,56422144,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2596,588579,1,1,,90341777,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2597,588579,1,1,,104171134,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2598,588579,1,1,,124879684,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2599,588579,1,1,,124879686,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2600,588579,1,1,,124879688,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2601,588579,1,1,,124879690,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2602,588579,1,1,,124879691,2818,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2603,588590,1,1,,50104084,2818,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2604,588590,1,1,,56422144,2818,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2605,588590,1,1,,124879688,2818,Active,154350220.0,11201.0,79.4328,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2606,588591,1,1,,50104084,2818,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2607,588591,1,1,,56422144,2818,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2608,588621,1,1,,56422144,2818,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2609,588627,1,1,,56422144,2818,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2610,588664,1,2,,56422144,2818,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2611,588664,1,2,,56422144,2818,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2612,588674,1,2,,56422144,2818,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2613,588675,1,1,,56422144,2818,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2614,588676,1,1,,56422144,2818,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2615,588685,1,1,,855811,2818,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2616,588689,1,1,,56422144,2818,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2617,588692,2,1,,56422144,2818,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2618,588726,1,2,,56422144,2818,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2619,588727,1,1,,56422144,2818,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2620,588795,1,1,,56422144,2818,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2621,588795,1,1,,90341777,2818,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2622,588795,1,1,,124879688,2818,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2623,588814,1,3,,56422144,2818,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2624,588819,1,4,,56422144,2818,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2625,588834,2,1,,26751524,2818,Active,325651834.0,3757.0,10.0,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2626,588834,2,1,,50104084,2818,Inconclusive,325651834.0,3757.0,25.1189,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2627,588850,1,1,,56422144,2818,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2628,588852,1,3,,56422144,2818,Active,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2629,588855,1,1,,56422144,2818,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2630,588855,1,1,,124879688,2818,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2631,588856,1,1,,56422144,2818,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2632,588856,1,1,,124879688,2818,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2633,593483,1,10,,103165765,2818,Active,118206.0,1813.0,,,Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells at 4 times IC50 for 5 mins measured after 60 mins by topcount scintillation counting,Other,21421319.0,
2634,593484,1,10,,103165765,2818,Unspecified,118206.0,1813.0,,,Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells at 1850 nM for 5 mins measured after 30 mins by topcount scintillation counting relative to total binding capacity,Other,21421319.0,
2635,599883,5,5,,103165765,2818,Active,112816.0,3358.0,0.015,Ki,Displacement of [3H]mesulergine from human 5HT2C receptor in human tsA201 cells,Confirmatory,20719507.0,
2636,599884,5,5,,103165765,2818,Active,1703010.0,3362.0,0.017,Ki,Displacement of [3H]5-LSD from human 5HT6 receptor expressed in human HeLa cells,Confirmatory,20719507.0,
2637,602123,1,1,,56422144,2818,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2638,602141,1,1,,56422144,2818,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2639,602162,1,1,,56422144,2818,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2640,602163,1,1,,56422144,2818,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2641,602179,1,2,,56422144,2818,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2642,602229,1,1,,56422144,2818,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2643,602233,1,1,,56422144,2818,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2644,602244,1,2,,56422144,2818,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2645,602247,1,2,,56422144,2818,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2646,602248,1,2,,56422144,2818,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2647,602250,1,2,,56422144,2818,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2648,602252,1,1,,56422144,2818,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2649,602252,1,1,,56422144,2818,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2650,602261,1,1,,56422144,2818,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2651,602274,1,2,,56422144,2818,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2652,602276,1,1,,855811,2818,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2653,602277,1,1,,855811,2818,Active,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2654,602281,1,1,,56422144,2818,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2655,602281,1,1,,56422144,2818,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2656,602310,1,2,,56422144,2818,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2657,602310,1,2,,124879688,2818,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2658,602313,1,1,,56422144,2818,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2659,602314,1,2,,92124300,2818,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2660,602314,1,2,,92125385,2818,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2661,602314,1,2,,99300918,2818,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2662,602329,1,1,,56422144,2818,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2663,602332,1,1,,11110968,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2664,602332,1,1,,56422144,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2665,602332,1,1,,90341777,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2666,602332,1,1,,104171134,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2667,602332,1,1,,124879684,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2668,602332,1,1,,124879686,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2669,602332,1,1,,124879688,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2670,602332,1,1,,124879690,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2671,602332,1,1,,124879691,2818,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2672,602340,1,2,,56422144,2818,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2673,602342,2,1,,56422144,2818,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2674,602346,1,1,,56422144,2818,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2675,602363,1,1,,56422144,2818,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2676,602393,1,1,,56422144,2818,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2677,602396,1,2,,56422144,2818,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2678,602399,1,2,,56422144,2818,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2679,602405,1,1,,56422144,2818,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2680,602410,1,1,,56422144,2818,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2681,602429,1,1,,56422144,2818,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2682,602438,1,1,,56422144,2818,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2683,602440,1,1,,56422144,2818,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2684,602449,1,2,,56422144,2818,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2685,602481,1,1,,56422144,2818,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2686,620966,5,5,,103165765,2818,Active,112812.0,24473.0,0.14,Ki,Displacement of [3H]8OH-DPAT from 5HT1A in rat brain cerebral cortex after 15 mins by scintillation counting,Confirmatory,21816515.0,
2687,620967,5,5,,103165765,2818,Active,112808.0,29595.0,0.0089,Ki,Displacement of [3H]ketanserin from 5HT2A in rat brain cerebral cortex after 20 mins by scintillation counting,Confirmatory,21816515.0,
2688,620968,5,5,,103165765,2818,Active,47117674.0,24318.0,0.13,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in rat striatum tissue after 20 mins by scintillation counting,Confirmatory,21816515.0,
2689,620969,1,4,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for rat 5HT2A receptor to Ki for rat dopamine D2 receptor,Other,21816515.0,
2690,623870,1,1,,56422144,2818,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2691,623870,1,1,,56422144,2818,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2692,623877,1,1,,56422144,2818,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2693,623901,1,1,,56422144,2818,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2694,624030,1,2,,104171134,2818,Inactive,160794.0,,40.5334,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2695,624031,1,2,,104171134,2818,Inconclusive,,,32.1968,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2696,624032,1,2,,104171134,2818,Inconclusive,8393992.0,24660.0,0.0128,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2697,624037,1,3,,56422144,2818,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2698,624038,1,3,,56422144,2818,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2699,624040,1,3,,56422144,2818,Active,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2700,624044,1,2,,104171134,2818,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2701,624125,1,4,,56422144,2818,Active,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2702,624126,1,3,,56422144,2818,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2703,624127,1,2,,56422144,2818,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2704,624146,1,1,,90341777,2818,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2705,624147,1,1,,90341777,2818,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2706,624148,1,2,,90341777,2818,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2707,624149,1,1,,90341777,2818,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2708,624156,1,1,,85788342,2818,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2709,624168,1,1,,56422144,2818,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2710,624169,1,1,,56422144,2818,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2711,624170,1,1,,56422144,2818,Inactive,71051501.0,2744.0,35.4813,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2712,624170,1,1,,104171134,2818,Inactive,71051501.0,2744.0,14.1254,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2713,624171,1,1,,56422144,2818,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2714,624172,1,1,,56422144,2818,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2715,624172,1,1,,104171134,2818,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2716,624173,1,3,,56422144,2818,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2717,624173,1,3,,104171134,2818,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2718,624178,1,1,,56422144,2818,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2719,624178,1,1,,124879688,2818,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2720,624180,1,1,,135650115,2818,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,7908055.0,
2721,624180,1,1,,135650115,2818,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8394362.0,
2722,624180,1,1,,135650115,2818,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8397408.0,
2723,624180,1,1,,135650115,2818,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8997630.0,
2724,624181,1,1,,135650115,2818,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,9720804.0,
2725,624181,1,1,,135650115,2818,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,11414657.0,
2726,624181,1,1,,135650115,2818,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,15821958.0,
2727,624183,1,1,,135650115,2818,Active,113865998.0,15566.0,,,Antagonists at Mouse 5-Hydroxytryptamine receptor 5-HT7,Other,8394987.0,
2728,624186,1,1,,135650115,2818,Active,84370345.0,15563.0,,,Antagonists at Mouse 5-Hydroxytryptamine receptor 5-ht5a,Other,11343685.0,
2729,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,7680751.0,
2730,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,7908055.0,
2731,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,8997630.0,
2732,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9225298.0,
2733,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9730917.0,
2734,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9732398.0,
2735,624190,1,1,,135650115,2818,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9798944.0,
2736,624192,1,1,,135650115,2818,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,8522988.0,
2737,624192,1,1,,135650115,2818,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,9284367.0,
2738,624192,1,1,,135650115,2818,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,9730917.0,
2739,624192,1,1,,135650115,2818,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,15821958.0,
2740,624194,1,1,,135650115,2818,Active,13236497.0,3361.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-ht5a,Other,7988681.0,
2741,624194,1,1,,135650115,2818,Active,13236497.0,3361.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-ht5a,Other,11343685.0,
2742,624199,1,1,,135650115,2818,Active,4504535.0,3352.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1D,Other,8935801.0,
2743,624202,1,1,,56422144,2818,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2744,624202,1,1,,124879688,2818,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2745,624204,1,2,,56422144,2818,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2746,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,9732398.0,
2747,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,10217294.0,
2748,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,10991983.0,
2749,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,12629531.0,
2750,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,15102927.0,
2751,624209,1,1,,135650115,2818,Active,377520139.0,3358.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2C,Other,15322733.0,
2752,624210,1,1,,135650115,2818,Active,55956923.0,3350.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,8935801.0,
2753,624210,1,1,,135650115,2818,Active,55956923.0,3350.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9732398.0,
2754,624210,1,1,,135650115,2818,Active,55956923.0,3350.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Other,9760039.0,
2755,624211,1,1,,135650115,2818,Active,4504533.0,3351.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1B,Other,8935801.0,
2756,624218,1,1,,135650115,2818,Active,222080049.0,3357.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B,Other,9459568.0,
2757,624218,1,1,,135650115,2818,Active,222080049.0,3357.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B,Other,9732398.0,
2758,624218,1,1,,135650115,2818,Active,222080049.0,3357.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B,Other,15322733.0,
2759,624222,1,1,,135650115,2818,Active,8393583.0,29595.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A,Other,9655845.0,
2760,624223,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,8935801.0,
2761,624223,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,9732398.0,
2762,624223,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,12629531.0,
2763,624223,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,15102927.0,
2764,624223,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Other,15322733.0,
2765,624230,1,1,,135650115,2818,Active,4504537.0,3354.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e,Other,8935801.0,
2766,624233,1,1,,135650115,2818,Active,10835197.0,3355.0,,,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F,Other,8935801.0,
2767,624246,1,1,,56422144,2818,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2768,624256,1,2,,56422144,2818,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2769,624263,1,1,,56422144,2818,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2770,624263,1,1,,56422144,2818,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2771,624263,1,1,,124879688,2818,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2772,624263,1,1,,124879688,2818,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2773,624267,1,2,,56422144,2818,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2774,624267,1,2,,56422144,2818,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2775,624268,1,3,,56422144,2818,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2776,624288,1,1,,56422144,2818,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2777,624296,1,1,,855811,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2778,624296,1,1,,26751524,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2779,624296,1,1,,56422144,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2780,624296,1,1,,104171134,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2781,624297,1,1,,855811,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2782,624297,1,1,,26751524,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2783,624297,1,1,,56422144,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2784,624297,1,1,,104171134,2818,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2785,624304,1,2,,56422144,2818,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2786,624330,1,2,,56422144,2818,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2787,624349,1,2,,92124300,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2788,624349,1,2,,92125385,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2789,624349,1,2,,92307686,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2790,624349,1,2,,92308909,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2791,624349,1,2,,121362530,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2792,624349,1,2,,121363056,2818,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2793,624352,1,1,,56422144,2818,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2794,624354,1,1,,56422144,2818,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2795,624377,1,1,,855811,2818,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2796,624414,1,1,,56422144,2818,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2797,624414,1,1,,124879688,2818,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2798,624415,1,2,,56422144,2818,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2799,624415,1,2,,124879688,2818,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2800,624416,1,1,,855811,2818,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2801,624417,1,1,,56422144,2818,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2802,624418,1,1,,56422144,2818,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2803,624455,1,1,,90341777,2818,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2804,624463,1,1,,56422144,2818,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2805,624464,1,1,,56422144,2818,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2806,624465,1,1,,56422144,2818,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2807,624466,1,3,,855811,2818,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2808,624467,1,1,,855811,2818,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2809,624483,1,1,,56422144,2818,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2810,624607,1,9,,103165765,2818,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
2811,624608,3,2,,103165765,2818,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
2812,624611,1,9,,103165765,2818,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
2813,625144,5,5,,103165765,2818,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2814,625145,4,7,,103165765,2818,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2815,625146,5,5,,103165765,2818,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2816,625147,4,7,,103165765,2818,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2817,625148,4,7,,103165765,2818,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2818,625149,4,7,,103165765,2818,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2819,625150,5,5,,103165765,2818,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2820,625151,4,7,,103165765,2818,Active,113118.0,1128.0,0.01,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2821,625152,4,7,,103165765,2818,Active,113122.0,1129.0,0.47600000000000003,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2822,625153,4,7,,103165765,2818,Active,113125.0,1131.0,0.078,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2823,625154,4,7,,103165765,2818,Active,23503039.0,1132.0,0.045,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2824,625155,4,7,,103165765,2818,Active,543761.0,1133.0,0.013000000000000001,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2825,625156,1,9,,103165765,2818,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2826,625157,6,2,,103165765,2818,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2827,625158,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2828,625159,5,5,,103165765,2818,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2829,625160,1,9,,103165765,2818,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2830,625161,4,7,,103165765,2818,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2831,625162,4,7,,103165765,2818,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2832,625163,4,7,,103165765,2818,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2833,625164,1,6,,103165765,2818,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2834,625165,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2835,625166,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2836,625167,5,5,,103165765,2818,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2837,625168,4,7,,103165765,2818,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2838,625169,1,6,,103165765,2818,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2839,625170,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2840,625171,4,7,,103165765,2818,Active,7531135.0,3757.0,10.571,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2841,625172,4,7,,103165765,2818,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2842,625173,5,5,,103165765,2818,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2843,625174,5,5,,103165765,2818,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2844,625175,5,5,,103165765,2818,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2845,625176,1,9,,103165765,2818,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2846,625177,5,5,,103165765,2818,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2847,625178,5,5,,103165765,2818,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2848,625179,1,9,,103165765,2818,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2849,625180,5,5,,103165765,2818,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2850,625181,5,5,,103165765,2818,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2851,625182,5,5,,103165765,2818,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2852,625183,5,5,,103165765,2818,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2853,625184,5,5,,103165765,2818,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2854,625185,5,5,,103165765,2818,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2855,625186,5,5,,103165765,2818,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2856,625187,5,5,,103165765,2818,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2857,625188,1,9,,103165765,2818,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2858,625189,1,7,,103165765,2818,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2859,625190,4,5,,103165765,2818,Active,,,0.491,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2860,625191,4,7,,103165765,2818,Active,112815.0,25075.0,2.109,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2861,625192,4,7,,103165765,2818,Active,543727.0,3356.0,0.0042,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2862,625193,5,5,,103165765,2818,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2863,625194,4,7,,103165765,2818,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2864,625195,4,7,,103165765,2818,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2865,625196,5,6,,103165765,2818,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2866,625197,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2867,625198,4,7,,103165765,2818,Active,1168247.0,29412.0,0.038,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2868,625199,4,7,,103165765,2818,Active,543734.0,24173.0,0.006490000000000001,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2869,625200,4,7,,103165765,2818,Active,1168243.0,146.0,0.035,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2870,625201,4,7,,103165765,2818,Active,1351829.0,150.0,0.09,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2871,625202,4,7,,103165765,2818,Active,613504690.0,151.0,0.023,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2872,625203,4,7,,103165765,2818,Active,20141211.0,152.0,0.00788,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2873,625204,4,7,,103165765,2818,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2874,625205,4,7,,103165765,2818,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2875,625206,4,7,,103165765,2818,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2876,625207,4,7,,103165765,2818,Active,128616.0,6530.0,1.47,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2877,625208,5,5,,103165765,2818,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2878,625209,4,7,,103165765,2818,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2879,625210,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2880,625211,1,6,,103165765,2818,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2881,625212,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2882,625213,4,7,,103165765,2818,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2883,625214,1,9,,103165765,2818,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2884,625215,3,4,,103165765,2818,Active,,,3.752,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2885,625216,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2886,625217,4,7,,103165765,2818,Active,1168220.0,3357.0,0.011000000000000001,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2887,625218,4,7,,103165765,2818,Active,112816.0,3358.0,0.00604,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2888,625219,3,4,,103165765,2818,Active,,,0.866,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2889,625220,4,7,,103165765,2818,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2890,625221,4,7,,103165765,2818,Active,1703010.0,3362.0,0.011000000000000001,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2891,625222,4,7,,103165765,2818,Active,400630.0,6532.0,0.546,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2892,625223,4,7,,103165765,2818,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2893,625224,3,4,,103165765,2818,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2894,625225,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2895,625226,4,7,,103165765,2818,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2896,625227,4,7,,103165765,2818,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2897,625228,4,7,,103165765,2818,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2898,625229,5,5,,103165765,2818,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2899,625230,1,6,,103165765,2818,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2900,625231,4,7,,103165765,2818,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2901,625232,1,9,,103165765,2818,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2902,625233,4,7,,103165765,2818,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2903,625234,3,4,,103165765,2818,Active,,,0.612,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2904,625235,4,7,,103165765,2818,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2905,625236,5,5,,103165765,2818,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2906,625237,4,7,,103165765,2818,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2907,625238,4,7,,103165765,2818,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2908,625239,4,7,,103165765,2818,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2909,625240,1,9,,103165765,2818,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2910,625241,4,7,,103165765,2818,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2911,625242,4,7,,103165765,2818,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2912,625243,5,5,,103165765,2818,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2913,625244,5,5,,103165765,2818,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2914,625245,5,5,,103165765,2818,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2915,625246,1,9,,103165765,2818,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2916,625247,5,5,,103165765,2818,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2917,625248,5,5,,103165765,2818,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2918,625249,5,5,,103165765,2818,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2919,625250,5,5,,103165765,2818,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2920,625251,5,5,,103165765,2818,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2921,625252,4,7,,103165765,2818,Active,118228.0,1812.0,0.107,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2922,625253,4,7,,103165765,2818,Active,118206.0,1813.0,0.387,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2923,625254,4,7,,103165765,2818,Active,1169206.0,1814.0,0.258,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2924,625255,4,7,,103165765,2818,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2925,625256,4,7,,103165765,2818,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2926,625257,4,7,,103165765,2818,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2927,625258,4,7,,103165765,2818,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2928,625259,4,7,,103165765,2818,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2929,625260,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2930,625261,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2931,625262,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2932,625263,4,7,,103165765,2818,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2933,625264,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2934,625265,1,6,,103165765,2818,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2935,625266,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2936,625267,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2937,625268,4,2,,103165765,2818,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2938,625268,4,2,,103165765,2818,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2939,625268,4,2,,103165765,2818,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2940,625268,4,2,,103165765,2818,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2941,625269,4,7,,103165765,2818,Active,547645.0,3269.0,0.00491,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2942,625270,4,7,,103165765,2818,Active,123120.0,3274.0,3.61,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2943,625271,5,5,,103165765,2818,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2944,625272,3,4,,103165765,2818,Active,,,0.384,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2945,625273,4,6,,103165765,2818,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2946,625274,1,6,,103165765,2818,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2947,625275,3,4,,103165765,2818,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2948,625277,1,3,,103165765,2818,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2949,625279,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2950,625280,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2951,625281,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2952,625282,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2953,625283,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2954,625284,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2955,625285,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2956,625286,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2957,625287,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2958,625288,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2959,625289,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2960,625290,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2961,625291,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2962,625292,1,3,,103165765,2818,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2963,628577,3,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed Swiss albino mouse assessed as inhibition of apomorphine-induced mesh climbing response administered 10 mins prior to apomorphine challenge measured at 5 mins intervals for up to 20 mins after 10 mins post dose,Other,21824691.0,
2964,628578,3,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed Swiss albino mouse assessed as inhibition of 5-hydoxytryptophan-induced head twitches behavior administered 30 mins prior to 5-hydoxytryptophan challenge measured at 10 mins intervals for 30 mins after 20 mins post dose,Other,21824691.0,
2965,629788,4,5,,103165765,2818,Inactive,7993747.0,10846.0,,IC50,Inhibition of N-terminal His-tagged human PDE10A expressed in Escherichia coli using [3H]cAMP after 1 hr by scintillation proximity assay,Confirmatory,21988093.0,
2966,629997,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK801-induced hyperactivity administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,21988093.0,
2967,629998,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK801-induced stereotyped sniffing administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,21988093.0,
2968,630006,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK801-induced hyperactivity at minimum effective dose administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,21988093.0,
2969,630254,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Wistar rat assessed as reduction in MK801-induced stereotyped sniffing at minimum effective dose administered 30 mins prior to MK801 challenge measured 1 hr after inducer challenge,Other,21988093.0,
2970,632452,6,5,,103165765,2818,Active,14194819.0,59340.0,0.19952999999999999,Ki,Displacement of [3H]histamine from human H4 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Confirmatory,22003888.0,
2971,640309,4,5,,103165765,2818,Inconclusive,8488960.0,3363.0,,Ki,Displacement of [3H]LSD from human 5HT7 receptor by liquid scintillation counting,Confirmatory,22245230.0,
2972,640310,4,5,,103165765,2818,Active,547645.0,3269.0,0.0018,Ki,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Confirmatory,22245230.0,
2973,640311,4,5,,103165765,2818,Inconclusive,20141211.0,152.0,,Ki,Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting,Confirmatory,22245230.0,
2974,640547,4,5,,103165765,2818,Active,113118.0,1128.0,0.0018,Ki,Displacement of [3H]QNB from human M1 receptor by liquid scintillation counting,Confirmatory,22245230.0,
2975,643383,1,6,,103165765,2818,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
2976,646277,1,3,,103165765,2818,Active,,,,,Antipsychotic activity in CD1 mouse assessed as reduction in spontaneous locomotor activity measuring number of crossings at 1.25 to 5 mg/kg every 5 mins for 1 hr,Other,22277589.0,
2977,646280,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in CD1 mouse assessed as inhibition of MK-801-induced hyperactivity measuring number of crossings measured every 5 mins for 1 hr,Other,22277589.0,
2978,651550,1,1,,56422144,2818,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2979,651560,1,1,,56422144,2818,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2980,651572,1,2,,855811,2818,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2981,651582,1,1,,56422144,2818,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2982,651602,1,1,,855811,2818,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2983,651602,1,1,,855811,2818,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2984,651602,1,1,,855811,2818,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2985,651610,2,1,,855811,2818,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2986,651631,4,1,,144203664,2818,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2987,651632,4,1,,144203664,2818,Inactive,296439460.0,79915.0,10.5909,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2988,651633,4,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2989,651634,4,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2990,651635,1,3,,11110968,2818,Inconclusive,171543895.0,6311.0,12.5893,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2991,651635,1,3,,56422144,2818,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2992,651635,1,3,,90341777,2818,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2993,651636,1,1,,56422144,2818,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2994,651640,1,1,,855811,2818,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2995,651644,1,1,,56422144,2818,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2996,651647,1,1,,56422144,2818,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2997,651654,1,1,,56422144,2818,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2998,651658,1,1,,855811,2818,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2999,651660,1,1,,56422144,2818,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3000,651661,2,1,,855811,2818,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3001,651687,1,1,,56422144,2818,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3002,651699,1,1,,56422144,2818,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3003,651699,1,1,,56422144,2818,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3004,651702,1,2,,56422144,2818,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
3005,651704,2,1,,855811,2818,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3006,651704,2,1,,56422144,2818,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3007,651710,1,1,,855811,2818,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3008,651711,2,1,,855811,2818,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3009,651718,1,2,,855811,2818,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
3010,651719,1,2,,855811,2818,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
3011,651723,1,1,,56422144,2818,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
3012,651724,1,1,,56422144,2818,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
3013,651725,1,1,,56422144,2818,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
3014,651768,1,2,,56422144,2818,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3015,651800,1,1,,855811,2818,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3016,651819,1,1,,56422144,2818,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3017,651820,1,1,,855811,2818,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3018,651820,1,1,,56422144,2818,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3019,651821,2,4,,855811,2818,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3020,651828,1,2,,92308909,2818,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3021,651828,1,2,,121360958,2818,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3022,651828,1,2,,121362530,2818,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3023,651957,1,1,,855811,2818,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3024,651958,1,1,,855811,2818,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3025,651965,1,1,,56422144,2818,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3026,651999,1,1,,56422144,2818,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3027,652010,1,1,,855811,2818,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3028,652017,1,1,,855811,2818,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3029,652025,1,1,,56422144,2818,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3030,652039,1,1,,855811,2818,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3031,652048,1,2,,56422144,2818,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3032,652048,1,2,,144203664,2818,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3033,652051,1,1,,56422144,2818,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3034,652051,1,1,,144203664,2818,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3035,652054,1,1,,56422144,2818,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3036,652067,1,4,,855811,2818,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3037,652104,1,1,,56422144,2818,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3038,652105,1,1,,56422144,2818,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3039,652106,1,1,,56422144,2818,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3040,652106,1,1,,90341777,2818,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3041,652106,1,1,,124879688,2818,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3042,652115,1,1,,855811,2818,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3043,652126,1,3,,855811,2818,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3044,652154,1,1,,855811,2818,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3045,652162,2,1,,855811,2818,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3046,652163,1,1,,855811,2818,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3047,652163,1,1,,56422144,2818,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3048,652197,1,1,,855811,2818,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3049,652257,1,1,,855811,2818,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3050,656078,7,2,,103165765,2818,Active,118206.0,1813.0,0.20600000000000002,IC50,Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay,Confirmatory,22243698.0,
3051,656079,7,2,,103165765,2818,Active,118206.0,1813.0,0.10232999999999999,Ki,Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting,Confirmatory,22243698.0,
3052,659849,4,5,,103165765,2818,Active,1351829.0,150.0,0.185,Ki,Displacement of [3H]-MK-912 from human cloned adrenergic alpha2A receptor expressed in insect Sf9 membranes after 60 mins by liquid scintillation counting,Confirmatory,22268448.0,
3053,659850,4,5,,103165765,2818,Active,543727.0,3356.0,0.00484,Ki,Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,22268448.0,
3054,659851,4,5,,103165765,2818,Active,1345939.0,1815.0,0.018000000000000002,Ki,Displacement of [3H]-YM09151-2 from human cloned dopamine D4 receptor expressed in insect Sf9 cells after 60 mins by liquid scintillation counting,Confirmatory,22268448.0,
3055,659852,4,5,,103165765,2818,Active,231454.0,3350.0,0.10099999999999999,Ki,Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,22268448.0,
3056,659853,1,3,,103165765,2818,Unspecified,,,,,"Lipophilicity, log K of the compound in IAM-PC-DD2 HPLC column by UV method",Other,22268448.0,
3057,678652,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed rat assessed as reduction of MK801-induced hyperactivity,Other,22902656.0,
3058,678653,1,3,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed rat assessed as reduction of MK801-induced stereotyped sniffing,Other,22902656.0,
3059,678712,1,8,,103165765,2818,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
3060,678713,1,8,,103165765,2818,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
3061,678714,1,8,,103165765,2818,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3062,678715,1,8,,103165765,2818,Unspecified,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3063,678716,1,8,,103165765,2818,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
3064,678717,1,8,,103165765,2818,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
3065,678722,1,5,,103165765,2818,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
3066,681619,2,7,,103165765,2818,Unspecified,238054374.0,5243.0,58.0,Km,TP_TRANSPORTER: ATP hydrolysis in membranes from MDR1-expressing insect cells,Confirmatory,12031686.0,
3067,686940,1,1,,855811,2818,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3068,686964,1,1,,855811,2818,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3069,686970,1,2,,56422144,2818,Inconclusive,49168486.0,3417.0,10.3225,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3070,686971,1,2,,56422144,2818,Inconclusive,,,29.0929,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3071,686977,2,1,,49698447,2818,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
3072,686978,1,1,,56422144,2818,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3073,686978,1,1,,124879684,2818,Active,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3074,686978,1,1,,124879686,2818,Inconclusive,79154014.0,55775.0,14.581,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3075,686978,1,1,,124879691,2818,Inconclusive,79154014.0,55775.0,25.929000000000002,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3076,686978,1,1,,144203664,2818,Active,79154014.0,55775.0,18.8375,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3077,686979,1,1,,56422144,2818,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3078,686979,1,1,,124879684,2818,Inconclusive,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3079,686979,1,1,,124879686,2818,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3080,686979,1,1,,124879691,2818,Active,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3081,686979,1,1,,144203664,2818,Inconclusive,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3082,686992,2,1,,855811,2818,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3083,686996,1,1,,855811,2818,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3084,687014,1,1,,855811,2818,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3085,687016,1,1,,855811,2818,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3086,687035,1,1,,163564230,2818,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3087,687037,1,3,,163564230,2818,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3088,691260,3,5,,103165765,2818,Active,1703010.0,3362.0,0.017,Ki,Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1.5 hrs by liquid scintillation counting,Confirmatory,22537153.0,
3089,692513,6,2,,103165765,2818,Active,547645.0,3269.0,,Ki,Binding affinity to human histamine H1 receptor,Confirmatory,21062081.0,
3090,694794,3,5,,103165765,2818,Active,8488960.0,3363.0,0.018000000000000002,Ki,Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells after 1 hr,Confirmatory,22926225.0,
3091,694795,6,2,,103165765,2818,Active,231454.0,3350.0,0.14300000000000002,Ki,Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells after 1 hr,Confirmatory,22926225.0,
3092,694796,3,5,,103165765,2818,Active,1703010.0,3362.0,0.004,Ki,Displacement of [3H]-LSD from human 5-HT6 receptor expressed in HEK293 cells after 1 hr,Confirmatory,22926225.0,
3093,694797,3,5,,103165765,2818,Active,118206.0,1813.0,0.07200000000000001,Ki,Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr,Confirmatory,22926225.0,
3094,699060,1,7,,103165765,2818,Active,8488960.0,3363.0,,,Antagonist activity at human 5HT7A receptor expressed in human HeLa cells assessed as inhibition of forskolin-induced cAMP accumulation by ELISA,Other,22738316.0,
3095,705396,2,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in sc dosed rat prepulse inhibition model,Other,22834877.0,
3096,705397,2,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in amphetamine-induced spontaneous locomotor activity,Other,22834877.0,
3097,705398,2,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in phencyclidine-induced locomotor activity,Other,22834877.0,
3098,705399,2,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in sc dosed rat assessed as decrease in spontaneous locomotor activity,Other,22834877.0,
3099,705400,2,2,,103165765,2818,Unspecified,,,,,Antipsychotic activity in sc dosed rat by conditioned avoidance response test,Other,22834877.0,
3100,720504,1,1,,56422144,2818,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3101,720508,1,1,,855811,2818,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3102,720509,1,1,,855811,2818,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3103,720511,1,1,,855811,2818,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3104,720516,2,1,,144203664,2818,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3105,720532,1,1,,11110968,2818,Inconclusive,420597.0,,8.9125,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3106,720532,1,1,,124879684,2818,Inconclusive,420597.0,,8.9125,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3107,720532,1,1,,124879686,2818,Inconclusive,420597.0,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3108,720532,1,1,,124879690,2818,Active,420597.0,,3.5481,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3109,720532,1,1,,124879691,2818,Active,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3110,720532,1,1,,144203664,2818,Active,420597.0,,10.0,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3111,720533,1,1,,11110968,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3112,720533,1,1,,124879684,2818,Active,,,25.1189,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3113,720533,1,1,,124879686,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3114,720533,1,1,,124879690,2818,Active,,,8.9125,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3115,720533,1,1,,124879691,2818,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3116,720533,1,1,,144203664,2818,Inconclusive,,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3117,720538,1,2,,90341777,2818,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3118,720542,1,2,,56422144,2818,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3119,720543,1,1,,855811,2818,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3120,720551,1,2,,56422144,2818,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3121,720552,2,1,,144203664,2818,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3122,720553,1,2,,56422144,2818,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3123,720554,1,3,,121362530,2818,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
3124,720559,1,2,,90341777,2818,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3125,720572,1,2,,90341777,2818,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3126,720573,1,2,,90341777,2818,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3127,720579,2,1,,56422144,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3128,720579,2,1,,124879686,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3129,720579,2,1,,124879691,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3130,720580,1,1,,56422144,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3131,720580,1,1,,124879686,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3132,720580,1,1,,124879691,2818,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3133,720582,1,1,,855811,2818,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3134,720596,1,1,,855811,2818,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3135,720634,2,1,,144203664,2818,Inactive,,,8.4127,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3136,720635,2,1,,144203664,2818,Inconclusive,,,7.4978,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3137,720637,2,1,,144203664,2818,Inconclusive,,,12.3481,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3138,720641,1,2,,92307686,2818,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3139,720641,1,2,,92308909,2818,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3140,720647,1,2,,855811,2818,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3141,720648,1,1,,855811,2818,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3142,720674,2,2,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3143,720675,2,2,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3144,720678,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3145,720679,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3146,720680,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3147,720681,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3148,720682,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3149,720683,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3150,720684,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3151,720685,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3152,720686,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3153,720687,2,2,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3154,720691,4,1,,144203664,2818,Inactive,311348376.0,2908.0,2.6832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3155,720692,3,1,,144203664,2818,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3156,720693,3,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3157,720700,1,4,,855811,2818,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3158,720702,1,1,,855811,2818,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3159,720704,1,4,,855811,2818,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3160,720707,1,2,,56422144,2818,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3161,720708,1,2,,56422144,2818,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3162,720709,1,2,,56422144,2818,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3163,720711,1,2,,56422144,2818,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3164,720717,1,3,,92124300,2818,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3165,720717,1,3,,92125385,2818,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3166,720717,1,3,,92307686,2818,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3167,720717,1,3,,92308909,2818,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3168,720717,1,3,,92310006,2818,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3169,720719,2,1,,144203664,2818,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3170,720725,2,1,,144203664,2818,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3171,733546,4,2,,103165765,2818,Active,112816.0,3358.0,0.00933,Ki,Displacement of [3H]mesulergine from human 5HT2C receptor expressed in tsA201 cell membranes after 1 hr by scintillation counting analysis,Confirmatory,23301527.0,
3172,733547,4,2,,103165765,2818,Active,543727.0,3356.0,0.03631,Ki,Displacement of [3H]ketanserin from human 5HT2A receptor expressed in tsA201 cell membranes after 1 hr by scintillation counting analysis,Confirmatory,23301527.0,
3173,733550,1,2,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for human 5HT2C receptor to Ki for human 5HT2A receptor,Other,23301527.0,
3174,733557,5,1,,103165765,2818,Active,112816.0,3358.0,0.07244,Ki,Antagonist activity at human 5HT2C receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced intracellular calcium release measured for 90 secs by fluorescence assay,Confirmatory,23301527.0,
3175,733558,5,1,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Antagonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced intracellular calcium release measured for 90 secs by fluorescence assay,Confirmatory,23301527.0,
3176,734508,1,2,,103165765,2818,Active,,,0.022000000000000002,Ki,Displacement of [3H]-QNB from muscarinic receptor in Wistar rat brain membrane after 60 mins by liquid scintillation counting,Confirmatory,23353740.0,
3177,734509,2,5,,103165765,2818,Active,543734.0,24173.0,0.028999999999999998,Ki,Displacement of [3H]-prazosin from alpha1B adrenergic receptor in Wistar rat liver membrane after 45 mins by liquid scintillation counting,Confirmatory,23353740.0,
3178,734510,2,5,,103165765,2818,Active,231461.0,25083.0,0.1,Ki,Displacement of [3H]-RX821002 from alpha2A adrenergic receptor in Wistar rat cortical membrane after 45 mins by liquid scintillation counting,Confirmatory,23353740.0,
3179,734511,2,5,,103165765,2818,Active,112816.0,3358.0,0.024,Ki,Displacement of [3H]-mesulergine from human 5HT2C receptor after 60 mins by liquid scintillation counting,Confirmatory,23353740.0,
3180,734512,2,5,,103165765,2818,Active,112812.0,24473.0,0.26,Ki,Displacement of [3H]-OH-8-DPAT from 5HT1A receptor in Wistar rat hippocampal membrane after 15 mins by liquid scintillation counting,Confirmatory,23353740.0,
3181,734513,2,5,,103165765,2818,Active,112808.0,29595.0,0.02,Ki,Displacement of [3H]-ketanserin from 5HT2A receptor in Wistar rat cortical membrane after 15 mins by liquid scintillation counting,Confirmatory,23353740.0,
3182,734514,2,5,,103165765,2818,Active,1345939.0,1815.0,0.06,Ki,Displacement of [3H]-YM-09151-2 from human D4 dopamine receptor after 120 mins by liquid scintillation counting,Confirmatory,23353740.0,
3183,734515,2,5,,103165765,2818,Active,47117674.0,24318.0,0.13,Ki,Displacement of [3H]-YM-09151-2 from D2 dopamine receptor in Wistar rat brain striatal membrane after 60 mins by liquid scintillation counting,Confirmatory,23353740.0,
3184,743012,3,1,,144203664,2818,Active,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3185,743014,3,1,,144203664,2818,Active,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3186,743015,3,1,,144203664,2818,Active,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3187,743033,3,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3188,743035,2,1,,144203664,2818,Inconclusive,124375976.0,367.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3189,743036,2,1,,144203664,2818,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3190,743040,3,1,,144203664,2818,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3191,743041,3,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3192,743042,3,1,,144203664,2818,Inconclusive,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3193,743053,2,1,,144203664,2818,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3194,743054,2,1,,144203664,2818,Active,124375976.0,367.0,28.7255,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3195,743063,2,1,,144203664,2818,Inconclusive,124375976.0,367.0,22.5767,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3196,743064,3,1,,144203664,2818,Active,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3197,743065,3,1,,144203664,2818,Active,399498506.0,24831.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3198,743066,3,1,,144203664,2818,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3199,743067,2,1,,144203664,2818,Inconclusive,399498506.0,24831.0,19.5704,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3200,743069,2,1,,144203664,2818,Inconclusive,348019627.0,2099.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3201,743074,2,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3202,743075,2,1,,144203664,2818,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3203,743077,2,1,,144203664,2818,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3204,743078,2,1,,144203664,2818,Inconclusive,348019627.0,2099.0,23.9145,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3205,743079,3,1,,144203664,2818,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3206,743080,3,1,,144203664,2818,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3207,743081,3,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3208,743083,3,1,,144203664,2818,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3209,743084,3,1,,144203664,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3210,743085,3,1,,144203664,2818,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3211,743086,3,1,,144203664,2818,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3212,743091,2,1,,144203664,2818,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3213,743094,3,1,,144203664,2818,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3214,743122,2,1,,144203664,2818,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3215,743126,1,1,,855811,2818,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3216,743139,2,1,,144203664,2818,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3217,743140,2,1,,144203664,2818,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3218,743191,3,1,,170464853,2818,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3219,743194,3,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3220,743199,2,1,,170464853,2818,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3221,743202,4,1,,170464853,2818,Inconclusive,20149576.0,4780.0,16.7842,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3222,743203,3,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3223,743205,1,1,,90341777,2818,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3224,743205,1,1,,90341777,2818,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3225,743206,1,1,,90341777,2818,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3226,743206,1,1,,90341777,2818,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3227,743207,1,1,,90341777,2818,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3228,743207,1,1,,90341777,2818,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3229,743209,3,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3230,743210,4,1,,170464853,2818,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3231,743211,3,1,,170464853,2818,Inconclusive,,,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3232,743212,3,1,,170464853,2818,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3233,743213,3,1,,170464853,2818,Inconclusive,,,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3234,743215,3,1,,170464853,2818,Inconclusive,216409690.0,5467.0,0.075,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3235,743217,3,1,,170464853,2818,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3236,743218,3,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3237,743219,3,1,,170464853,2818,Inconclusive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3238,743220,3,1,,170464853,2818,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3239,743221,3,1,,170464853,2818,Inconclusive,,,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3240,743222,3,1,,170464853,2818,Inconclusive,216409708.0,7421.0,0.5955,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3241,743223,3,1,,170464853,2818,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3242,743224,3,1,,170464853,2818,Inconclusive,,,21.13,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3243,743225,3,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3244,743226,2,1,,170464853,2818,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3245,743227,2,1,,170464853,2818,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3246,743228,3,1,,170464853,2818,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3247,743238,1,1,,855811,2818,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3248,743239,2,1,,170464853,2818,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3249,743240,2,1,,170464853,2818,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3250,743241,2,1,,170464853,2818,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3251,743242,2,1,,170464853,2818,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3252,743244,1,1,,90341777,2818,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3253,743244,1,1,,144203664,2818,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3254,743247,1,2,,855811,2818,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3255,743247,1,2,,56422144,2818,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3256,743255,1,1,,56422144,2818,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3257,743266,1,2,,56422144,2818,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3258,743268,1,1,,172080790,2818,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3259,743269,1,1,,855811,2818,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3260,743269,1,1,,855811,2818,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3261,743270,1,1,,172080790,2818,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3262,743271,1,1,,172080790,2818,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3263,743272,1,1,,172080790,2818,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3264,743279,1,2,,56422144,2818,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3265,743344,1,1,,104171134,2818,Inactive,,,18.8212,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3266,743345,1,1,,104171134,2818,Inactive,,,21.1177,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3267,743346,1,1,,104171134,2818,Inactive,,,4.7277,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3268,743347,1,1,,104171134,2818,Inactive,,,0.0421,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3269,743397,1,1,,855811,2818,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3270,743398,1,1,,855811,2818,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3271,743398,1,1,,56422144,2818,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3272,750619,1,1,,103165765,2818,Unspecified,,,,,"Therapeutic Index, ratio of ED50 for catalepsy in mouse to ED50 for antipsychotic activity in po dosed mouse assessed as reduction in MK-801-induced hyperactivity",Other,23675993.0,
3273,750620,1,1,,103165765,2818,Unspecified,,,,,"Therapeutic Index, ratio of ED50 for catalepsy in mouse to ED50 for antipsychotic activity in po dosed mouse assessed as reduction in apomorphine-induced climbing behavior",Other,23675993.0,
3274,750622,1,1,,103165765,2818,Unspecified,,,,,Toxicity in po dosed mouse assessed as induction of catalepsy,Other,23675993.0,
3275,750623,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed mouse assessed as reduction in MK-801-induced hyperactivity administered for 30 mins prior to MK-801-challenge measured after 90 mins,Other,23675993.0,
3276,750624,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed mouse assessed as reduction in apomorphine-induced climbing behavior administered for 30 mins prior to apomorphine-challenge measured at 10 to 30 mins post-dose,Other,23675993.0,
3277,750648,2,3,,103165765,2818,Active,7531135.0,3757.0,0.65,IC50,Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay,Confirmatory,23675993.0,
3278,750649,2,3,,103165765,2818,Active,399889.0,100730517.0,0.0038,Ki,Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum after 60 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3279,750650,2,3,,103165765,2818,Active,118211.0,29238.0,0.2398,Ki,Displacement of [3H]7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle after 60 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3280,750651,2,3,,103165765,2818,Active,112808.0,29595.0,0.0116,Ki,Displacement of [3H]ketanserin from 5HT2A receptor in rat cerebral cortex after 15 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3281,750652,2,3,,103165765,2818,Active,112812.0,24473.0,0.1416,Ki,Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat cerebral cortex after 30 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3282,750653,2,3,,103165765,2818,Active,47117674.0,24318.0,0.1287,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in rat striatum after 15 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3283,750654,2,3,,103165765,2818,Active,112817.0,25187.0,0.0162,Ki,Displacement of [3H]mesulergine from 5HT2C receptor in rat cerebral cortex after 15 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3284,750655,1,1,,103165765,2818,Active,,,0.0325,Ki,Displacement of [3H]prazosin from alpha-1 adrenergic receptor in rat cerebral cortex after 60 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3285,750656,1,1,,103165765,2818,Active,,,0.0556,Ki,Displacement of [3H]rauwolscine from alpha-2 adrenergic receptor in rat cerebral cortex after 60 mins by liquid scintillation counting analysis,Confirmatory,23675993.0,
3286,751888,1,1,,103165765,2818,Active,,,0.04,IC50,Binding affinity to human dopamine D4.4 receptor by radioligand displacement assay,Confirmatory,23466604.0,
3287,752249,1,1,,103165765,2818,Active,,,0.032,IC50,Binding affinity to human dopamine D4.4 receptor by radioligand displacement assay,Confirmatory,23582449.0,
3288,759364,2,3,,103165765,2818,Active,8488960.0,3363.0,0.018000000000000002,Ki,Displacement of [3H]5-CT from human 5HT7b receptor expressed in HEK293 cells after 1 hr,Confirmatory,23787101.0,
3289,759365,2,3,,103165765,2818,Active,1703010.0,3362.0,0.004,Ki,Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1 hr,Confirmatory,23787101.0,
3290,759366,2,3,,103165765,2818,Active,231454.0,3350.0,0.14300000000000002,Ki,Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in HEK293 cells after 1 hr,Confirmatory,23787101.0,
3291,763633,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in CF1 mouse assessed as prevention of ketamine-induced hyperlocomotion at 1 mg/kg, po administered 30 mins prior ketamine challenge measured for 20 mins post challenge",Other,23792350.0,
3292,763636,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in CF1 mouse assessed as prevention of apomorphine-induced climbing behaviour at 15 mg/kg, po administered 30 mins prior apomorphine challenge measured 5 to 30 mins post challenge",Other,23792350.0,
3293,763652,2,3,,103165765,2818,Active,543734.0,24173.0,0.025,Ki,Displacement of [3H]-prozosin from alpha1B adrenoreceptor in rat liver membranes after 45 mins by liquid scintillation counting,Confirmatory,23792350.0,
3294,763653,1,2,,103165765,2818,Active,,,0.022000000000000002,Ki,Displacement of [3H]-QNB from muscarinic receptor in rat brain cortical membranes after 60 mins by liquid scintillation counting,Confirmatory,23792350.0,
3295,763654,1,2,,103165765,2818,Active,,,0.1,Ki,Displacement of [3H]-RX821002 from alpha2 adrenoreceptor in rat brain cortical membranes after 45 mins by liquid scintillation counting,Confirmatory,23792350.0,
3296,763655,2,3,,103165765,2818,Active,112816.0,3358.0,0.023,Ki,Displacement of [3H]-mesulergine from human 5HT2C receptor after 60 mins by liquid scintillation counting,Confirmatory,23792350.0,
3297,763656,2,3,,103165765,2818,Active,112808.0,29595.0,0.021,Ki,Displacement of [3H]-ketanserin from 5HT2A receptor in rat brain cortical membranes after 15 mins by liquid scintillation counting,Confirmatory,23792350.0,
3298,763657,2,3,,103165765,2818,Active,112812.0,24473.0,0.26,Ki,Displacement of [3H]-8-OH-DPAT from 5HT1A receptor in rat brain hippocampal membranes after 15 mins by liquid scintillation counting,Confirmatory,23792350.0,
3299,763658,2,3,,103165765,2818,Active,1345939.0,1815.0,0.06,Ki,Displacement of [3H]-YM-09151-2 from human D4 receptor after 120 mins by liquid scintillation counting,Confirmatory,23792350.0,
3300,763659,2,3,,103165765,2818,Active,47117674.0,24318.0,0.14,Ki,Displacement of [3H]-YM-09151-2 from D2 receptor in rat brain striatal membranes after 60 mins by liquid scintillation counting,Confirmatory,23792350.0,
3301,781326,1,2,,103165765,2818,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
3302,781328,1,2,,103165765,2818,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
3303,781329,1,2,,103165765,2818,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
3304,781330,1,2,,103165765,2818,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
3305,924530,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020716,Other,,
3306,924531,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020716,Other,,
3307,924532,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020716,Other,,
3308,924533,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020716,Other,,
3309,924534,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020716,Other,,
3310,924535,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020716,Other,,
3311,924536,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020716,Other,,
3312,924537,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020716,Other,,
3313,924538,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020716,Other,,
3314,924728,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020716,Other,,
3315,924729,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020716,Other,,
3316,924730,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020716,Other,,
3317,924731,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020716,Other,,
3318,943105,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020716,Other,,
3319,943106,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020716,Other,,
3320,943107,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020716,Other,,
3321,943108,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020716,Other,,
3322,943109,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020716,Other,,
3323,943110,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020716,Other,,
3324,943111,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020716,Other,,
3325,943112,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020716,Other,,
3326,943113,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020716,Other,,
3327,943114,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020716,Other,,
3328,943115,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020716,Other,,
3329,943116,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020716,Other,,
3330,943117,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020716,Other,,
3331,949559,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020716,Other,,
3332,949560,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020716,Other,,
3333,949561,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020716,Other,,
3334,949562,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020716,Other,,
3335,949563,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020716,Other,,
3336,949564,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020716,Other,,
3337,949565,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020716,Other,,
3338,949566,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020716,Other,,
3339,950198,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020716,Other,,
3340,950199,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020716,Other,,
3341,950200,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020716,Other,,
3342,957952,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020716,Other,,
3343,957953,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020716,Other,,
3344,957954,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020716,Other,,
3345,957955,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020716,Other,,
3346,976816,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020716,Other,,
3347,976817,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020716,Other,,
3348,976818,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020716,Other,,
3349,976819,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020716,Other,,
3350,976820,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020716,Other,,
3351,976821,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020716,Other,,
3352,976822,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020716,Other,,
3353,976823,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020716,Other,,
3354,976824,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020716,Other,,
3355,976825,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020716,Other,,
3356,976826,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020716,Other,,
3357,976827,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020716,Other,,
3358,976828,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020716,Other,,
3359,976829,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020716,Other,,
3360,976830,1,3,,103165765,2818,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020716,Other,,
3361,977599,1,1,,103165765,2818,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3362,977602,1,2,,103165765,2818,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3363,979355,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3364,979356,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3365,979357,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R020716",Other,,
3366,979358,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R020716",Other,,
3367,979359,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3368,980832,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R020716",Other,,
3369,980833,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3370,980834,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3371,980835,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R020716",Other,,
3372,980836,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R020716",Other,,
3373,980837,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R020716",Other,,
3374,980838,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R020716",Other,,
3375,980839,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R020716",Other,,
3376,980840,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3377,980841,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3378,980842,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R020716",Other,,
3379,980843,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3380,980844,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R020716",Other,,
3381,980845,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R020716",Other,,
3382,980846,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3383,980847,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R020716",Other,,
3384,980848,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3385,981318,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3386,981319,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020716",Other,,
3387,981320,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R020716",Other,,
3388,981321,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R020716",Other,,
3389,981322,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3390,981323,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3391,981324,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R020716",Other,,
3392,981325,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R020716",Other,,
3393,981326,1,3,,103165765,2818,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020716",Other,,
3394,1053175,2,1,,178126372,2818,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3395,1053187,1,2,,188124665,2818,Inactive,113121.0,25229.0,,,Confirmed allosteric antagonists of M1 Muscarinic receptor,Other,,
3396,1053188,2,1,,56422144,2818,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3397,1053197,1,1,,855811,2818,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3398,1054120,2,3,,103165765,2818,Unspecified,118206.0,1813.0,,IC50,Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
3399,1062947,1,1,,103165765,2818,Unspecified,,,,,Selectivity ratio of pKi for human 5-HT2A receptor to pKi for human D2 receptor,Other,24316025.0,
3400,1062948,2,3,,103165765,2818,Active,118206.0,1813.0,0.22386999999999999,Ki,Displacement of [3H]spiperone from human D2 receptor,Confirmatory,24316025.0,
3401,1062949,2,3,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Displacement of [3H]ketanserin from human 5-HT2A receptor,Confirmatory,24316025.0,
3402,1063799,4,2,,103165765,2818,Active,1703010.0,3362.0,0.00603,Ki,Displacement of [3H]LSD from 5-HT6 receptor (unknown origin),Confirmatory,24365159.0,
3403,1063800,4,2,,103165765,2818,Active,8488960.0,3363.0,0.00589,Ki,Displacement of [3H]LSD from 5-HT7 receptor (unknown origin),Confirmatory,24365159.0,
3404,1063804,4,2,,103165765,2818,Active,543727.0,3356.0,0.007409999999999999,Ki,Displacement of [3H]Ketanserin from 5-HT2A receptor (unknown origin),Confirmatory,24365159.0,
3405,1067095,1,1,,103165765,2818,Inactive,,,,,"Antipsychotic activity in albino lyka mouse assessed as reversal of apomorphine-induced stereotypy at 2.5 to 5 mg/kg, ip administered 10 mins prior to apomorphine challenge measured 10 to 30 mins post challenge",Other,24495776.0,
3406,1067099,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed albino lyka mouse assessed as reversal of apomorphine-induced mesh climbing response administered 10 mins prior to apomorphine challenge measured 10 to 30 mins post challenge,Other,24495776.0,
3407,1067106,2,3,,103165765,2818,Active,1703010.0,3362.0,0.017,IC50,Displacement of [3H]LSD from human cloned 5-HT6 receptor expressed in HeLa cells,Confirmatory,24495863.0,
3408,1071720,1,1,,103165765,2818,Unspecified,,,,,"Therapeutic index, ratio of ED50 for induction of catalepsy to ED50 for antipsychotic activity in po dosed Kunming mouse assessed as reduction in MK801-induced hyperactivity",Other,24487191.0,
3409,1071721,1,1,,103165765,2818,Unspecified,,,,,"Therapeutic index, ratio of ED50 for induction of catalepsy to ED50 for antipsychotic activity in po dosed Kunming mouse assessed as reversal of apomorphine-induced cage climbing response",Other,24487191.0,
3410,1071722,1,1,,103165765,2818,Unspecified,,,,,Toxicity in po dosed Kunming mouse assessed as induction of catalepsy,Other,24487191.0,
3411,1071723,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Kunming mouse assessed as reduction in MK801-induced hyperactivity compound administered 30 mins prior to MK801 challenge measured for 90 mins post challenge,Other,24487191.0,
3412,1071724,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Kunming mouse assessed as reversal of apomorphine-induced cage climbing response compound administered 30 mins prior to apomorphine challenge measured for 30 mins post challenge,Other,24487191.0,
3413,1071726,2,3,,103165765,2818,Active,399889.0,100730517.0,0.0068,Ki,Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum homogenate after 60 mins by liquid scintillation counting,Confirmatory,24487191.0,
3414,1071727,2,3,,103165765,2818,Active,118211.0,29238.0,0.2601,Ki,Displacement of [3H]7-OH-DPA from dopamine D3 receptor in Sprague-Dawley rat olfactory tubercle homogenate after 60 mins by liquid scintillation counting,Confirmatory,24487191.0,
3415,1071728,2,3,,103165765,2818,Active,47117674.0,24318.0,0.1307,Ki,Displacement of [3H]spiperone from dopamine D2 receptor in Sprague-Dawley rat striatum homogenate after 30 mins by liquid scintillation counting,Confirmatory,24487191.0,
3416,1071729,2,3,,103165765,2818,Active,112808.0,29595.0,0.0129,Ki,Displacement of [3H]Ketanserin from 5HT2A receptor in Sprague-Dawley rat brain cortex homogenate after 30 mins by liquid scintillation counting,Confirmatory,24487191.0,
3417,1071730,2,3,,103165765,2818,Active,112812.0,24473.0,0.1856,Ki,Displacement of [3H]8-OH-DPAT from 5HT1A receptor in Sprague-Dawley rat brain cortex homogenate after 30 mins by liquid scintillation counting,Confirmatory,24487191.0,
3418,1077333,2,3,,103165765,2818,Active,14194819.0,59340.0,0.5011899999999999,Ki,Displacement of [3H]histamine from wild type human histamine H4 receptor transfected in HEK293T cells after 1 hr by liquid scintillation counting analysis,Confirmatory,,
3419,1079931,1,1,,103165765,2818,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3420,1079932,1,1,,103165765,2818,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3421,1079933,1,1,,103165765,2818,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3422,1079934,1,1,,103165765,2818,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3423,1079935,1,1,,103165765,2818,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3424,1079936,1,1,,103165765,2818,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3425,1079937,1,1,,103165765,2818,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3426,1079938,1,1,,103165765,2818,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3427,1079939,1,1,,103165765,2818,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3428,1079940,1,1,,103165765,2818,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3429,1079941,1,1,,103165765,2818,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3430,1079942,1,1,,103165765,2818,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3431,1079943,1,1,,103165765,2818,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3432,1079944,1,1,,103165765,2818,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3433,1079945,1,1,,103165765,2818,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3434,1079946,1,1,,103165765,2818,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3435,1079947,1,1,,103165765,2818,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3436,1079948,1,1,,103165765,2818,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3437,1079949,1,1,,103165765,2818,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3438,1084843,1,2,,103165765,2818,Unspecified,,,,,"Antipsychotic activity in ip dosed Mus musculus Swiss albino (mouse) assessed as inhibiton of 5-HTP-induced head twitches pretreated 30 min before 50 mg/kg, sc 5-HTP administration measured at 10 min intervals for 30 min, starting 20 min after 5-HTP challenge",Other,,
3439,1084844,1,2,,103165765,2818,Unspecified,,,,,"Antipsychotic activity in ip dosed Mus musculus Swiss albino (mouse) assessed as inhibition of aporphomine -induced climbing behavior pretreated 10 min prior to 2.5 mg/kg, ip apomorphine administration measured at 5 min intervals for up to 20 min starting 10 min after apomorphine challenge",Other,,
3440,1093070,1,2,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for Rattus norvegicus (rat) wild type dopamine D3 receptor to Ki for Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor,Other,,
3441,1093071,1,2,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for Rattus norvegicus (rat) wild type dopamine D2 receptor to Ki for Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor,Other,,
3442,1093077,2,3,,103165765,2818,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3443,1093078,2,3,,103165765,2818,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3444,1093079,1,4,,103165765,2818,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3445,1093079,1,4,,103165765,2818,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3446,1093080,1,4,,103165765,2818,Active,118211.0,29238.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3447,1093080,1,4,,103165765,2818,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3448,1093081,2,3,,103165765,2818,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3449,1093082,2,3,,103165765,2818,Active,47117674.0,24318.0,,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
3450,1097336,1,3,,103165765,2818,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
3451,1106487,1,2,,103165765,2818,Inactive,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as inhibition of PTZ-induced seizure at 3 mg/kg, ip administered 1 hr prior to PTZ-challenge measured after 2 to 4 min relative to control",Other,,
3452,1106488,1,2,,103165765,2818,Unspecified,,,,,"Neurotoxicity against Mus musculus albino (mouse) assessed as inability to climb horizontal screen at 3 mg/kg, ip after 30 min by horizontal screen test relative to control",Other,,
3453,1106489,1,2,,103165765,2818,Unspecified,,,,,"Neurotoxicity against Mus musculus albino (mouse) assessed as fall from horizontal screen at 3 mg/kg, ip after 30 min by horizontal screen test relative to control",Other,,
3454,1106490,1,2,,103165765,2818,Unspecified,,,,,"Neurotoxicity against Mus musculus albino (mouse) at 3 mg/kg, ip after 30 min by rotarod test",Other,,
3455,1106491,1,2,,103165765,2818,Unspecified,,,,,"CNS depressant activity in Mus musculus albino (mouse) assessed as immobility time at 3 mg/kg, ip measured after 24 hr by forced swim test (Rvb = 120 +/- 5.1 secs)",Other,,
3456,1106492,1,2,,103165765,2818,Unspecified,,,,,"Antipsychotic activity in Mus musculus albino (mouse) assessed as ptosis at 3 mg/kg, ip relative to control",Other,,
3457,1113280,2,3,,103165765,2818,Unspecified,400630.0,6532.0,10.0,IC50,Inhibition of 5-HT uptake at SERT (unknown origin),Confirmatory,,
3458,1113281,1,2,,103165765,2818,Unspecified,,,,,Ratio of pKi for 5-HT2A receptor (unknown origin) to pKi for dopamine D2 receptor (unknown origin),Other,,
3459,1113282,2,3,,103165765,2818,Active,112816.0,3358.0,0.00288,Ki,Binding affinity to 5-HT2C receptor (unknown origin),Confirmatory,,
3460,1113283,2,3,,103165765,2818,Active,1168222.0,3359.0,0.18621,Ki,Binding affinity to 5-HT3 receptor (unknown origin),Confirmatory,,
3461,1113284,4,2,,103165765,2818,Active,543727.0,3356.0,0.00857,Ki,Binding affinity to 5-HT2A receptor (unknown origin),Confirmatory,,
3462,1113285,4,2,,103165765,2818,Active,231454.0,3350.0,0.006379999999999999,Ki,Binding affinity to 5-HT1A receptor (unknown origin),Confirmatory,,
3463,1113286,4,2,,103165765,2818,Active,118206.0,1813.0,0.007109999999999999,Ki,Binding affinity to dopamine D2 receptor (unknown origin),Confirmatory,,
3464,1113288,4,2,,103165765,2818,Active,118228.0,1812.0,0.0075,Ki,Binding affinity to dopamine D1 receptor (unknown origin),Confirmatory,,
3465,1117298,1,2,,170464853,2818,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3466,1117301,1,2,,170464853,2818,Inactive,,,28.1838,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3467,1117302,1,2,,170464853,2818,Inactive,,,5.0119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3468,1117303,1,2,,170464853,2818,Inactive,,,19.96,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3469,1117304,1,2,,170464853,2818,Active,,,15.8489,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3470,1117305,1,2,,170464853,2818,Active,,,14.1254,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3471,1117310,1,1,,170464853,2818,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3472,1117311,1,1,,170464853,2818,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3473,1117312,1,1,,170464853,2818,Active,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3474,1117314,1,1,,170464853,2818,Inactive,,,15.8489,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3475,1117315,1,1,,170464853,2818,Inactive,,,5.01187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3476,1117318,1,1,,170464853,2818,Inactive,,,19.9526,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3477,1117319,1,2,,855811,2818,Inconclusive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3478,1117319,1,2,,855811,2818,Inconclusive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3479,1117326,1,1,,170464853,2818,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3480,1117329,1,1,,170464853,2818,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3481,1117336,1,1,,170464853,2818,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3482,1117340,1,1,,170464853,2818,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3483,1117341,1,1,,170464853,2818,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3484,1117342,1,1,,170464853,2818,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3485,1117343,1,1,,170464853,2818,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3486,1117346,1,1,,170464853,2818,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3487,1119145,2,2,,103165765,2818,Active,118206.0,1813.0,0.22386999999999999,Ki,Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay,Confirmatory,,
3488,1119146,2,2,,103165765,2818,Active,543727.0,3356.0,0.00912,Ki,Displacement of [3H]ketanserin from human cloned 5-HT2A receptor by in vitro binding assay,Confirmatory,,
3489,1119148,1,1,,103165765,2818,Unspecified,,,,,Ratio of pKi for human cloned 5-HT2A receptor to pKi for human cloned D2 receptor,Other,,
3490,1119672,2,2,,103165765,2818,Active,231454.0,3350.0,1.0,Ki,Binding affinity to serotonin 5-HT1A receptor (unknown origin) by PDSP assay,Confirmatory,,
3491,1119673,2,2,,103165765,2818,Active,112821.0,3351.0,1.0,Ki,Binding affinity to serotonin 5-HT1B receptor (unknown origin) by PDSP assay,Confirmatory,,
3492,1119674,2,2,,103165765,2818,Unspecified,112819.0,3352.0,1.0,Ki,Binding affinity to serotonin 5-HT1D receptor (unknown origin) by PDSP assay,Confirmatory,,
3493,1119675,2,2,,103165765,2818,Active,112822.0,3354.0,1.0,Ki,Binding affinity to serotonin 5-HT1E receptor (unknown origin) by PDSP assay,Confirmatory,,
3494,1119676,2,2,,103165765,2818,Active,543727.0,3356.0,0.01,Ki,Binding affinity to serotonin 5-HT2A receptor (unknown origin) by PDSP assay,Confirmatory,,
3495,1119678,2,2,,103165765,2818,Active,112816.0,3358.0,0.1,Ki,Binding affinity to serotonin 5-HT2C receptor (unknown origin) by PDSP assay,Confirmatory,,
3496,1119679,2,2,,103165765,2818,Active,1168222.0,3359.0,1.0,Ki,Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay,Confirmatory,,
3497,1119681,2,2,,103165765,2818,Unspecified,1345607.0,3361.0,1.0,Ki,Binding affinity to serotonin 5-HT5A receptor (unknown origin) by PDSP assay,Confirmatory,,
3498,1119682,2,2,,103165765,2818,Active,1703010.0,3362.0,0.1,Ki,Binding affinity to serotonin 5-HT6 receptor (unknown origin) by PDSP assay,Confirmatory,,
3499,1119683,2,2,,103165765,2818,Active,8488960.0,3363.0,0.1,Ki,Binding affinity to serotonin 5-HT7 receptor (unknown origin) by PDSP assay,Confirmatory,,
3500,1119684,2,2,,103165765,2818,Active,118228.0,1812.0,1.0,Ki,Binding affinity to dopamine D1 receptor (unknown origin) by PDSP assay,Confirmatory,,
3501,1119685,2,2,,103165765,2818,Active,118206.0,1813.0,1.0,Ki,Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay,Confirmatory,,
3502,1119686,2,2,,103165765,2818,Active,1169206.0,1814.0,1.0,Ki,Binding affinity to dopamine D3 receptor (unknown origin) by PDSP assay,Confirmatory,,
3503,1119687,2,2,,103165765,2818,Active,1345939.0,1815.0,0.1,Ki,Binding affinity to dopamine D4 receptor (unknown origin) by PDSP assay,Confirmatory,,
3504,1119688,2,2,,103165765,2818,Active,118214.0,1816.0,1.0,Ki,Binding affinity to dopamine D5 receptor (unknown origin) by PDSP assay,Confirmatory,,
3505,1119689,2,2,,103165765,2818,Active,1168246.0,148.0,0.01,Ki,Binding affinity to adrenergic alpha1A receptor (unknown origin) by PDSP assay,Confirmatory,,
3506,1119690,2,2,,103165765,2818,Active,116241241.0,147.0,0.01,Ki,Binding affinity to adrenergic alpha1B receptor (unknown origin) by PDSP assay,Confirmatory,,
3507,1119692,2,2,,103165765,2818,Active,1351829.0,150.0,1.0,Ki,Binding affinity to adrenergic alpha2A receptor (unknown origin) by PDSP assay,Confirmatory,,
3508,1119693,2,2,,103165765,2818,Active,613504690.0,151.0,0.1,Ki,Binding affinity to adrenergic alpha2B receptor (unknown origin) by PDSP assay,Confirmatory,,
3509,1119694,2,2,,103165765,2818,Active,20141211.0,152.0,0.1,Ki,Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay,Confirmatory,,
3510,1119695,2,2,,103165765,2818,Active,547645.0,3269.0,0.01,Ki,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,Confirmatory,,
3511,1119697,2,2,,103165765,2818,Active,113118.0,1128.0,0.1,Ki,Binding affinity to M1 receptor (unknown origin) by PDSP assay,Confirmatory,,
3512,1119698,2,2,,103165765,2818,Active,113122.0,1129.0,0.1,Ki,Binding affinity to M2 receptor (unknown origin) by PDSP assay,Confirmatory,,
3513,1119699,2,2,,103165765,2818,Active,113125.0,1131.0,0.1,Ki,Binding affinity to M3 receptor (unknown origin) by PDSP assay,Confirmatory,,
3514,1119700,2,2,,103165765,2818,Active,23503039.0,1132.0,0.1,Ki,Binding affinity to M4 receptor (unknown origin) by PDSP assay,Confirmatory,,
3515,1119701,2,2,,103165765,2818,Active,543761.0,1133.0,0.1,Ki,Binding affinity to M5 receptor (unknown origin) by PDSP assay,Confirmatory,,
3516,1123431,3,1,,103165765,2818,Active,,,8.0,IC50,Displacement of [3H]-dopamine from dopamine receptor in calf caudate nucleus after 10 mins by liquid scintillation counting analysis,Confirmatory,34721.0,
3517,1123432,3,1,,103165765,2818,Active,,,0.18,IC50,Displacement of [3H]-haloperidol from dopamine receptor in calf caudate nucleus after 10 mins by liquid scintillation counting analysis,Confirmatory,34721.0,
3518,1123433,3,1,,103165765,2818,Active,,,0.84,IC50,Displacement of [3H]-spiroperidol from dopamine receptor in calf caudate nucleus after 20 mins by liquid scintillation counting analysis,Confirmatory,34721.0,
3519,1123434,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed CD-F rat assessed as blockade of conditioned avoidance response measured at 30 mins post-injection,Other,34721.0,
3520,1123436,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed Crl:COBS-CD-1(ICR)BR mouse assessed as inhibition of amphetamine-induced gnawing behavior after 30 to 90 mins,Other,34721.0,
3521,1123440,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed Crl:COBS-CD-1(ICR)BR mouse assessed as inhibition of amphetamine-induced licking behavior after 30 to 90 mins,Other,34721.0,
3522,1123444,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed Crl:COBS-CD-1(ICR)BR mouse assessed as inhibition of amphetamine-induced sniffing behavior after 30 to 90 mins,Other,34721.0,
3523,1123448,1,1,,103165765,2818,Unspecified,,,,,Blockade of amphetamine-induced lethality in ip dosed Crl:COBS-CD-1(ICR)BR mouse after 30 mins,Other,34721.0,
3524,1123450,1,1,,103165765,2818,Unspecified,,,,,Toxicity in amphetamine-induced ip dosed Crl:COBS-CD-1(ICR)BR mouse assessed as lethality,Other,34721.0,
3525,1123451,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in amphetamine-induced Crl:COBS-CD-1(ICR)BR mouse assessed as depression at 10 to 320 mg/kg, ip",Other,34721.0,
3526,1123452,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in amphetamine-induced Crl:COBS-CD-1(ICR)BR mouse assessed as ataxia at 10 to 320 mg/kg, ip",Other,34721.0,
3527,1123453,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in amphetamine-induced Crl:COBS-CD-1(ICR)BR mouse assessed as chronic seizures at 10 to 320 mg/kg, ip",Other,34721.0,
3528,1123454,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in amphetamine-induced Crl:COBS-CD-1(ICR)BR mouse assessed as respiratory depression at 10 to 320 mg/kg, ip",Other,34721.0,
3529,1123455,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in amphetamine-induced Crl:COBS-CD-1(ICR)BR mouse assessed as flacidity at 10 to 320 mg/kg, ip",Other,34721.0,
3530,1123529,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in po dosed rat assessed as concentration required to cause 50% reduction of motor activity,Other,37338.0,
3531,1123530,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in po dosed mouse assessed as inhibition of d-amphetamine sulfate-induced lethality administered for 0.5 hrs followed by d-amphetamine sulfate challenge measured after 24 hrs,Other,37338.0,
3532,1123533,1,1,,103165765,2818,Inactive,,,,,"Antidepressant activity in mouse assessed as inhibition of tetrabenazine hexamate-induced depression at 25 mg/kg, po administered 1 hr followed by tetrabenazine hexamate challenge measured after 30 mins",Other,37338.0,
3533,1123535,1,1,,103165765,2818,Unspecified,,,,,Induction of catalepsy in po dosed rat measured for 0.5 to 18 hrs,Other,37338.0,
3534,1125020,3,2,,103165765,2818,Active,118206.0,1813.0,0.08865,Ki,Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting,Confirmatory,24631727.0,
3535,1125021,3,2,,103165765,2818,Active,,,0.05754,Ki,Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting,Confirmatory,24631727.0,
3536,1126946,1,3,,103165765,2818,Active,8488960.0,3363.0,0.025,Ki,Displacement of [3H]-5-CT from human recombinant 5-HT7 receptor expressed in HEK293 cell membrane after 1 hr by Microbeta scintillation counting analysis,Confirmatory,24691057.0,
3537,1128452,1,3,,103165765,2818,Active,543727.0,3356.0,0.0096,Ki,Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cells,Confirmatory,24559051.0,
3538,1128453,1,3,,103165765,2818,Active,112816.0,3358.0,0.013000000000000001,Ki,Displacement of [125]DOI from human recombinant full length 5HT2C receptor expressed in HEK293E cells,Confirmatory,24559051.0,
3539,1128454,1,3,,103165765,2818,Active,47117674.0,24318.0,0.19,Ki,Displacement of [3H]-N-methylspiperone from rat recombinant dopamine D2 short receptor expressed in CHO cells,Confirmatory,24559051.0,
3540,1128455,1,1,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for human recombinant full length 5HT2C receptor to Ki for human recombinant full length 5HT2A receptor,Other,24559051.0,
3541,1128456,1,1,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for rat recombinant dopamine D2 short receptor to Ki for human recombinant full length 5HT2A receptor,Other,24559051.0,
3542,1128459,1,3,,103165765,2818,Active,231454.0,3350.0,0.14,Ki,Inhibition of human 5HT1A receptor,Confirmatory,24559051.0,
3543,1128460,1,3,,103165765,2818,Active,547645.0,3269.0,0.001,Ki,Inhibition of histamine H1 receptor (unknown origin),Confirmatory,24559051.0,
3544,1128462,1,3,,103165765,2818,Active,1168246.0,148.0,0.019,Ki,Inhibition of adrenergic alpha1A receptor (unknown origin),Confirmatory,24559051.0,
3545,1128464,1,3,,103165765,2818,Active,543734.0,24173.0,0.012,Ki,Inhibition of rat adrenergic alpha1B receptor,Confirmatory,24559051.0,
3546,1128466,1,3,,103165765,2818,Active,1345939.0,1815.0,0.04,Ki,Inhibition of human dopamine D4 receptor,Confirmatory,24559051.0,
3547,1128468,1,1,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for adrenergic alpha1A receptor (unknown origin) to Ki for human recombinant full length 5HT2A receptor,Other,24559051.0,
3548,1128469,1,1,,103165765,2818,Unspecified,,,,,Selectivity ratio of Ki for adrenergic alpha1B receptor (unknown origin) to Ki for human recombinant full length 5HT2A receptor,Other,24559051.0,
3549,1128474,1,1,,103165765,2818,Unspecified,,,,,Inhibition of quipazine-induced head twitches in po dosed rat head twitch model administered 25 mins prior to quipazine challenge measured after 30 mins,Other,24559051.0,
3550,1134096,1,1,,103165765,2818,Active,,,6.0,IC50,Antagonist activity at dopamine receptor in Sprague-Dawley rat olfactory tubercles assessed as inhibition of dopamine-induced adenylate cyclase activity after 5 mins,Confirmatory,853510.0,
3551,1134098,1,1,,103165765,2818,Inactive,,,,IC50,Antagonist activity at dopamine receptor in Sprague-Dawley rat olfactory tubercles assessed as inhibition of adenylate cyclase activity after 5 mins,Confirmatory,853510.0,
3552,1134099,1,1,,103165765,2818,Unspecified,,,,,Antagonist activity at dopamine receptor in Sprague-Dawley rat olfactory tubercles assessed as inhibition of adenylate cyclase activity at 100 uM after 5 mins,Other,853510.0,
3553,1136082,3,1,,103165765,2818,Active,,,8.0,IC50,Displacement of [3H]-DA from dopamine receptor in calf caudate membranes after 15 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
3554,1136083,3,1,,103165765,2818,Active,,,0.18,IC50,Displacement of [3H]-HALO from dopamine receptor in calf caudate membranes after 10 mins by liquid scintillation counting analysis,Confirmatory,25967.0,
3555,1136084,1,1,,103165765,2818,Unspecified,,,,,Ratio of IC50 for displacement of [3H]-DA from dopamine receptor in calf caudate membranes to IC50 for displacement of [3H]-HALO from dopamine receptor in calf caudate membranes,Other,25967.0,
3556,1136085,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in ip dosed HAM/ICR mouse assessed as protection against d-amphetamine-induced lethality administered 30 mins followed by d-amphetamine challenge measured after 30 mins,Other,25967.0,
3557,1136087,1,1,,103165765,2818,Unspecified,,,,,"Antipsychotic activity in HAM/ICR mouse assessed as blockade of conditioned avoidance response at 10 mg/kg, ip measured after 30 mins relative to control",Other,25967.0,
3558,1136382,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as inhibition of amphetamine-induced stereotyped behaviour administered 15 mins after d-amphetamine challenge,Other,31480.0,
3559,1136383,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as conditioned active avoidance failure after 30 mins,Other,31480.0,
3560,1136384,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as dose required to decrease the continuous (Sidman) lever-pressing response to <50%,Other,31480.0,
3561,1136385,1,1,,103165765,2818,Unspecified,,,,,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as protection against epinephrine-induced mortality administered 1 hr prior to epinephrine injection,Other,31480.0,
3562,1136386,1,1,,103165765,2818,Unspecified,,,,,Toxicity in ip dosed Sprague-Dawley rat assessed as induction of maximum catalepsy,Other,31480.0,
3563,1136414,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 5 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
3564,1136415,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in mouse assessed as protection against amphetamine-induced lethality at 50 mg/kg, ip treated 30 mins before amphetamine challenge",Other,31487.0,
3565,1136416,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in 0.2 mA footshock-induced conditioned stimulus rat assessed as decrease in avoidance response at 5 mg/kg, ip after 30 mins",Other,31487.0,
3566,1136417,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in 0.2 mA footshock-induced conditioned stimulus rat assessed as decrease in avoidance response at 20 mg/kg, ip after 30 mins",Other,31487.0,
3567,1136418,1,1,,103165765,2818,Active,,,,,"Antipsychotic activity in mouse assessed as increase in brain dopamine turnover at 25 to 30 mg/kg, ip pretreated with 200 mg/kg, ip alpha-methyl-p-tyrosine tyrosine hydroxylase inhibitor",Other,31487.0,
3568,1136419,3,2,,103165765,2818,Active,117786.0,81636.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3569,1136419,3,2,,103165765,2818,Active,117787.0,64508.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3570,1136419,3,2,,103165765,2818,Active,117788.0,54223.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3571,1136419,3,2,,103165765,2818,Active,416857.0,25289.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3572,1136419,3,2,,103165765,2818,Active,729243.0,29241.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3573,1136419,3,2,,103165765,2818,Active,2833201.0,64532.0,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3574,1136419,3,2,,103165765,2818,Active,81900271.0,,0.14,IC50,Inhibition of dopamine-sensitive rat brain adenylyl cyclase activity assessed as cAMP level,Confirmatory,31487.0,
3575,1152647,2,1,,103165765,2818,Active,1703010.0,3362.0,,IC50,Antagonist activity at human recombinant 5-HT6 receptor assessed as inhibition of serotonin-induced cAMP accumulation,Confirmatory,24805037.0,
3576,1152654,2,1,,103165765,2818,Active,1345939.0,1815.0,0.168,IC50,Antagonist activity at human recombinant at D4 receptor assessed as inhibition of dopamine-induced cAMP accumulation,Confirmatory,24805037.0,
3577,1152662,1,1,,103165765,2818,Unspecified,,,,,Antidepressant-like activity in po dosed Wistar rat assessed as decrease in immobility after 60 mins by forced swimming test,Other,24805037.0,
3578,1152687,1,3,,103165765,2818,Active,1345939.0,1815.0,0.017,Ki,Displacement of [3H]methylspiperone from human recombinant D4 receptor expressed in CHO cells,Confirmatory,24805037.0,
3579,1159386,1,2,,103165765,2818,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
3580,1159387,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3581,1159388,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
3582,1159389,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3583,1159390,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3584,1159391,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3585,1159393,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole guinea pig plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3586,1159394,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3587,1159395,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
3588,1159396,1,2,,103165765,2818,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3589,1159397,1,2,,103165765,2818,Unspecified,,,,,ASTRAZENECA: Second most basic pKa value (pKa B2) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
3590,1159509,1,1,,170464853,2818,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3591,1159515,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3592,1159516,1,1,,170464853,2818,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3593,1159517,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3594,1159518,1,1,,170464853,2818,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3595,1159519,1,1,,170464853,2818,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3596,1159520,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3597,1159521,1,1,,170464853,2818,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3598,1159523,1,1,,170464853,2818,Inconclusive,15928672.0,19885.0,6.68242,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3599,1159524,1,1,,56422144,2818,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3600,1159524,1,1,,124879684,2818,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3601,1159524,1,1,,124879686,2818,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3602,1159524,1,1,,124879691,2818,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3603,1159525,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3604,1159526,1,1,,170464853,2818,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3605,1159527,1,1,,170464853,2818,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3606,1159528,1,1,,170464853,2818,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3607,1159529,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3608,1159531,1,1,,170464853,2818,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3609,1159550,3,1,,252402397,2818,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3610,1159551,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3611,1159552,1,1,,170464853,2818,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3612,1159553,2,1,,170464853,2818,Inactive,325495463.0,5914.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3613,1159555,1,1,,170464853,2818,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3614,1159580,2,1,,268734772,2818,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3615,1159580,2,1,,273002758,2818,Inconclusive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3616,1159583,2,1,,178126372,2818,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3617,1159606,1,1,,56422144,2818,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3618,1159607,2,1,,312309796,2818,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3619,1159614,1,2,,170464853,2818,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3620,1159620,1,1,,103165765,2818,Active,,,,,Summary of drug indications.,Other,,
3621,1169860,1,2,,103165765,2818,Active,118206.0,1813.0,0.21,Ki,Binding affinity to dopamine D2 receptor (unknown origin),Confirmatory,25343529.0,
3622,1169861,1,2,,103165765,2818,Active,1169206.0,1814.0,0.319,Ki,Binding affinity to dopamine D3 receptor (unknown origin),Confirmatory,25343529.0,
3623,1169862,1,2,,103165765,2818,Active,231454.0,3350.0,0.16,Ki,Binding affinity to 5HT1A receptor (unknown origin),Confirmatory,25343529.0,
3624,1169863,1,2,,103165765,2818,Active,543727.0,3356.0,0.01,Ki,Binding affinity to 5HT2A receptor (unknown origin),Confirmatory,25343529.0,
3625,1169864,1,2,,103165765,2818,Active,112816.0,3358.0,0.0048,Ki,Binding affinity to 5HT2C receptor (unknown origin),Confirmatory,25343529.0,
3626,1169865,1,1,,103165765,2818,Unspecified,,,,,Effect on spontaneous exploratory locomotor activity in sc dosed NMRI mouse measured for 30 mins with activity counts each 5 mins,Other,25343529.0,
3627,1169867,1,1,,103165765,2818,Inconclusive,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in MK801-induced locomotor activity dosed 15 to 30 mins before administration of MK801 measured for 60 mins,Other,25343529.0,
3628,1169869,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in methamphetamine-induced locomotor activity dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins,Other,25343529.0,
3629,1169871,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic-like activity in sc dosed NMRI mouse assessed as reduction in PCP-induced locomotor activity dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins,Other,25343529.0,
3630,1169928,1,1,,103165765,2818,Unspecified,,,,,"Toxicity in mouse assessed as induction of memory impairment by measuring increase in latency to enter dark compartment at 10 mg/kg, po administered 30 mins before training by passive avoidance test",Other,25343529.0,
3631,1169929,1,1,,103165765,2818,Active,,,,,"Antipsychotic-like activity in NMRI mouse assessed as reduction in PCP-induced locomotor activity at 1 mg/kg, sc dosed 15 to 30 mins before administration of methamphetamine measured for 60 mins",Other,25343529.0,
3632,1172032,1,2,,103165765,2818,Active,8488960.0,3363.0,0.018000000000000002,Ki,Displacement of [3H]]-5-CT from human cloned 5-HT7R expressed in HEK293 cells,Confirmatory,25435254.0,
3633,1195622,1,1,,103165765,2818,Active,,,,,"Antischizophrenic activity in mouse assessed as inhibition of apomorphine-induced climbing behavior at 5 mg/kg, po",Other,25900218.0,
3634,1196332,1,2,,103165765,2818,Active,1345939.0,1815.0,0.017,Ki,Displacement of [3H]methylspiperone from human dopamine D4 receptor expressed in CHO cells,Confirmatory,25557493.0,
3635,1207733,1,1,,103165765,2818,Active,,,3.6,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
3636,1209455,1,2,,103165765,2818,Unspecified,262527527.0,8647.0,126.1,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3637,1209456,1,2,,103165765,2818,Unspecified,12585136.0,83569.0,196.5,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3638,1209457,1,1,,103165765,2818,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
3639,1209855,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3640,1209856,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3641,1209857,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3642,1209858,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3643,1209859,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3644,1209860,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3645,1209861,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C8 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3646,1209862,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3647,1209863,1,2,,103165765,2818,Unspecified,67476954.0,1562.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3648,1209864,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C19 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3649,1209865,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as clozapine N-oxide metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3650,1209866,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as desmethylclozapine metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3651,1209867,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-1 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3652,1209868,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-3 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3653,1209869,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-4 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3654,1209870,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-5 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3655,1209871,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3656,1209872,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3657,1209873,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3658,1209874,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3659,1209875,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3660,1209876,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3661,1209877,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3662,1209878,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3663,1209879,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-6 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3664,1209880,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as CG-7 GSH conjugate formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3665,1209881,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as C-3 metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3666,1209882,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as C-4 metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3667,1209883,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as retention time of 7-hydroxyclozapine metabolite formation at 100 uM after 30 mins by liquid chromatography mass spectrometry-quadrupole time of flight analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3668,1209884,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as retention time of 9-hydroxyclozapine metabolite formation at 100 uM after 30 mins by liquid chromatography mass spectrometry-quadrupole time of flight analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3669,1209885,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as 7-hydroxyclozapine metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3670,1209887,1,2,,103165765,2818,Unspecified,,,,,"Drug metabolism in pooled human liver microsomes assessed as total GSH conjugate metabolite formation (CG-1, CG-4, CG-5 and CG-6) at 100 uM after 30 mins by HPLC analysis in presence of GSH, hGST P1-1 and 2 to 20 uM CYP3A inhibitor ketoconazole",Other,23297297.0,
3671,1209888,1,2,,103165765,2818,Unspecified,,,,,"Drug metabolism in pooled human liver microsomes assessed as total GSH conjugate metabolite formation (CG-1, CG-4, CG-5 and CG-6) at 100 uM after 30 mins by HPLC analysis in presence of GSH, hGST P1-1 and 2 uM CYP2D6 inhibitor quinidine",Other,23297297.0,
3672,1209889,1,2,,103165765,2818,Unspecified,,,,,"Drug metabolism in pooled human liver microsomes assessed as total GSH conjugate metabolite formation (CG-1, CG-4, CG-5 and CG-6) at 100 uM treated 15 mins after 20 uM CYP2E1 inhibitor diethyldithiocarbonate addition measured after 30 mins by HPLC analysis in presence of GSH and hGST P1-1",Other,23297297.0,
3673,1209890,1,2,,103165765,2818,Unspecified,,,,,"Drug metabolism in pooled human liver microsomes assessed as clozapine N-oxide metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH, hGST P1-1 and 2 to 20 uM CYP3A inhibitor ketoconazole",Other,23297297.0,
3674,1209891,1,2,,103165765,2818,Unspecified,,,,,"Drug metabolism in pooled human liver microsomes assessed as N-desmethylclozapine metabolite formation at 100 uM after 30 mins by HPLC analysis in presence of GSH, hGST P1-1 and 10 uM CYP1A2 inhibitor furafylline",Other,23297297.0,
3675,1209892,1,2,,103165765,2818,Unspecified,,,,,Drug metabolism in pooled human liver microsomes assessed as N-desmethylclozapine metabolite formation at 100 uM treated 15 mins after 2 to 20 uM CYP3A inhibitor ketoconazole addition measured after 30 mins by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3676,1209893,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3677,1209894,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3678,1209895,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3679,1209896,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C8 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3680,1209897,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3681,1209898,1,2,,103165765,2818,Unspecified,67476954.0,1562.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3682,1209899,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C19 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3683,1209900,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3684,1209901,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3685,1209902,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3686,1209903,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3687,1209904,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3688,1209905,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C8 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3689,1209906,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3690,1209907,1,2,,103165765,2818,Unspecified,67476954.0,1562.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3691,1209908,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C19 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3692,1209909,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3693,1209910,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3694,1209911,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3695,1209912,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3696,1209913,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3697,1209914,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3698,1209915,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3699,1209916,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C8 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3700,1209917,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3701,1209918,1,2,,103165765,2818,Unspecified,67476954.0,1562.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3702,1209919,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C19 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3703,1209920,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3704,1209921,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3705,1209922,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3706,1209923,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3707,1209924,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3708,1209925,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3709,1209926,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3710,1209927,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3711,1209928,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3712,1209929,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3713,1209930,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated total GSH conjugate formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3714,1209931,1,2,,103165765,2818,Unspecified,117139.0,1543.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A1 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3715,1209932,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Drug metabolism in supersomes expressing human recombinant CYP1A2 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3716,1209933,1,2,,103165765,2818,Unspecified,48429256.0,1545.0,,,Drug metabolism in supersomes expressing human recombinant CYP1B1 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3717,1209934,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated total GSH conjugate formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of GSH and hGST P1-1,Other,23297297.0,
3718,1209935,1,2,,103165765,2818,Unspecified,67476954.0,1562.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3719,1209936,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C19 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3720,1209937,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3721,1209938,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Drug metabolism in supersomes expressing human recombinant CYP2J2 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3722,1209939,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3723,1209940,1,2,,103165765,2818,Unspecified,117157.0,1577.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A5 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3724,1209941,1,2,,103165765,2818,Active,116241312.0,1576.0,30.3,Km,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated total GSH conjugate formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3725,1209942,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3726,1209943,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3727,1209944,1,2,,103165765,2818,Active,84028191.0,1565.0,21.9,Km,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated total GSH conjugate formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3728,1209945,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3729,1209946,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3730,1209947,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,126.0,Km,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated total GSH conjugate formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3731,1209948,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3732,1209949,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in human liver microsomes assessed as CYP3A4-mediated total GSH conjugate formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3733,1209950,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,92.7,Km,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3734,1209951,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3735,1209952,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3736,1209953,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,84.1,Km,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3737,1209954,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3738,1209955,1,2,,103165765,2818,Unspecified,308153612.0,1548.0,,,Drug metabolism in supersomes expressing human recombinant CYP2A6 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3739,1209956,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C8 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3740,1209957,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,Other,23297297.0,
3741,1209958,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3742,1209959,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,250.0,Km,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated clozapine N-oxide metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3743,1209960,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3744,1209961,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in human liver microsomes assessed as CYP3A4-mediated clozapine N-oxide metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3745,1209962,1,2,,103165765,2818,Active,116241312.0,1576.0,47.6,Km,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3746,1209963,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3747,1209964,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP3A4 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3748,1209965,1,2,,103165765,2818,Active,84028191.0,1565.0,25.3,Km,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3749,1209966,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3750,1209967,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Ratio of Vmax to Km in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3751,1209968,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,268.0,Km,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated N-demethyl clozapine metabolite formation after 15 mins by Michaelis-Menten equation analysis,Confirmatory,23297297.0,
3752,1209969,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Drug metabolism in human liver microsomes assessed as CYP3A4-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3753,1209970,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Ratio of Vmax to Km in human liver microsomes assessed as CYP3A4-mediated N-demethyl clozapine metabolite formation after 15 mins measured per nmol P450 by Michaelis-Menten equation analysis,Other,23297297.0,
3754,1209971,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Drug metabolism in supersomes expressing human recombinant CYP2D6 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,Other,23297297.0,
3755,1210013,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control,Other,22328583.0,
3756,1210014,1,2,,103165765,2818,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
3757,1210069,1,2,,103165765,2818,Active,21264413.0,1573.0,14.1,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
3758,1210070,1,2,,103165765,2818,Active,84028191.0,1565.0,18.0,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
3759,1210071,1,2,,103165765,2818,Active,116241312.0,1576.0,46.3,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
3760,1210072,1,2,,103165765,2818,Active,6686268.0,1559.0,21.2,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
3761,1210073,1,2,,103165765,2818,Active,60416369.0,1557.0,45.3,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
3762,1210074,1,2,,103165765,2818,Unspecified,117144.0,1544.0,50.0,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
3763,1210791,1,2,,103165765,2818,Active,215273968.0,316.0,5.1,Ki,Competitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as free enzyme by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
3764,1210792,1,2,,103165765,2818,Inconclusive,215273968.0,316.0,,Ki,Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
3765,1210793,1,2,,103165765,2818,Inconclusive,215273968.0,316.0,,,Ratio of Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase to Ki for competitive inhibition of human liver cytosolic aldehyde oxidase,Other,22996261.0,
3766,1211293,1,2,,103165765,2818,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
3767,1211294,1,1,,103165765,2818,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
3768,1211295,1,1,,103165765,2818,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
3769,1211296,1,2,,103165765,2818,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
3770,1211297,1,1,,103165765,2818,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
3771,1211298,1,1,,103165765,2818,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
3772,1211405,1,1,,103165765,2818,Unspecified,,,,,"AUC (0 to infinity) in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3773,1211408,1,1,,103165765,2818,Active,,,,,"Cmax in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3774,1211411,1,1,,103165765,2818,Unspecified,,,,,"Tmax in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3775,1211413,1,2,,103165765,2818,Unspecified,,,,,AUC (0 to infinity) in rat,Other,22736307.0,
3776,1211415,1,1,,103165765,2818,Unspecified,,,,,"Central volume of distribution in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3777,1211418,1,1,,103165765,2818,Unspecified,,,,,"Systemic clearance in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3778,1211421,1,1,,103165765,2818,Unspecified,,,,,"Absorption rate constant in Wistar rat extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3779,1211426,1,1,,103165765,2818,Unspecified,,,,,"Unbound volume of distribution in Wistar rat brain at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3780,1211429,1,1,,103165765,2818,Unspecified,,,,,"Uptake clearance in Wistar rat brain extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3781,1211432,1,1,,103165765,2818,Unspecified,,,,,"Efflux clearance in Wistar rat brain extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3782,1211435,1,1,,103165765,2818,Unspecified,,,,,"Ratio of uptake clearance to efflux clearance in Wistar rat brain extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3783,1211438,1,2,,103165765,2818,Unspecified,,,,,"Ratio of unbound AUC in extracellular fluid to unbound AUC in plasma of Wistar rat at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3784,1211441,1,2,,103165765,2818,Unspecified,,,,,"Ratio of steady state drug level in extracellular fluid to unbound drug level in plasma of Wistar rat at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3785,1211444,1,1,,103165765,2818,Unspecified,,,,,"Equilibration rate constant in Wistar rat brain extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3786,1211447,1,1,,103165765,2818,Unspecified,,,,,"Equilibration half life in Wistar rat brain extracellular fluid at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3787,1211450,1,2,,103165765,2818,Unspecified,,,,,"Fraction unbound in Wistar rat plasma at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3788,1211453,1,1,,103165765,2818,Unspecified,,,,,"Unbound AUC (0 to infinity) in Wistar rat plasma at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3789,1211456,1,1,,103165765,2818,Active,,,,,"Unbound Cmax in Wistar rat plasma at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3790,1211459,1,1,,103165765,2818,Unspecified,,,,,"Unbound Tmax in Wistar rat plasma at 10 mg/kg, sc by HPLC-MS/MS analysis",Other,22736307.0,
3791,1215120,1,1,,103165765,2818,Active,,,0.775,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
3792,1215121,1,2,,103165765,2818,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
3793,1215122,1,1,,103165765,2818,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
3794,1215123,1,2,,103165765,2818,Unspecified,124028612.0,24186.0,78.8,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
3795,1215124,1,1,,103165765,2818,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
3796,1215125,1,1,,103165765,2818,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay,Other,21071520.0,
3797,1215126,1,2,,103165765,2818,Unspecified,,,,,Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
3798,1215128,1,1,,103165765,2818,Unspecified,,,,,"Ratio, ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM dosed as discrete compounds after 5 hrs by TRANSIL assay to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay",Other,21071520.0,
3799,1215866,1,2,,103165765,2818,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as hecogenin-mediated inhibition of recombinant UGT1A4 (unknown origin)-catalyzed clozapine glucuronidation at 10 uM,Other,23371966.0,
3800,1217704,1,2,,103165765,2818,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3801,1217705,1,2,,103165765,2818,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3802,1217706,1,2,,103165765,2818,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3803,1217707,1,2,,103165765,2818,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
3804,1217708,1,2,,103165765,2818,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3805,1217709,1,2,,103165765,2818,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3806,1217710,1,2,,103165765,2818,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
3807,1217711,1,2,,103165765,2818,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3808,1217712,1,2,,103165765,2818,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3809,1217727,1,2,,103165765,2818,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3810,1217728,1,1,,103165765,2818,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
3811,1217729,1,1,,103165765,2818,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
3812,1222782,1,1,,103165765,2818,Unspecified,,,,,Unbound hepatobiliary clearance in psychiatric patient,Other,23454828.0,
3813,1222783,1,1,,103165765,2818,Unspecified,,,,,Unbound renal clearance in psychiatric patient,Other,23454828.0,
3814,1222784,1,1,,103165765,2818,Unspecified,,,,,Systemic clearance in psychiatric patient,Other,23454828.0,
3815,1222785,1,1,,103165765,2818,Unspecified,,,,,Fraction unbound in psychiatric patient,Other,23454828.0,
3816,1224818,1,1,,312344401,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3817,1224819,1,1,,312344401,2818,Inconclusive,325495545.0,2101.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3818,1224820,1,1,,312344401,2818,Inactive,325495545.0,2101.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3819,1224821,1,1,,312344401,2818,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3820,1224822,1,1,,312344401,2818,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3821,1224823,1,1,,312344401,2818,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3822,1224824,1,1,,104171134,2818,Inactive,,,0.1865,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3823,1224825,1,1,,104171134,2818,Inactive,,,11.7704,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3824,1224834,3,1,,170464853,2818,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3825,1224835,1,1,,170464853,2818,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3826,1224836,1,1,,170464853,2818,Inconclusive,,,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3827,1224837,1,1,,170464853,2818,Inconclusive,,,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3828,1224838,1,1,,170464853,2818,Inactive,66775687.0,9970.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3829,1224839,1,1,,170464853,2818,Inconclusive,66775687.0,9970.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3830,1224840,3,1,,170464853,2818,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3831,1224841,3,1,,170464853,2818,Inconclusive,325495545.0,2101.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3832,1224842,3,1,,170464853,2818,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3833,1224843,1,1,,170464853,2818,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3834,1224844,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3835,1224845,1,1,,170464853,2818,Inconclusive,344243002.0,100757539.0,61.9315,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3836,1224846,1,1,,170464853,2818,Inconclusive,11995455.0,3091.0,2.1314,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3837,1224847,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3838,1224848,3,1,,170464853,2818,Inconclusive,325495545.0,2101.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3839,1224849,3,1,,170464853,2818,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3840,1224857,2,1,,104171134,2818,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3841,1224857,2,1,,170464853,2818,Inactive,,,14.1254,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3842,1224857,2,1,,312344401,2818,Inconclusive,,,3.1623,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3843,1224859,2,1,,90341777,2818,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3844,1224859,2,1,,104171134,2818,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3845,1224859,2,1,,170464853,2818,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3846,1224863,1,1,,176484140,2818,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3847,1224863,1,1,,176484873,2818,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3848,1224863,1,1,,316919987,2818,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3849,1224864,1,2,,316934025,2818,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3850,1224865,1,2,,56422144,2818,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3851,1224867,1,1,,170464853,2818,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3852,1224868,1,1,,170464853,2818,Inconclusive,,,11.9856,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3853,1224869,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3854,1224870,1,1,,170464853,2818,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3855,1224871,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3856,1224872,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3857,1224873,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3858,1224874,1,1,,170464853,2818,Inconclusive,,,15.089,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3859,1224875,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3860,1224876,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3861,1224877,1,1,,170464853,2818,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3862,1224878,1,1,,170464853,2818,Active,,,23.9145,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3863,1224879,1,1,,170464853,2818,Active,,,23.9145,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3864,1224880,1,1,,170464853,2818,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3865,1224881,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3866,1224882,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3867,1224883,1,1,,170464853,2818,Active,,,23.9145,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3868,1224884,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3869,1224885,1,1,,170464853,2818,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3870,1224886,1,1,,170464853,2818,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3871,1224887,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3872,1224888,1,1,,170464853,2818,Active,,,4.2527,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3873,1224889,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3874,1224890,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3875,1224892,1,1,,170464853,2818,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3876,1224893,1,1,,170464853,2818,Inconclusive,66775687.0,9970.0,7.4978,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3877,1224894,1,1,,170464853,2818,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3878,1224895,1,1,,170464853,2818,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3879,1224896,1,1,,170464853,2818,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3880,1224905,2,1,,92308909,2818,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3881,1224905,2,1,,92308909,2818,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3882,1224905,2,1,,121360958,2818,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3883,1224905,2,1,,121360958,2818,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3884,1227382,1,1,,103165765,2818,Active,,,47.863,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay,Confirmatory,,
3885,1227931,1,1,,103165765,2818,Active,8488960.0,3363.0,0.037000000000000005,Ki,Displacement of [3H]LSD from human recombinant 5-HT7 receptor expressed in HEK cell membranes by radioligand binding assay,Confirmatory,25695425.0,
3886,1227936,1,1,,103165765,2818,Active,543727.0,3356.0,0.018000000000000002,Ki,Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in HEKT cell membranes by radioligand binding assay,Confirmatory,25695425.0,
3887,1242908,1,1,,103165765,2818,Active,543727.0,3356.0,0.00535,Ki,Binding affinity to 5-HT2A receptor (unknown origin),Confirmatory,26227779.0,
3888,1256663,1,1,,103165765,2818,Active,47117674.0,24318.0,0.155,Ki,Displacement of [3H]spiperone from dopaminergic D2 receptor in rat striatum homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3889,1256664,1,1,,103165765,2818,Active,112812.0,24473.0,0.161,Ki,Displacement of [3H]8-OH-DPAT from 5-HT1A receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3890,1256665,1,1,,103165765,2818,Active,112808.0,29595.0,0.0145,Ki,Displacement of [3H]ketanserine from 5-HT2A receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3891,1256666,1,1,,103165765,2818,Active,461440.0,65032.0,0.0626,Ki,Displacement of [3H]-5-CT from 5-HT7 receptor in rat hypothalamus homogenates after 120 mins by liquid scintillation counting,Confirmatory,26483200.0,
3892,1256667,1,1,,103165765,2818,Active,,,0.0388,Ki,Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3893,1256668,1,1,,103165765,2818,Active,,,0.0519,Ki,Displacement of [3H]-rauwolscine from adrenergic alpha2 receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3894,1256669,1,1,,103165765,2818,Active,399889.0,100730517.0,0.0122,Ki,Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3895,1256670,1,1,,103165765,2818,Active,112817.0,25187.0,0.0419,Ki,Displacement of [3H]mesulergine from 5-HT2C receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting,Confirmatory,26483200.0,
3896,1256674,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Chinese Kun Ming mouse assessed as inhibition of apomorphine-induced climbing administered 30 mins before apomorphine challenge measured up to 30 mins,Other,26483200.0,
3897,1256675,1,1,,103165765,2818,Unspecified,,,,,Antipsychotic activity in po dosed Chinese Kun Ming mouse assessed as inhibition of DOI-induced head twitch administered 60 mins before DOI challenge measured up to 15 mins,Other,26483200.0,
3898,1256676,1,1,,103165765,2818,Unspecified,,,,,Toxicity in po dosed Chinese Kun Ming mouse assessed as induction of catalepsy by measuring immobility score of 30 seconds administered 30 mins before first assessment,Other,26483200.0,
3899,1256677,1,1,,103165765,2818,Unspecified,,,,,Ratio of ED50 for Chinese Kun Ming mouse assessed as induction of catalepsy to ED50 for Chinese Kun Ming mouse assessed as inhibition of apomorphine-induced climbing behaviour,Other,26483200.0,
3900,1256678,1,1,,103165765,2818,Unspecified,,,,,Ratio of ED50 for Chinese Kun Ming mouse assessed as induction of catalepsy to ED50 for Chinese Kun Ming mouse assessed as inhibition of DOI-induced head twitch,Other,26483200.0,
3901,1257655,1,1,,103165765,2818,Active,543727.0,3356.0,0.0096,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, aA1, 5-HT2C and H1 Receptors.",Confirmatory,,
3902,1257656,1,1,,103165765,2818,Unspecified,400630.0,6532.0,1.0,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
3903,1257657,1,1,,103165765,2818,Active,112816.0,3358.0,0.013000000000000001,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
3904,1257658,1,1,,103165765,2818,Active,,,0.001,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
3905,1257659,1,1,,103165765,2818,Active,118206.0,1813.0,0.19,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
3906,1257660,1,1,,103165765,2818,Active,1168246.0,148.0,0.019,Ki,"BindingDB_Patents: Binding Assay. Binding assay using 5-HT2A, Dopamine D2, SERT, alpha;A1, 5-HT2C and H1 Receptors.",Confirmatory,,
3907,1259241,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3908,1259242,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3909,1259243,1,1,,170464853,2818,Active,124375976.0,367.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3910,1259244,1,1,,170464853,2818,Inconclusive,348019627.0,2099.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3911,1259247,1,1,,170464853,2818,Active,124375976.0,367.0,6.18872,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3912,1259248,1,1,,170464853,2818,Inconclusive,348019627.0,2099.0,21.1317,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3913,1259252,1,1,,104171134,2818,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3914,1259253,1,1,,104171134,2818,Inconclusive,169655958.0,,37.2212,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3915,1259255,1,1,,104171134,2818,Inconclusive,169655958.0,,37.2212,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3916,1259256,1,1,,104171134,2818,Inconclusive,169655958.0,,29.5659,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3917,1259309,1,1,,178126372,2818,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3918,1259310,1,1,,104170165,2818,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3919,1259310,1,1,,321942439,2818,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3920,1259310,1,1,,332876581,2818,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3921,1259310,1,1,,332876672,2818,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3922,1259310,1,1,,332876771,2818,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3923,1259311,1,1,,178126372,2818,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3924,1259313,1,1,,56422144,2818,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3925,1259318,1,1,,855811,2818,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3926,1259325,1,2,,336954265,2818,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3927,1259344,1,1,,144203664,2818,Inconclusive,,,12.5893,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3928,1259354,1,1,,348414147,2818,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3929,1259355,1,1,,26751524,2818,Inconclusive,,,10.0,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3930,1259356,1,1,,104171134,2818,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3931,1259364,1,1,,170464853,2818,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3932,1259365,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3933,1259366,1,1,,170464853,2818,Active,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3934,1259367,1,1,,170464853,2818,Inconclusive,,,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3935,1259368,1,1,,170464853,2818,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3936,1259369,1,1,,170464853,2818,Inconclusive,109731339.0,2737.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3937,1259370,2,2,,124637706,2818,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3938,1259370,2,2,,124637706,2818,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3939,1259370,2,2,,124637706,2818,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3940,1259377,1,1,,170464853,2818,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3941,1259378,1,1,,170464853,2818,Inconclusive,54288833.0,2100.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3942,1259379,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3943,1259380,1,1,,170464853,2818,Active,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3944,1259381,1,1,,170464853,2818,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3945,1259382,1,1,,170464853,2818,Inconclusive,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3946,1259383,1,1,,170464853,2818,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3947,1259384,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3948,1259385,1,1,,170464853,2818,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3949,1259386,1,1,,170464853,2818,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3950,1259387,1,1,,170464853,2818,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3951,1259388,1,1,,170464853,2818,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3952,1259389,1,1,,124637706,2818,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3953,1259390,1,1,,170464853,2818,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3954,1259391,1,1,,170464853,2818,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3955,1259392,1,1,,170464853,2818,Inconclusive,109731339.0,2737.0,8.41267,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3956,1259393,1,1,,170464853,2818,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3957,1259394,1,1,,170464853,2818,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3958,1259395,1,1,,170464853,2818,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3959,1259396,1,1,,170464853,2818,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3960,1259400,1,1,,170464853,2818,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3961,1259401,1,1,,170464853,2818,Inconclusive,325495545.0,2101.0,15.8465,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3962,1259402,1,1,,170464853,2818,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3963,1259403,1,1,,170464853,2818,Inconclusive,325495545.0,2101.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3964,1259404,1,1,,170464853,2818,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3965,1259406,1,1,,363920378,2818,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3966,1259406,1,1,1.0,363920378,2818,Active,26638650.0,3778.0,0.295554,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3967,1259406,1,1,2.0,363920378,2818,Active,4758626.0,3779.0,0.177297,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3968,1259406,1,1,3.0,363920378,2818,Active,5031823.0,10242.0,0.388675,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3969,1259406,1,1,4.0,363920378,2818,Active,26051275.0,27345.0,0.214104,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3970,1259406,1,1,5.0,363920378,2818,Inactive,160410009.0,389816.0,0.0716133,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3971,1259406,1,1,6.0,363920378,2818,Inactive,26638650.0,3778.0,0.07160219999999999,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3972,1259406,1,1,7.0,363920378,2818,Active,4758626.0,3779.0,0.15553599999999998,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3973,1259406,1,1,8.0,363920378,2818,Active,5031823.0,10242.0,0.106181,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3974,1259406,1,1,9.0,363920378,2818,Active,26051275.0,27345.0,0.136533,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3975,1259406,1,1,10.0,363920378,2818,Inactive,5031823.0,10242.0,0.0195192,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3976,1259407,1,1,,363907118,2818,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3977,1259413,1,2,,104170165,2818,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3978,1259415,1,1,,855811,2818,Inconclusive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3979,1259416,1,2,,855811,2818,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3980,1259416,1,2,,340083402,2818,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3981,1259416,1,2,,375178422,2818,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3982,1259419,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,8935801.0,
3983,1259419,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,9732398.0,
3984,1259419,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,12629531.0,
3985,1259419,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,15102927.0,
3986,1259419,1,1,,135650115,2818,Active,260099679.0,3356.0,,,Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Other,15322733.0,
3987,1259421,1,1,,340083402,2818,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3988,1259421,1,1,,375178422,2818,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3989,1259423,1,2,,354781760,2818,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3990,1259423,1,2,,354918126,2818,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3991,1259423,1,2,,354945785,2818,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3992,1259423,1,2,,354991928,2818,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
